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Abstract

Bacterial resistance to multiple classes of antibiotics, termed multi-drug
resistance (MDR) and resulting treatment failures is an increasing global concern
problem. This thesis describes the design, synthesis and biological evaluation of new
class of antibacterials which aim to address the problem of antibiotic resistance,
including infections arising from Methicillin resistant Staphylococcus aureus
(MRSA) and Clostridium difficile.
Drug efflux is a major mechanism used by bacteria to counter the effects of
antibiotics and plays a key role in clinically relevant multidrug resistance (MDR).
One strategy to overcome resistance is pharmacological inhibition of bacterial efflux
pumps. Chapter 1 provides a review of small molecule-based approaches to
countering efflux-mediated antibiotic resistance. The review summarises the many
different classes of efflux pump inhibitors (EPIs) that have been described along with
studies that report their use in combination with antibiotics. The review concludes
with a summary of new approaches that link the EPI and antibacterial into a single
hybrid molecule as a solution to the problem associated with co-administration of the
separate agents. A promising approach of this type involves linking of the EPI INF55
(5-nitro-2-phenyl indole) with the antibacterial alkaloid berberine, as described in
previous reports from the Bremner/Kelso groups.
One shortcoming of the berberine-INF55 hybrids was that their minimum
inhibitory concentrations (MICs) against S. aureus species remained too high to be
clinically useful (>1 µg/mL). In Chapter 2 attempts were made to increase the
antimicrobial potency of these hybrids through the creation of action prodrugs. The
vii

first prodrug target 90 was designed to release INF55 from the prodrug after
interaction of the berberine portion with bacterial DNA. However, the final step in
the synthesis of 90 did not proceed and a second hybrid prodrug 96 was subsequently
designed and successfully synthesised. Unfortunately the antibacterial potency of 96
was not significantly higher than previous (non-cleavable) hybrids from the
Bremner/Kelso groups leading us to focus efforts in other directions.
The previous studies from the Bremner/Kelso groups had demonstrated the
potential of the berberine-INF55 class of hybrid anti-bacterials but they hadn‘t
established whether the compounds function as originally designed; i.e. with the
INF55 moiety functioning to block MDR pumps (e.g. NorA) and the berberine
moiety providing antibacterial action. In Chapter 3 a study was conducted which
attempted to disconnect these activities and establish whether the proposed
mechanism was indeed underpinning the activity of the hybrids. To explore the
hypothesis, INF55 44 and two of its analogues which show reduced efflux pump
inhibitory activity were designed and synthesized and three berberine-INF55 hybrids
88, 110 and 117 which link 44, 100, 101 to berberine 13-position were also
synthesized. The aim of this work was to investigate whether the three hybrids show
decreasing antibacterial potency that parallels the decreased efflux pump inhibitory
activity of the INF55 analogues they incorporate, which would be consistent with the
mechanism by which they were designed to act. The three hybrids 88, 110 and 117
were found to show identical antibacterial effects against S. aureus strains varying in
levels of expression of the NorA efflux pump and they were also shown to be taken
up in similar amounts in these cells. Additionally, the three hybrid show identical
curative effects of C. elegans live infection models where the worms are infected

viii

with live MRSA or E. faecalis. These findings confirmed that while there are
significant differences in the berberine potentiation potencies of the three attached
pump inhibitors, these do not produce corresponding differences in antibacterial
effects when incorporated into berberine–INF55 hybrids. It was concluded that the
antibacterial mechanisms of action of the hybrids must be different from the
mechanisms at play when berberine is co-administered with the pump inhibitors.
Clostridium

difficile-associated

diarrhoea

(CDAD),

also

known

as

Clostridium difficile infection (CDI), is the leading cause of infectious nosocomial
gastrointestinal illness. Section 2 of thesis investigated a new class of agents that are
highly selective for Clostridium difficile over other gut commensals and show
activity against stationary phase cells. High-throughput screening carried out at
Northeastern University initially identified 4 hits (121-124) against C. difficile
CD196 were essentially inactive (MIC > 50 μg/mL) across a gut commensal panel.
In contrast, metronidazole 118, vancomycin 119 and fidaxomicin 120, the standard
antibiotics used for CDAD, all showed high potency against C. difficile accompanied
by significant activity against commensals. In Chapter 4 several structural analogs
140-150 were synthesised to answer specific structure-activity questions about the
new class of compounds (i.e. diarylacylhydrazones). This SAR work demonstrated
that only certain diarylacylhydrazones act as narrow-spectrum antibacterials with
selectivity for C. difficile and C. perfringens over gut commensals. Identifying that
CCCP 64 shows similar activity to diarylacylhydrazones against the gut panel and
against stationary phase C. difficile cells also suggested that a protonophoric
mechanism may play a role in the selectivity.

ix

High-throughput screening of the NCI (set V) compound collection by
Northeastern University identified NSC 293884 167 as another potent and selective
lead compound against C. difficile (MIC 1.56 μg/mL). Two analogs of 167 (i.e. 168
and 169) were synthesized to establish whether the chemistry was amenable to
analogue elaboration and to observe whether structure-activity relationships existed
for the class, which would support further questions. Excitingly the 4-phenoxy
analogue 169 showed very high potency against CD196 (MIC 0.78 µg/mL) and no
activity against any other gut panel members (including C. perfringens) making it a
truly C. difficile selective compound. Plans are being put in place to extensively
explore this compound and the class.
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Chapter 1
Small Molecule-Based Strategies for Countering Efflux-Mediated
0B

Antibiotic Resistance
1 Introduction
1.1 Bacterial resistance to antimicrobials
Bacteria have evolved numerous strategies for overcoming environmental
and chemical challenges and their increasing resistance to antibiotics has become a
major global concern.1 The discovery of penicillin in 1928 hailed the new era of
H

H

antibiotics but reports of resistant strains of Staphylococcus aureus were emerging by
1946. Within a decade resistant traits were also being noted for related antibiotics
like methicillin.2 By 2003 in the US more than 50% of S. aureus strains isolated from
H

H

blood borne infections were methicillin resistant (i.e. methicillin resistant
Staphylococcus aureus, MRSA).3 In 2011 it was estimated that 70% of all
H

H

staphylococcus infections arise from MRSA.4 While vancomycin has for some time
H

H

been an effective defence against MRSA resistance to this drug has been observed
since 1996.5 Resistance has now extended to Enterococcus faecium species with
H

H

vancomycin-resistant (VRE) infections rising from less than one percent in 1990 to
over 28% in 2003. Enterococcus species are now showing resistance to newer
antibiotics like daptomycin, tigecycline and linezolid.6-9
H

H

H

Bacterial resistance to multiple classes of antibiotics, termed multi-drug
resistance (MDR), is an alarming clinical concern. Gram-negative pathogens such as
Pseudomonas aeruginosa and acinetobacter species are causing serious challenges

1

due to their resistance to fluoroquinolones, trimethoprim-sulfamethoxazole
combinations and the most recent carbapenams.10 Infections caused by these
H

H

pathogens continue to escalate, particularly in hospitals where they are responsible
for increasing morbidity and mortality. The Centres for Disease Control and
Prevention (CDC) estimates that in the US, 1.7 million hospital-associated infections
(HAI) from all bacterial pathogens contribute to 99,000 deaths annually and cost the
US economy between 4.5 and 11 billion dollars.11 It is clear that effective new
H

H

antimicrobials are urgently needed to provide new solutions to the escalating
problem of drug resistance. Recently, the Infectious Disease Society of America
(IDSA) launched a collaborative programme with various organisations titled the 10
x '20 initiative, which aims to develop at least 10 new antibiotics by 2020
specifically

targeting

Staphylococcus
U

U

the

aureus,

―ESKAPE‖

Klebsiella
U

U

pathogens;

pneumoniae,

Enterococcus
U

U

Acinetobacter
U

U

faecium,
baumannii,

Pseudomonas aeruginosa and Enterobacter species.12
U

U

U

U

H

1.2 Mechanisms of antibiotic resistance
Bacterial pathogens can develop resistance to antimicrobials by several
mechanisms, with three of the major mechanisms being:13 (1) enzymatic inactivation
H

H

of antibiotics, (2) alteration of the drug target, (3) decreased intracellular drug
accumulation through reduced membrane permeability13,18 or over-expression of
H

H

membrane efflux pumps.9
1.2.1 Enzymatic inactivation of antibiotics
Many bacterial pathogens express enzymes that reside within bacterial cells
or near the cell surface which selectively inactivate antibiotic molecules before
reaching their targets.13 For example, deactivation of β-lactam antibiotics is effected
H

H

2

by the β-lactamases family of enzymes, which are classified into four types; the class
A pencillinases, class B metallo-β-lactamases, class C cephalosporinases and class D
oxacillinases. Classes A, C and D are serine-dependant hydrolases and class B is
metal-dependant.13, 14 These enzymes hydrolyse the crucial β-lactam nucleus of the
H

H

H

H

antibiotics to produce biologically inert compounds. Both Gram-positive and Gramnegative bacteria are known to produce β-lactamases. Examples from the Grampositives

include

Staphylococcus

aureus,

coagulase-negative

staphylococci,

Enterococcus faecalis, and Bacillus cereus. Many Gram-negative bacteria that
produce β-lactamases secrete them into the periplasmic space. Examples include
members from Enterobacteriaceae, Pseudomonas sp, Xanthomonas maltophilia,
Acinetobacter sp, Moraxella caterrhalis, Haemophilus influenzae, Legionella sp,
Neisseria gonorrhoea and bacteroides.15
H

H

1.2.2 Alteration of the drug target
Resistance of this type arises when pathogens mutate or otherwise make
modifications to the target site rendering antibiotics ineffective at inhibiting vital
microbial cell functions. This mechanism is the most frequent cause of vancomycin
resistance in Enterococcus species (i.e. vancomycin resistant enterococci, VRE).16
H

H

Peptidoglycan is an important building block required for bacterial cell wall
synthesis, acting to strengthen the cell wall through cross linking at its D-Ala-D-Ala
terminus. Vancomycin binds the D-Ala-D-Ala terminus of peptidoglycan precursor
and interferes with cross linking. Resistance to vancomyicn arises when bacteria use
an alternate pathway for cell wall biosynthesis that switches the peptidoglycan
precursor from D-Ala-D-Ala to D-Ala-D-lactate or D-Ala-D-Ser.
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Resistance to β-lactams can arise through mutations in the target penicillin
binding proteins (PBPs). For example, resistance to methicillin in S. aureus (MRSA)
can arise from reduced affinity for PB2a. Resistance to fluoroquinolones can arise
due to mutations in DNA gyrase (i.e gyrA) or topoisomerase IV enzymes (i.e parC).
The most common mechanism of resistance to macrolides is modification of the 23S
rRNA component of the 50S ribosomal subunit. These modifications involve
methylation or demethylation of an adenine residue by N-methyltransferases
(methylases, MTases). Mutations in 23S rRNA close to the site of methylation can
also lead to macrolide resistance.13, 17
H

H

H

H

1.2.3 Expression of membrane bound efflux pumps
The third major resistance mechanism and the focus of this review arises due
to the action of efflux pumps, which play a major role in clinically relevant multidrug resistance.9 These membrane-bound transport proteins are found in both
H

H

prokaryotic and eukaryotic organisms and function to shuttle molecules between the
cell cytoplasm and the extracellular environment.18 They are responsible for
H

H

importing some essential nutrients into the cytoplasm and for exporting toxic agents,
including dyes, drugs, cationic agents and metabolites.19 Some efflux pumps
H

H

selectively extrude specific antibiotics while others transport a wide variety of
structurally diverse compounds, including unrelated classes of antibiotics. These
pumps, termed Multi Drug Resistance (MDR) pumps,20 play central roles in cellular
H

H

metabolism, physiology and pathogenicity. Both Gram-positive and Gram-negative
bacteria are known to possess MDR pumps.
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Figure 1.1 Three major mechanisms of bacterial resistance to antibiotics; (1)
enzymatic inactivation, (2) alteration of the drug target and (3) expression of
membrane-bound efflux pumps. Figure modified from Ref 21.
H

H

1.3 Efflux pumps: classification and mechanisms
Bacterial efflux pumps identified to date belong to five superfamilies and are
divided into two types depending on their mechanism. Primary transporters, also
known as ATP-binding cassette (ABC) transporters, are mostly found in mammalian
cells and use hydrolysis of ATP to ADP as an energy source. Secondary transporters
use non-ATP dependant energy sources and are sub-categorized into the Major
Facilitator superfamily (MFS), the Resistance Nodulation Division (RND)
superfamily and the Small Multi-drug Resistance (SMR) superfamily. Each of these
families uses proton gradients as a primary energy source. Another class known as
the Multi-drug and Toxic Compound Extrusion (MATE) subfamily, uses Na+ as an
energy source for extrusion of compounds.22 A summary of the major classes of
H

H
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bacterial efflux pumps and some of the antibiotics whose activities they effect is
provided in Figure 1.2.

Figure 1.2 The five super-families of bacterial efflux pumps and some antibiotics
whose activities they effect. Abbrevations: ABC: ATB-binding cassettes, MFS:
major facilitator superfamily, RND: resistance-nodulation-division, SMR: small
multi-drug resistance, MATE: multi-drug and toxic compound extrusion, MFP:
membrane

fusion

fluoroquinolones,

protein,
CHL:

MACs:

macrolides,

chloramphenicol,

CD:

TETs:

tetracyclines,

cationic

drugs,

FQs:

AMGs:

aminoglycosides, BLAs: beta-lactams. Figure modified from Ref 22
1.4 Efflux pumps in Gram-positive bacteria
Clinically relevant efflux pumps in Gram-positive bacteria are usually nonRND proteins belonging to the ABC, MFS, SMR or MATE superfamilies, which can
confer resistance against a wide variety of antimicrobials.23 For brevity, only selected
H

H

examples of pumps from the important bacterial pathogens Enterococcus faecium,
6

Streptococcus pneumoniae and S. aureus are discussed here. In E. faecium, EfmA
pumps from the MFS superfamily confer intrinsic resistance to

many

fluoroquinolones, tetraphenylphosphonium ions and quinupristin. MsrC pumps are
ABC transporters in E. faecium that confer resistance to macrolides and
quinuprisitin. Analysis of food-borne infections revealed that Tet (L), Tet (M) and
Tet (K) pumps are present in E. faecium and Enterococcus faecalis. In S.
pneumoniae, MFS pumps include MefA, MefE and PmrA, which are involved in
macrolide and fluoroquinolone resistance.24,25 MATE pumps in S. aureus include
H

H

H

H

mepA and SMR pumps include SepA. These pumps tend to be chromosomally
encoded whereas MsrA and SMR type QacA/B pumps tend to be plasmid encoded.
In 1999 Gill et al identified that the PmrA pump of S. pnuemoniae shares 42 %
identity with the NorA pump and 43% with the Bmr pump.26 Efflux pumps
H

H

belonging to the MFS superfamily in S. aureus include NorA, NorB, NorC, SdrM
and Tet38. Recent studies showed that 50% of 232 blood stream S. aureus isolates
were able to efflux more than two substrates. Frequencies of over expressed genes
were mepA 4%, mdeA 11%, norA 23%, norB 25% and norC 17%. Another 20% of
the strains over-expressed two or more efflux genes.27
H

H

ABC transporters in Gram-positive bacteria include patA and patB, AbcA
and

Sav1866.

Over-expression

of

these

pumps

confers

resistance

to

fluoroquinolones, ciprofloxacin and azithromycin.23 A crystal structure of the
H

H

Sav1866 pump from S. aureus, whose biochemical characteristics and primary
sequence identify it as a homologue of human multi-drug ABC transporters, was
reported in 2006 (Figure 1.3).28 The crystal structure (refined to 3.0 Å) showed that
the protein is 120 Å long, 65 Å wide and 55 Å deep.28 Although the structure did not
H

H
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directly reveal the substrate binding site(s) the location of these site(s) has been
identified previously by mutagenesis and biochemical and cross linking data
accumulated over many years of research.29
H

H

Figure 1.3 X-Ray crystal structure of Sav1866 from S. aureus. The homodimeric
protein is presented in ribbon form with the subunits coloured yellow and turquoise.
ADP bound to the high affinity binding site is shown in ball and stick representation.
The view reveals the membrane-planted wings of the protein; grey box depicts the
possible location of the lipid bilayer based on the predicted hydrophobicity of the
protein surface; TMDs transmembrane domains; NBDs nucleotide binding domains;
ICL intracellular loops. Figure modified from Ref 28.
Sav 1866 is a homodimeric ABC transporter consisting of two identical
subunits, containing transmembrane domains (TMDs) covalently coupled to inwardfacing nucleotide binding domains (NBDs). The NBDs contain high affinity
substrate binding sites and are responsible for hydrolysis of ATP to ADP. A large
pocket is present at the interface of the two transmembrane domains directing out
8

towards the extracellular space. Depending upon the hydrophobicity of the ligands,
the bound substrates from the cell interior may escape into the outer membrane or
into the aqueous environment. These mechanisms of ATP-driven ABC-mediated
efflux may apply to other multi-drug ABC transporters and Sav1866 from S. aureus
may also serve as an efflux model for related human homologues.28
H

H

1.5 Efflux pumps in Gram-negative bacteria
Clinically relevant efflux pumps in Gram-negative bacteria are most
frequently from the MFS and RND superfamilies.23 The RND family is ubiquitous
H

H

with its members spread widely across many kingdoms. Several members of the
RND superfamily encoded in the human genome are homologues of bacterial RND
pumps (16% identity).29,30 Examples include permase (NPC1), which plays a role in
H

H

H

H

the autosomal recessive disorder Niemann-Pick disease type C1 and is responsible
for pumping cholesterol into lysosomes,31 and the homologue of the drosophilia
H

H

morphogen receptor patched, which is thought to be crucial for protecting against
basal cell carcinoma.32 RND transporters have been shown to be essential for cellular
H

H

invasion and resistance to natural host substances, such as bile salts as well as
specialized host defence molecules.33 The RND transporter MexGHI-OpM in P.
H

H

aeruginosa facilitates cell-cell communication (quorum signalling) and is thought to
contribute to persistant infections.34
H

H

RND transporters are organised into three component (tripartite) systems,
consisting of the cytoplasmic membrane components, an outer membrane (OM)
channel and the large periplasmic accessory proteins, all working in concert to
extrude substrates to the extracellular medium.35 In this section, representative
H

H
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examples of pumps from the important pathogens P. aeruginosa and E. coli are
discussed.
The tripartiate complex AcrAB-TolC in E. coli is formed by conjugation of
the RND pump AcrB with the membrane fusion protein (MFP) AcrA and the low
permeability outer membrane protein TolC.29 The AcrAB-TolC complex is
H

H

chromosomally encoded by the acrAB-tolC genes36 and the complex is capable of
H

H

extruding a wide variety of compounds, including chloramphenicol, lipophillic βlactams, tetracycline, rifamipicin, novabicin, fusidic acid, naldixic acid, ethidium
bromide, acraflavine, bile salts, short-chain fatty acids, SDS, Triton X-100 and
Triclosan.33
H

H

In E. coli the acrD and acrF operons encode efflux pumps, with AcrD pumps
known to efflux aminoglycosides.37,38 Other pumps in E. coli include EmrB, MdfA
H

H

H

H

and TetA, which belong to the MFS (major facilitator superfamily). In P. aeruginosa
MexB is the principal multi-drug exporter of clinical relevance.39 It cooperates with
H

H

both an outer membrane channel OprM and a membrane fusion protein MexA,
forming a tripartiate complex pump MexAB-OprM.39,40 Other clinically relevant
H

H

H

H

efflux pumps in P. aerugionsa include MexCD-OprJ, MexEF-OprN and MexXYOprM. These pumps are constitutively expressed in wild-type cells and confer
intrinsic resistance to a wide variety of antimicrobials.41 Expression of MexCD-OprJ
H

H

and MexEF-OprN has only been observed in multi-drug resistant mutant strains.42
H

H

Over-expression of pumps occurs as a result of mutations in operons within local
transcriptional regulatory proteins located immediately upstream. The best
characterised mexR member of the MarR family of proteins acts as a repressor of
transcription of the mexAB-oprM operon, which is a homologue of the AcrB of E.
10

coli and mtrCDE of Neisseria gonorrhoe efflux systems.43-44 Over-expression of
H

H

H

H

mexAB-OprM in nalB mutant strains is due to mutations in the mexR gene, which
confers multi-drug resistance in P. aeruginosa.45 Other genes involved in the overH

H

expression of MexAB-OprM include nalC and nalD. Hyper-expression of MexCDOprJ in nfxB mutants of P. aeruginosa contributes to resistance against
fluoroquinolones and fourth generation cephems (e.g. cefpriome and cefozopran).
The MexEF-OprN operon is over-expressed in mutant nfxC cells which are resistant
to fluoroquinolones and imipenem.46
H

Numerous studies on tripartite efflux pumps (AcrAB-TolC of E. coli and
MexAB-OprM of P. aerugionsa) serve as models for other drug transport
mechanisms in the RND superfamily. An X-ray crystal structure of the AcrAB
transporter at 3.5 Å resolution solved by the Yamaguchi laboratory (Figure 1.4A)
provided exquisite structural details regarding the mechanism of drug capture and
transport.47 The structure showed that the AcrAB protein is a symmetrical trimer of
H

H

~110 kD sub units, with each subunit containing 12 putative transmembrane helices
and two large hydrophilic loops on periplasmic domains that protrude deep into the
periplasm. The AcrB protein functions as a trimer of 1,049 residue protomers and has
the overall appearance of a jelly fish. AcrB is composed of a 70 Å periplasmic region
and a thick 50 Å transmembrane region (Figure 1.4B). The three transmembrane
domains form a large cavity with a diameter of 30 Å. The AcrB trimer comprises
three layers stacked upon one another parallel to the membrane, with a
transmembrane domain, a portal or pore domain and the TolC docking domain. TolC
is also a trimer and forms a channel across the periplasm through the outer
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membrane (Figure 1.4B). The total length of the AcrAB and TolC complex is 170
Å.47
H

H

Substrates located in the cytoplasm are thought to be transported through a
transmembrane groove at the periphery of each transmembrane domain,
accumulating in the central cavity. From there active transport of substrates into the
upper portal domain occurs via a funnel-like channel that opens through three
vestibules in the periplasmic space of the TolC docking domains, extruding
substrates into the outer membrane (Figure 1.4B). Co-crystallisation studies reported
by Yu et al showed that four structurally diverse ligands were able to bind to the
hydrophobic amino acid residues found at several locations in the large central cavity
(5000 Å) of the transmembrane domains of AcrAB from E. coli.48 The ligands bound
H

H

to the proteins via hydrophobic, aromatic stacking and van der Waals interactions,
highlighting the importance of polarity in drugs binding to the protein.48 Other
H

H

structures by Murkami S. et al showed that spacious binding pockets exist in the
porter domains of each protomer. Based on the different conformations displayed by
the protomers of AcrB it has been proposed that drugs are effluxed via a functionally
rotating mechanism, where the substrates undergo ordered changes upon binding.49
H

H

Ongoing efforts by several research groups aimed at improving the resolution of the
structures and identifying drug binding sites and efflux mechanisms should
eventually create opportunities for the rational design of RND efflux pump
inhibitors.
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Figure 1.4A Side view of the three AcrAB proteomers (blue, green and red). The Nterminal and C-terminal halves of the proteomers are represented in dark and pale
colours. The extra-membrane (periplasmic space) head piece, TolC docking domains
and pore domains are at the top. (Figure modified from Ref 47)

Figure 1.4B Model of AcrB-AcrA-TolC complex and proposed mechanism of
substrate efflux. The interface between AcrB and TolC were aligned by manual
docking. (Figure modified from Ref 47)
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1.6 Strategies for overcoming efflux-mediated antibiotic resistance
The clinical importance of bacterial efflux systems has led to growing interest in
strategies for overcoming this type of resistance. Approaches studied to date can be
divided into three categories:
(1) By-pass of efflux systems: This strategy aims to improve the efficacy of old
antimicrobials by modifying their structure such that they are no longer substrates for
pumps. For example, newer fluoroquinolones such as sparfloxacin and trovafloxacin
are less susceptible to efflux than their predecessor variants like nalidixic acid and
norfloxacin.50,51
H

H

H

(2) Biological inhibition of efflux pumps: Efflux activity can in-principle be impaired
by either blocking the efflux proteins themselves (using, for example, neutralising
antibodies) or by repressing their expression with, for example, antisense approaches.
One patented strategy employs antisense oligonucleotides or small interfering RNAs
(siRNAs) to interfere with transcription and translation of pumps.52 This strategy is
H

H

being developed for inhibition of the AcrAB efflux pump expressed in E. coli but
could be expanded to other pumps. The promise of this strategy is highlighted by
studies showing that deletion of the acrAB gene in E.coli restores sensitivity to
several antimicrobials.53
H

H

(3) Pharmacological inhibition of efflux pumps: The simplest and perhaps most
attractive method for improving the clinical efficacy of efflux-susceptible antibiotics
is to identify and develop new compounds that selectively block efflux pumps (i.e.
efflux pump inhibitors, EPIs). These compounds could conceivably be coadministered with antibiotics to restore efficacy. The sections below elaborate on
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various inhibitors of bacterial efflux pumps that have been identified in Gramnegative and Gram-positive bacteria.54
H

H

1.7 EPIs against Gram-negative bacteria
In the late 1990s Microcide and Daiichi Pharmaceuticals were the first to
search for broad-spectrum efflux pump inhibitors against the four clinically relevant
pumps in P. aeruginosa (i.e. MexAB-OprM, MexCD-OprJ, MexEF-OprN and
MexXY-OprM).29 High-throughput screening identified the low molecular weight
H

H

dipeptide inhibitor MC-207110 1 (Figure 1.5), also known as phenylalanine arginylβ-naphthylamide (PAβN).55
H

H

Compound 1 was shown to reduce Mex-mediated

resistance to fluoroquinolones in P. aeruginosa and AcrAB-TolC mediated
resistance in E. coli, K. pneumoniae, S. typhimurium and E. aerogenes.50, 56, 57, 58 The
H

H

H

H

H

H

H

H

compound inhibits all four pumps and reduces intrinsic levofloxacin resistance in P.
aeruginosa about 8-fold in wild type cells at 10 µg/ml, while pump over-expressing
strains showed a decrease in MIC to levoflaxcin of about 64-fold.29 MC-207110 1
H

H

created much excitement and has become a valuable tool for efflux inhibition studies.
however, MC-207110 itself is a substrate for efflux pumps, suggesting that
antibiotics may bind to different sites within transporters.29
H

H

Medicinal chemistry efforts aimed at improving the pharmacokinetics of 1
produced MC-002595 2 (Figure 1.5), which although not as active, showed a better
overall profile (low intrinsic MIC and cytotoxicity). Compound 2 lowered the MIC
of levofloxacin 8-fold and showed serum stability of more than 24 h in a mouse
model.59 Several analogues of MC-002595 potentiate the activity of levofloxacin
H

H

against P. aeruginosa60 including MC-004124 3 (Figure 1.5), which exhibits reduced
H

H

toxicity and good serum stability.61
H
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Figure 1.5 Structures of Gram-negative EPIs MC-207110, MC-002595, and MC004124.
Protein synthesis in prokaryotic organisms uses N-formyl methionine, with
post–translational deformylation occuring through the action of peptidyl deformylase
(PDF). Agents that selectively block PDF are considered as attractive candidates for
development into new antibiotics. Novartis has reported a novel class of PDF
inhibitors in Gram-negative bacteria that includes LBM415 4 and LBK611 5 (Figure
1.6). Protection afforded by the outer membrane permeability barrier and overexpression of RND pumps limited the effectiveness of these compounds. The
combination of PDF inhibitor LBM415 with efflux pump inhibitor MC-207110 1
was shown to potentiate the activity of clindamycin against H. influenzae, with the
increased effect attributed to blocking of the AcrAB-TolC pump.62
H

H

Figure 1.6 Peptide deformylase inhibitors effective against Gram-negative bacteria.

16

A study of Mex efflux systems in P. aeruginosa by Poole et al63 reported that
H

H

under conditions of severe iron deficiency over-expression of MexAB-OprM occurs
and plays a vital role in P. aeruginosa survival. Based on these results, Liu et al64
H

H

investigated combinations of several iron chelators (2,2‘dipyridyl, acetohydroxamic
acid and EDTA) with MC-207110 1. Results showed that the efflux pump inhibitor
acted synergistically with all of the iron chelators to inhibit P. aeruginosa growth
and biofilim formation with the EDTA combination proving most effective.
Mpex Pharmaceuticals and GlaxoSmith Kline recently formed a worldwide
strategic alliance to discover and develop new antimicrobial combinations, consisting
of Mpex‘s EPIs and GSK‘s novel development stage antimicrobials (as well as
existing commercial antibiotics). The alliance aims to improve potency and broaden
the Gram-negative spectrum of antibacterial activity.65 Rempex Pharmaceuticals
H

H

have investigated a method for treating ophthalmic and otic infections caused by
Gram-negative pathogens that uses pentamidine to inhibit MDR pumps, including
the Mex pumps of P. aerugonisa. Combinations of pentamidine and β-lactams were
shown to be effective. Pentamidine is currently used for the treatment of
Pneumocystis carinii, Leishmania donovani, Trypanosoma brucei, T. gambiense and
T. rhodesiense infections. At concentrations of 10-20 µg/mL pentamidine potentiates
the activity of levofloxacin against resistant strains lowering its MIC 8-fold. Several
analogues of pentamidine and antimicrobials were also found to be effective.66
H

H

1.7.1 Inhibitors of the MexAB-OprM pump in P. aeruginosa
EPIs have been identified which bind pumps at sites distinct from those
involved in substrate binding.67 Conceptually, this should allow potentiation of the
H

H

activity of multiple classes of antibiotics. Structurally diverse compounds, such as
17

MC-510051 6 from Microcide and compounds from the pyridopyrimidine series
exemplified by 7 from Daiichi pharmaceuticals (Figure 1.7), specifically inhibit
MexAB-OprM. Compound 6 lowered the MIC of levofloxacin 4-fold against P.
aeruginosa at 0.625 µg/mL but moderate cytotoxcity (IC50 = 57 µg/mL in eukaryotic
cell lines) limited interest in the compound.68 The modified pyridopyrimidine
H

H

derivative D13-9001 8 (Figure 1.7) potentiates the activity of levofloxacin and
azetronam against a PAM1723 laboratory strain of P. aeruginosa. An 8-fold decrease
in the MIC of azetronam at 2 µg/mL was observed with the good potency attributed
to the compounds quaternary ammonium salt.

Figure 1.7 MexAB-OprM inhibitors MC-510051 6, pyridopyrimidine 7 and D139001 8.
1.7.2 Quinoline-based EPIs
A series of quinoline-based EPIs were discovered during a screening
campaign against MDR clinical isolates of Enterobacter aerogenes.69 The
H

H

compounds were shown to be potent inhibitors of the AcrAB-TolC pump complexes.
Compounds 814 9 and 733 10 (Figure 1.8) produced 16-fold decreases in the MIC of
chloramphenicol at 0.5 and 0.2mM concentrations, respectively. Notably, compound
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9 was found to accumulate in E. aerogenes EA27 cells to similar levels as MC207110 1.70
H

Studies by Mallea et al70 showed that the maximum exclusion space of
H

H

alkylaminoquinolines is 20Å, suggesting that they could fit into the central pore of
the AcrAB inner-membrane (internal diameter 35 Å). It was hypothesized that
inhibition could occur at the inner-membrane protein itself or at the junction of the
inner and outer membranes. Alkoxyquinolines 11 and thioalkylquinolines 12 (Figure
1.8) carrying piperidinoethyl chains were able to restore susceptibility to
chloramphenicol in E. aerogenes.71 Several pyridoquinoline derivatives were shown
H

H

to be potent potentiators in E. aerogenes strains affecting MarA-mediated efflux
processes. Among these derivatives, compound 13 (32 µg/mL) was effective at
restoring norfloxacin and ciprofloxacin accumulation and decreased their MICs by 8fold.71
H

Figure 1.8 Structures of alkylaminoquinoline, alkoxy, thioalkylquinoline and
pyridoquinoline EPIs.
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1.7.3 Substituted disiloxane, aryl piperazine and paromycin EPIs
Disiloxane compound SILA 421 14 (Figure 1.9) was shown to be a potent
inhibitor of efflux mediated antibiotic resistance in E. coli and showed intrinsic
antibacterial activity against multi-drug resistant tuberculosis (MDR-TB) at
concentrations not toxic to eukaryotic cells.72 1-(1-naphthylmethyl)-piperazine
H

H

(NMP) 15 (Figure 1.9) was shown to be a moderate reverser of MDR in clinical
strains of E. coli, enhancing the activity of levoflaxacin 4-fold.73 NMP 15 also
H

H

showed MDR reversal activity in clinical strains of Acinetobacter baumannni, C.
freundii and E. aerogenes (but not P. aeruginosa), enhancing intracellular
concentrations of linezolid, chloramphenicol, tetracycyline, macrolides and
fluoroquinolones.74 A comparison of the activities of NMP and MC-207110 1
H

H

showed that they differ in their spectrum of activity, suggesting their modes of action
are probably different. Unfortunately, aryl piperazines tend to have serotonergic
activity and appear too toxic for use in humans.51
H

The effectiveness of aminoglycoside antibiotics is gradually declining and
efflux by RND transporters, including AcrD of E.coli, MexXY-OprM of P.
aeruginosa and a few efflux pumps from the MFS superfamily, is playing a significant
role.51 The charged and hydrophilic aminoglycosides are easily captured in the
H

H

periplasmic space and extruded into the external medium through the OM channel.75
H

H

Several recent aminoglycoside analogues such as polyazaalkane, N-benzyl
polyaminoalkane, mixed N-benzylated poly (aza/amino) alkanes and paromycin have
been identified as EPIs. The compounds show high intrinsic activity against deleted
Acr strains of H. influenzae. The 2-chloro benzyl substituted paromycin analogue 16

20

(Figure 1.9) produced 4-fold decreases in the MIC of tetracycline, doxycycline and
gentamicin against H. influenzae.76
H

Figure 1.9 Structures of EPIs SILA421, NMP and a substituted paromycin.
1.8 EPIs in Gram-positive bacteria
1.8.1 Natural product EPIs
The anti-hypertensive plant alkaloid reserpine 17 (Figure 1.10), first isolated
from the roots of Rauwolfia vomitoria, shows EPI activity against Bmr pumps that
mediate tetracycline efflux in Bacillus subtilis. Bmr inhibition by reserpine is
achieved through binding to amino acid residues Phe-143 and Phe-306.77 In S.
H

H

aureus, where NorA is the major MDR transporter and causes significant decreases
in susceptibility towards fluoroquinolones, reserpine can reverse NorA (and Bmr)
mediated resistance towards norfloxacin and ciprofloxacin.78,79 Reserpine also
H

H

H

H

enhances the activity of norfloxacin against clinical strains of S. aureus (SA-1199
and SA1199B). Schimitz et al showed that reserpine reduces the MIC of
ciprofloxacin, norfloxacin and sparfloxacin 4-fold against S. aureus clinical isolates
and increases susceptibility of wild-type S. pneumoniae to fluoroquinolones.79
H

H

Initially it was thought that the observed potency increases of fluoroquinolones were
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due to inhibition of PmrA but the differences in fluoroquinolone accumulation by
mutant strains of S. pneumoniae R6N (efflux phenotype derived by alteration of R6
strain with DNA strain IN271) versus R6 (easily altered laboratory strain) suggested
that reserpine interacts with another protein.80 Reserpine cannot be used clinically
H

H

due to neurotoxicity issues but it is useful for exploring efflux susceptibility in new
and old antibiotics.81
H

It has been proposed that multiple plant-derived compounds may act in
combination to afford plants with antimicrobial defence while having little
antibacterial effect on their own.82 This key idea was investigated by Lewis et al
H

H

using the plant alkaloid berberine 18 (Figure 1.10). Berberine alkaloids are widely
spread throughout the plant kingdom and are commonly found in Barberry (Berberis)
plants. Berberine is the principal component of the medicinal plant golden seal
Hydrastis canadensis. The compound is a hydrophobic amphipathic cation that
exerts antibacterial effects by increasing membrane permeability and intercalating
into DNA.83,84 Due to its positive charge berberine would accumulate in bacterial
H

H

H

H

cells due to their negative membrane potentials, but hydrophobic cations are the
preferred substrate of many classes of MDR pumps. Lewis et al proposed that a
solution used by plants to overcome this efflux issue was to additionally synthesize
5-methoxy-hydnocarpin (5‘-HMC) 19. Lewis & Stermitz observed that 5‘-MHC has
no antimicrobial activity alone but potentiates the antibacterial activity of berberine
16-fold.85 The combination of (5‘-MHC) with berberine thus appears to provide a
H

H

potent antimicrobial combination and this intelligent solution in plants suggests that
antimicrobials used in combination with EPIs should be a useful approach for
treating bacterial infections in humans.85
H

H
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Other MDR inhibitors identified from natural sources include pheophorbide
20 (from Artemisa capillaris) and the milk thistle (Silybum marianum) flavolignan
silyban 21 (Figure 1.10), isolated as an isomeric mixture of 21a and 21b. These
compounds are also not antibacterial alone but produce synergistic effects with
berberine against NorA expressing S. aureus strains.79
H

H

Methoxyflavones chrysosplenol-D 22 and chyrysosplentin 23, isolated from
Aremisma annuaa, and isoflavones genistein 24, orobol 25 and biochanin 26 from
Lupinus argenteus, polyacylated neohesperidosides 27 and 28 from Geranium
species and chalcones 29 and stilbenes 30 from Dalea Versicolor all inhibit the NorA
pump in S. aureus and potentiate the activity of berberine (Figure 1.10). For
isoflavones the MIC of berberine is lowered 16-fold while for norfloxacin it is
reduced 4-fold. Polyacylated compound 28 increases the efficacy of berberine,
ciprofloxacin, norfloxacin and rhein, an antibacterial component of rhubarb, and
chalcone 29 potentiated the activity of berberine against S. aureus NorA knock out
strain that lacks NorA efflux pump. Compound 29 in combination with 30 enhanced
the activity of berberine against B. cereus 30-fold.79
H

H

A series of polyacylated oligosaccharides known as the orizabins 31-33
(Figure 1.10) show potentiation effects against the NorA over-expressing mutant S.
aureus strain SA-1199B.86 The amphipatic orazabin 31 increased the antibacterial
H

H

activity of norfloxacin 4-fold (8 mg/L from 32 mg/L), while orizabin 32 completely
inhibited growth of SA-1199B at 1 µg/mL in the presence of 2 µg/mL norfloxacin.
Ethidium bromide efflux inhibition assays using SA-1199B strains demonstrated that
orzabins 32 and 33 are nearly equipotent and show better activity at lower
concentrations (10 µM or less) than reserpine.86 The polyphenolic catechin gallates
H

H
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from tea (e.g. 34 and 35, Figure 1.10) have been shown to reverse methicillin
resistance in MRSA strains.87 Interestingly, these compounds are reported to activate
H

H

efflux at low concentrations suggesting that the transporter protein might have two
binding sites.88 Compound 35 was shown to enhance tetracycline activity 4-and 8H

H

fold, in Tet K resistant strains of S. epidermidis and S. aureus, respectively.79
H

H

Piperine 36 (Figure 1.10), a major plant alkaloid present in black pepper
(Piper nigrum) and long pepper (Piper longum) was identified as an EPI89 after
H

H

screening a library of approximately 200 piperine analogues. Several compounds
including SK-20 37 and SK-56 38 were found to be more potent inhibitors of the
NorA pump in S. aureus. In the presence of SK-20 37 or SK-56 38 at concentrations
of 6.25 µg/mL and 12.5 µg/mL respectively, ciprofloxacin activity was enhanced 4and 8-fold against strains SA1199 and SA119B.89
H

H

Recently Holler et al identified kaempferol-3-O-α-L-(2,4-bis-E-p-coumaroyl)
rhamnoside 39 (Figure 1.10) as an EPI using bioassay-guided (ethidium bromide
uptake) fractionation of ethanolic extracts of Persea lingue.90 At 1.56 mg/L the
H

H

compound increased the activity of ciprofloxacin 8-fold against Nor A enriched
everted membrane vesicles from E. coli. IC50 determinations showed the compound
is more potent than reserpine and at concentrations of 1.56 µg/mL it showed better
potentiation of fluoroquinolones than related methoxyflavones and isoflavones at 25
mg/mL and 6 mg/mL, respectively. The compound shows lower acute toxicity when
compared to other plant based EPIs.90
H

H
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Figure 1.10 Structures of selected natural product EPIs.
1.8.2 Synthetic EPIs
Sello et al91 showed that MC-207110 1 potentiates the activity of
H

H

chloramphenicol by inhibiting the two chloramphenicol-specific MFS efflux pumps
in Streptomyces coelicolor, a Gram-positive bacterium related to the human pathogen
Mycobacterium tuberculosis. The MIC of chloamphenicol decreased 8-fold in the
presence of MC-207110 1 at 75 µg/mL. Several dipeptide analogues of MC-002595
2 analogues synthesized by the same group identified BU-005 40 (Figure 1.11) as
being 3-fold more potent.91
H

Gibbons et al92 showed that GG918 41 (Figure 1.11), a synthetic inhibitor of
H

H

mammalian P-glycoprotein, was equipotent with reserpine in enhancing the in vitro
activity of norfloxacin and ciprofloxacin against S. aureus. At 10 µg/mL the
compound lowered the MIC of norfloxacin and ciprofloxacin 8-fold against the
NorA over-expressing strain SA-1199B, whereas in strain SA-K2068, which
expresses pumps distinct from Nor A, it reduced MICs by only 2-fold. GG918 41
and reserpine lowered the MIC of norfloxacin and ciprofloxacin 2-4 fold in strains
expressing MsrA and TetK proteins, which usually mediate resistance to macrolides
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and tetracylines, suggesting that several uncharacterised pumps for the two
antibiotics were inhibited.92
H

Compounds VX-710 42 and VX-853 43 (Figure 1.11) were identified as
mammalian pump inhibitors that increase drug accumulation in P-glycoproteinexpressing multi-drug resistant tumours.51 Vertex Pharmaceuticals commenced
H

H

Phase II trials with VX-710 42 as an adjuvant for use with the cancer treatments
paclitaxel, mitoxantrone or anthracycylines. Compound 43 was shown to have
acceptable toxicity and pharmacokinetics in humans and it was then proposed that
these compounds might be useful as efflux pump inhibitors in combination with
antibiotics. Both compounds potentiate the activity of several fluoroquinolones,
showing results similar to those observed with reserpine.93 In vitro studies suggested
H

H

that VX-710 42 is more consistently active than VX-853 43, however it was unable
to restore susceptibility in highly resistant clinical isolates.93
H

Figure 1.11 Structures of selected synthetic EPIs.
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Screening of 9,600 structurally unrelated compounds was carried out by the
Influx Inc. in searching for inhibitors of the NorA pump in S. aureus.81 Compounds
H

H

were initially tested at 20 µg/mL and a hit–rate of 4% (399 compounds) was
obtained. The major classes of active compounds included indoles (e.g INF55 44),
aromatic amides (e.g INF240 45) and bisaryl urea derivatives (e.g INF271 46).81
H

H

Other minor classes included compounds like INF277 47 and INF392 48.
Potentiation experiments revealed that INF55, IN271, INF240, INF277 and INF392
(Figure 1.12) are all potent NorA inhibitors, decreasing the MIC of ciprofloxacin
against S. aureus strain SA-1199 4-fold at concentrations of 0.2-1.5 µg/mL. The EPIs
were shown to be over 50-fold more potent than reserpine. Structure-activity studies
around INF55 reported by Samsorn et al
H

94
H

identified 49 as being equipotent with

INF55 at inhibiting the NorA pump, decreasing the MIC of berberine from 500
µg/mL to 2 µg/mL. Derivatives of INF55 50 and 51 (Figure 1.12) reported by
Ambrus et al were found to be slightly more potent inhibitors.95
H

H

Figure 1.12 Synthetic EPIs from Influx Inc. and some synthesised analogues of
INF55 44.
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This study highlighted the importance of the indole C5 position, where an electron
withdrawing group enhances activity. The importance of ortho and meta substituents
in the C2 aryl ring were also explored which showed varying effects.
Inhibition of the NorA pump in S. aureus by INF55 spurred Chabert et al to
investigate 2-arylbenzothiophenes, 2-arylbenzofuran and diarylthiophenes as EPIs.96
H

H

Several were found to inhibit the NorA pump, with compounds 52-55 (Figure 1.13)
restoring the efficacy of ciprofloxacin against resistant strains 1199B and ATCC
25923. The compounds decreased the MIC of ciprofloxacin (and ethidium bromide)
4-fold at 20 µg/mL. These compounds were not cytotoxic and hold some potential
for use as broad spectrum EPIs in combination with antimicrobials known to be
NorA substrates. Citral-derived synthetic amides 56 and 57 show NorA inhibitory
activity in S. aureus.97 Replacing the methyl group at the C9 position of 56 with a
H

H

formyl group to give 57 produced 4-fold reductions in the MIC of ciprofloxacin at 25
µg/mL.
Omeprazole 58 (Figure 1.13), a pump inhibitor thought to function by
interfering with proton gradients, restores the efficacy of various fluoroquinolones,
reducing their MICs 4-16 fold against various S. aureus strains.98 Vidallic et al
H

H

synthesized a series of 11 pyrrolo-[1,2-a]-quinoxaline derivatives based on
omeprazole and showed they are inhibitors of NorA. At 128 µg/mL these compounds
restored activity of norfloxacin against the NorA over-expressing strain SA-1199B.
Decreases in the norfloxacin MIC ranged from 4-16-fold. Compound 59 was the
most potent inhibitor, consistently decreasing the MIC 16-fold.99 Structure-activity
H

H

relationships revealed that the benzimidazole nucleus is essential for efflux inhibition
and that the halogen at position seven is also important.
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Screening of a 300,000-compound library by Brincat et al (using a
NorA/ethidium bromide efflux assay) identified four novel classes of NorA
inhibitors.100 The compounds AE-848/42434549 60, AN-465/42885978 61, AMH

H

807/41624543 62, AH-487/41139966 63, respectively (Figure 1.13), all displayed
synergistic activities with ciprofloxacin at concentrations above 6.25 µg/mL.

Figure 1.13 Selected synthetic efflux pump inhibitors against Gram-positive
bacteria.
1.9 EPIs effective against Gram-positive and Gram-negative bacteria
Some broad spectrum EPIs are known to function by interfering with
membrane energy processing in bacteria. For example, carbonyl cyanide mchlorophenylhydrazone (CCCP) 64 (Figure 1.14), can effect the viability of bacterial
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cells by halting efflux of various substrates.50 These compounds tend to be cytotoxic
H

H

however, and to date none have been explored for clinical development. Verapmil 65
(Figure 1.14) is an MDR reversing agent that blocks calcium transporters.101
H

H

Phenothiazines chlorpromazine 66a and prochloroperazine 66b potentiate the
activity of aminoglycosides and macrolides by inhibiting the BpeAB-OprB and
AmrAB-OprA efflux pumps in Bukholderia pseudomallei.102
H

H

Intrinsic multi-drug resistance in Salmonella enterica is due to overexpression of the ramA gene, which induces acrB mutants resistant to
chloramphenicol, tetracycline, nalidixic acid and triclosan.103 Chlorpromazine 66a
H

H

acts synergistically with common antimicrobials and increases ethidium uptake in S.
enterica strains and decreases acrB mutants, suggesting that phenothiazines can
influence gene expression in addition to acting as EPIs. Verapamil 65 is a wellknown inhibitor of human P-glycoprotein that also inhibits several bacterial ABC
transporters, including LmrA.104 The transporter genes drrAB expressed by
H

H

Mycobacterium smegmatis confer intrinsic resistance to structurally unrelated
antibiotics that is reversed by verapamil. The compound also enhances isoniazid
uptake in the ATP-dependant extrusion system of M. smegmatis and increases
intracellular accumulation of azithromycin in L. monocytogenes.105,106 It is
H

H

H

H

commonly used as a reference compound to evaluate efflux pump inhibition in
Gram-positive bacteria.50
H

1.9.1 Aryl piperidine inhibitors
Selective serotonin reuptake inhibitors (SSRIs), including the antidepressant
paroxetine 67 and its diastereomer 68 (Figure 1.14), interfere with the efflux activity
of NorA and MepA pumps in S. aureus and partially affect the RND AcrAB-TolC
31

pump in E. coli.107 SAR studies revealed the importance of spacer length between the
H

H

aryl and piperidine rings and that halo substitution at the aryl ring increases potency.
Dihaloaryl compound 69 (Figure 1.14) was shown to increase accumulation of
linezolid in E. coli at 64 µg/mL.108
H

H

Figure 1.14 Structures of selected compounds that inhibit pumps in both Gramnegative and Gram-positive bacteria.
1.9.2 Tetracycline and fluoroquinolone analogues as EPIs
In recent years the clinical efficacy of broad spectrum tetracycline antibiotics
has declined due to efflux susceptibility.109 Tetracycline efflux is mediated by
H

H

tetracycline resistance determinants A-E in enteric species of Gram-negative bacteria
and K and L class tet pumps in Gram-positive bacteria.109,110 Nelso et al identified
H

H

H

H

that 13-alkylthio derivatives of 5-hydroxy-6-deoxytetracycline 70 and 70a (Figure
1.15) inhibit tetracycline efflux in an inverted membrane vesicle assay. The
compounds produced synergistic activity with doxycycline against E. coli expressing
class A and B tetracycline determinants and showed intrinsic antibacterial activity
against S. aureus expressing tet pumps of class K and L. A greater inhibitory effect
32

was observed against Gram-positives than Gram-negatives.111 An alliance between
H

H

Partek pharmaceuticals and GlaxoSmithKline exploring novel tetracyclines showed
that 70 has intrinsic antibacterial activity against LPS-deficient E. coli, S. aureus and
Enterococcus hirae.112
H

H

Pfizer has reported a novel resistance reverser UK-57562-01 71 (Figure 1.15),
which at 50-100 µg/mL lowers the MIC of tetracycline against tetracycline resistant
Gram-negative pathogens Pasteurella haemolytica, P. multocida and E. coli. MIC
reductions of 8-32 fold were observed when treated with 0.5 x MIC UK-5762-01.
The effect of the compound on Gram-positive pathogens was less producing 4-fold
reductions. Attempts to confirm that the synergistic activity with tetracycline was
occurring through inhibition of the AcrA/B efflux pump were inconclusive, although
it was postulated that the synergy may has arisen via disruption of the outer
membrane channel.112
H

Efficacy of fluoroquinolone antibiotics used extensively in the treatment of
Gram-positive and Gram-negative pathogens has been declining in recent times due
to efflux mechanisms.113 Resistance is mediated mostly by Nor A and mep-A encoded
H

H

efflux pumps in Gram-positives and mexAB efflux pumps in Gram-negatives.113,114
H

H

H

H

Fluoroquinolone analogues 72-75 act as EPIs and are able to increase the
antibacterial activity of other antibiotics. SAR studies showed that modifications at
positions 1, 7, and 8 are important.51
H

H
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Figure 1.15 Tetracycline and fluoroquinolone analogues which show EPI activity
against both Gram-positive and Gram-negative bacteria.
1.10 Hybrids of EPIs and fluoroquinolone antibiotics
The above discussion demonstrates the promise of several classes of small
molecule pump inhibitors being used in combination with antibiotics as a method for
countering efflux-mediated resistance. A potential disadvantage of this approach,
however, is the requirement for matching the pharmacokinetic and physicochemical
properties of two structurally unrelated molecules when used clinically. One solution
to this problem being investigated is to covalently link the pump inhibitor and
antibacterial components together into a single non-cleavable hybrid molecule.115-119
H

H

H

H

Designed hybrids of this type carry the potential advantage of delivering equimolar
quantities of the two agents to bacterial cells whilst avoiding the complications
arising from co-administration.120,121 German et al115 have investigated several EPIH

H

H

H

H

H

antibacterial hybrids that incorporate EPIs INF271 46 and variants of PAβN 1/MC004124 3 at the C-7 position of fluoroquinolones. The hybrids 76-79 (Figure 1.16)
displayed modest activity against E. coli and P. aeruginosa. Compound 77 at 0.5 µM
34

was found to be a potent inhibitor of NorA and MepA pumps in S. aureus where at
10 µM more than 84% inhibition was achieved. Hybrids 78 and 79 containing
variants of MC-207110 1 showed little activity indicating that the extra aryl groups
in 1 are essential for activity.

Figure 1.16 EPI-antibacterial hybrids containing EPIs linked to fluoroquinolones.
1.10.1 Aminoquinoline EPI-antibacterial hybrids
Aminoquinolines are a class of EPIs that restore susceptibility of structurally
unrelated antibiotics, such as tetracycline, norfloxacin and chloramphenicol, by
inhibiting AcrAB-TolC pumps. Paulmed (SA) and CNRS (France) have patented a
large number of hybrids where aminoquinoline EPIs are covalently linked to various
antibacterials. Among the hybrids produced, compound 80 (Figure 1.17) containing a
cephalosporin displayed low oral toxicity (100 % survival in murine model of
septicaemia after administration of 100, 200, 400 mg/Kg) and showed synergistic
activities against Gram-positives. Hybrid 81 showed improved antibacterial activity
against Gram-positives such as, E. faecalis, B. subtilis, B. thuringiensis along with
ciprofloxacin resistant S. aureus strains. The compound also showed potency against
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some Gram-negatives, including E. coli, H. influenza, and P. aeruginosa. Other
hybrids studied were compounds 82-85 which showed greater activity than the parent
antibiotics against methicillin susceptible S. aureus (MSSA) and S. pneumoniae, but
minimal activity was observed against Gram-negatives.122
H

Figure 1.17 Aminoquinolone EPI-antibacterial hybrids.
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1.10.2 EPI-Berberine hybrids
In 2006 Bremner et al reported an EPI-antibacterial hybrid, termed o-SS14
86,116 comprising the antibacterial alkaloid berberine substituted at its 13-position
H

H

with a non-cleavable 2'-CH2 linkage to 5-nitro-2-phenyindole 44 (INF55), the
known inhibitor of NorA (see section 1.8.2).81 In designing o-SS14 it was reasoned
H

H

that the berberine moiety could elicit its antimicrobial effects (membrane activity
and interactions with DNA)83 whilst the INF55 component served to inhibit NorA
H

H

and reduce efflux of the hybrid. o-SS14 was shown to accumulate in wild-type,
NorA-knockout and NorA over-expressing strains of S. aureus and to have higher
antibacterial potency than either berberine alone or berberine in combination with
INF55.116 A follow-up study by the same group explored the effects of varying the
H

H

relative orientation of the antibacterial and pump-blocking components in these
hybrids by comparing activities of the isomers o-SS14 86, m-SS14 87 and p-SS14
88 (Figure 1.18).123
H

H

Figure 1.18 Structures of Berberine-INF55 hybrids.
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The three hybrid isomers showed remarkably similar MICs, which were
essentially unchanged against wild-type, NorA knockout, and NorA over-expressing
S. aureus cells, suggesting that the compounds are not substrates for NorA. The
three hybrids also showed similar accumulation levels in S. aureus cells and curative
effects in a Caenorhabditis elegans live infection model. Another study from
Bremner et al exploring an o-SS14 analogue carrying a methylene ether linkage
(compound 89 Figure18) showed that this compound shows similar activity (MIC =
1.7 M) that remains unchanged against the three S. aureus strains.
Studies with SS14-type hybrids aimed at raising their antibacterial potency
(Chapter 2) and probing their mechanism of action (Chapter 3) are the focus of
Section A in the thesis.
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Section 1
Synthesis and Biological Evaluation of
Berberine-INF55 Hybrid
Antimicrobials

53

sChapter 2
Synthesis and Preliminary Evaluation of a Prototype Berberine–
INF55 Dual-Action Prodrug
2.1 Background
Prodrugs are pharmacologically inert precursors of parent drug molecules that
require enzymatic or chemical transformation within the body to release the active
(parent) drug. This is usually accompanied by release of a pharmacologically inert
promoiety (Figure 2.1).1 Many prodrug strategies aim to mask undesirable properties
H

H

such as poor absorption, bioavailability/solubility etc. in drug candidates. The
promoiety linked to the parent drug serves to improve these properties or overcome
other barriers in delivering drugs to their target site(s). Linkers are often designed so
that the drug is released under specific conditions, such as in the presence of a tissuespecific enzyme or by a change in pH. Esters are the most common linkages
employed because they are easily synthesized and can be readily hydrolysed either
chemically or by esterases in the blood, liver and other organs. Other common
linkers include amides, disulfides, thioethers and oxime/imines.2
H

Prodrugs have become a powerful and versatile tool in drug discovery and
their application often results in enhanced therapeutic effects. Several prodrugs are
used clinically;3 for example valacyclovir, a prodrug of acyclovir, is used for the
H

H

treatment of shingles in immunocompromised patients.4
H

H
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Figure 2.1 Illustration of the prodrug concept.
Dual-action prodrugs are an emerging area of interest in drug discovery.
These are composed of two drug molecules linked via a cleavable tether, which is
designed to be chemically or enzymatically cleaved in vivo to simultaneously release
both active molecules, which can subsequently act upon their respective targets. In
the field of antimicrobials it is possible to conceptualise the use of prodrugs to create
the ―perfect antimicrobial‖. As shown in Figure 2.2, a perfect antimicrobial prodrug
might consist of a carrier linked via a cleavable tether to a ―masked reagent.‖ If the
prodrug were able to enter bacterial cells and then undergo a reaction selectively
inside these cells, the highly reactive unmasked reagent (e.g electrophile, radical,
etc.) could undergo reaction with cellular components leading to death of the cell.
The advantages of this approach are three-fold: (1) release of the reactive species
would be localised to the interior of bacterial cells, thereby minimising any effects on
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host cells and associated toxicity, (2) cleavage of the prodrug inside of bacterial cells
would drive additional prodrug into the cell (according to the Lechatelier‘s
equilibrium principle) to enhance the toxic effect and (3) use of a non-selective
highly reactive species in killing cells would minimise the potential for development
of target-based resistance. Furthermore, it may also be possible to take advantage of
the ―carrier‖ moiety in the prodrug to provide some additional function, thus creating
a dual-action prodrug.

Figure 2.2 Illustration of the ―perfect‖ antimicrobial‖ concept.
2.2 Design principles for Dual-Action Berberine-INF55 Prodrugs
The previous studies from the Bremner/Kelso groups demonstrated the
promising antibacterial properties of Berberine-INF55 hybrid antibacterials
(compound 86-89, Chapter 1.10.2).5,6,7 All of these hybrids contained the
H

H

H

H

H

H

antibacterial berberine linked to the Nor A pump-blocking INF55 moiety via a non56

cleavable tether. The hybrids all showed good activities against bacterial cells (S.
aureus in particular) but invariably their MICs were above 10 µM. If the compounds
are to be advanced towards clinical utility these MICs should ideally be lowered into
the sub-micromolar range. This section of thesis work aimed to create novel dualaction prodrugs of SS14-type molecules in efforts aimed at lowering these MICs.
The principals of creating the ―perfect antimicrobial‖ were applied when designing
the compounds.
The mechanistic rationale for designing the prototype SS14-type dual-action
prodrug is summarised in Scheme 2.1. Compound 90 in Scheme 2.1 comprises
berberine linked via its 13-position to INF55, as found in the SS14 hybrid series.
However, the linkage in 90 is now a carbamate attached to INF55 via the indole
nitrogen. It is known that berberine itself intercalates into DNA and previous work
from the Bremner/Kelso groups showed that hybrids also interact with DNA.8 Upon
H

H

DNA binding, nucleophillic sites in the DNA, such as the guanine N7, could thus
conceivably react with the electrophilic C8 of the berberine portion of 90, triggering
release of the INF55 44 moiety according to the mechanism shown. The driving
force for the reaction would be mostly entropic due to formation of multiple
molecular species and release of CO2. The relatively low basicity of the 5-nitro-2phenyl indole nitrogen anion leaving group was considererd less likely to hinder this
mechanism than attachment of the carbamate at any other portion on the INF55
molecule. Reaction of the prodrug with DNA and ejection of INF55 could
conceivably produce a highly electophilic species 91, which in turn could undergo
non-specific reactions with nearby cellular nucleophiles to produce toxic effects. A
second guanine base, for example could then react via its N7 atom with the exocyclic
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alkene carbon to produce covalently cross-linked DNA, which should be toxic to
bacterial cells. Other cellular nucleophiles such as protein thiol and amino groups
could also conceivably react with the electrophillic species to produce the toxic
effects inside bacterial cells.
The proposed mechanism for the SS14 prodrug 90 parallels the requirements
of a ―perfect antimicrobial.‖ The prodrug should accumulate in bacterial cells as
previously demonstrated with other SS14 hybrids. Ideally this accumulation would
occur selectively in bacterial cells and not eukaryotic cells due to the INF55 portion
blocking the Nor A pump, which is not found in human cells. The reaction leading to
release of INF55 would drive further entry of prodrug into bacterial cells via Le
chatalier‘s principle, leading to an increased toxic effect. The released INF55 unit
might also enhance accumulation of the prodrug due to its blocking effect on the
NorA pump, serving the ―other function‖ role described in Figure 2.2 Intermediate
91 would serve as the ―highly reactive species.‖

Scheme 2.1 Proposed mechanism of berberine-INF55 prodrug activation inside
bacterial cells.
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2.3 Attempted synthesis of dual-action berberine-INF55 prodrug 90
The proposed route towards 90 is shown in Scheme 2.2. The route invokes
the known tendency of 8-allyl berberine 94 or 13-acetonyl berberine 94 to react as
carbon-nucleophiles via their enamine function with alkyl halides of various types,
with the alkylated products subsequently undergoing re-aromatisation to yield 13substituted berberines.10 The proposed synthesis required preparation of the
previously unreported N-halomethylcarbamoyl INF55 derivative 92 (or 93).

Scheme 2.2 Proposed synthesis of 90.
2.3.1 Synthesis of N-Chloromethylcarbamoyl-INF55 92
N-acylation of INF55 44 with chloromethyl chloroformate was investigated
in the presence of various bases acting to deprotonate the indole N-H, including
BuLi, NaH, KOH, NaOH, and K2CO3. The best conditions identified used 1.5 eq
NaH in anhydrous THF followed by dropwise addition of a solution of
chloromethylchloroformate (1.0 eq) in anhydrous THF at room temperature. The
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chloromethyl carbamate 92 was obtained in 50 % yield after column chromatography
(EtOAc:hexane, 1:4).

Scheme 2.3 Synthesis of N-chloromethyl carbomyl-INF55 92; Reagents and
conditions: (a) NaH, anhydrous THF, chloromethylchloroformate, rt, 50%.
The structure of 92 was confirmed by 1H NMR and high resolution mass
spectroscopy. The 1H NMR spectrum revealed the presence of a chloromethyl CH2
signal at 5.76 ppm and loss of the NH signal at 11.19. This suggested that acylation
had occurred at the indole nitrogen. The presence of a characteristic signal at 6.75
ppm attributed to the indole H3 further confirmed N-acylation. The structure of 92
was supported by high resolution ESI mass spectrometry, with a peak at m/z
353.0305 observed corresponding to the C16H11ClN2O4 [M + Na] + ion.
2.3.2 Attempted coupling of N-chloromethylcarbamoyl INF55 92 with 8allyberberine 94 and 8-acetonyl berberine 95
Coupling of the key precursor 92 with 8-allylberberine 94 and 8-acetonyl
berberine 95 was attempted using the procedure that had previously been developed
for the synthesis of SS14 hybrids.9 8-Allylberberine or 8-acetonyl berberine, were
H

H

prepared by the literature methods10,11 and heated with 92 to 80-110 oC in CH3CN in
H

H

H

H

a sealed tube and the reaction monitored by TLC (Pet. Sprit:EtOAc, 2:1).
Unfortunately, no evidence for the formation of 90 was observed by TLC, 1H NMR
or ESI MS in any of the reactions attempted. Catalytic NaI (10 mol %) was added to
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several reactions in an attempt to generate the potentially more reactive Niodomethylcarbamoyl INF55 93 in situ but again no evidence was observed for the
formation of the target prodrug 90. The decision was then made to synthesise, isolate
and purify the iodide 93 before submitting it to reactions with 8-allyl berberine 94 or
8-acetonyl berberine 95.
2.4 Synthesis of N-iodomethylcarbamoyl INF55 93
The chloromethylcarbmate 92 was converted to the iodide 93 in 79% yield
using Finkelstein conditions (i.e. excess sodium iodide, (5.0 eq) in anhydrous
acetone). The reaction was monitored by mass spectrometry and NMR. The 1H
NMR spectrum of the product revealed that after overnight reflux the methylene CH2
signal had shifted from 4.2 ppm to 4.5 ppm. 13C NMR spectroscopy showed that the
methylene CH2 of the product had moved upfield to 31.0 ppm from 70.0 ppm,
consistent with formation of 93. Additional confirmation of the structure was
obtained from high resolution electrospray mass spectrometry, which showed a peak
at m/z 422.9839 corresponding to the C16H12IN2O4 [M + H+] ion.

Scheme 2.4 Synthesis of N-iodomethyl carbamoyl-INF55 93; Reagents and
conditions: (a) NaI, acetone, reflux 79%.
Unfortunately, all attempts to react 93 with 8-allyl berberine 94 or 8-acetonyl
berberine 95 were also unsuccessful. Only trace amounts of the product was ever
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observed by mass spectrometry so at this stage the synthesis of prodrug 90 was
abandoned.
2.5 Redesign of berberine-INF55 prodrug target
The unsuccessful synthesis of 90 led us to re-evaluate the prodrug design in
the search for a more synthetically accessible target. While 90 was considered the
ideal target for the reasons outlined in Section 2.2, compound 96 was considered a
reasonable alternative. According to Scheme 2.5, entry of prodrug 96 into bacterial
cells and binding to DNA could result in reaction of the electrophilic berberine C8
with the nucleophilic N7 of a guanine base, as described earlier for 90. Electron
movement could then lead to release of INF55, potentially driven by production of
two gases, CO2 and ethylene (C2H2). Generation of the highly electrophilic DNAbeberine intermediate 90 and release of INF55 would be expected to produce toxic
effects inside bacterial cells, as described in Section 2.2.

Scheme 2.5 Proposed mechanism of activation of berberine-INF55 prodrug 96.
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2.6 Synthesis of berberine-INF55 prodrug 96
The route chosen to pursue towards 96 is shown in Scheme 2.6. The strategy
revolved around preparing the key bromoacetyl ester intermediate 98, which could
be subjected to reaction with 8-acetonyl berberine 95 (or 8-allyl berberine 94) to
afford 96. The final reaction was predicted to proceed well based on results from a
previous UOW PhD student, Siritron Samosoron, who‘d shown that bromoacetyl
esters can undergo reaction with allyl berberine 94.12
H

H

The ethanol spacer was attached to the indole-NH of INF55 44 by Nalkylation using 2-bromoethanol (3 eq) in acetone with 10N NaOH as base. The
reaction was monitored by TLC (EtOAc:hexane, 1:1) and found to be 95% complete
after 18 h. Workup and purification by silica gel column chromatography afforded 97
in 40% yield. 1H NMR spectroscopy confirmed introduction of the ethanol spacer,
which confirmed the disappearance of the INF55 44 NH signal at δ 11.19 and the
appearance of new signals at 3.86 ppm and 4.37 ppm corresponding to the ethyl CH2
protons. New carbon signals at δ 42.8 and 61.8 in the 13C spectrum further supported
introduction of the ethyl group. A peak at m/z 281.0938 observed in the high
resolution mass spectrum corresponding to the molecular formula C16H13N2O3 [MH]- supported formation of 97.
Acylation of the alcohol 97 with bromoacetyl chloride proceeded smoothly
affording the bromoacetyl ester 98 in 55% isolated yield. In this reaction, alcohol 97
was stirred for 15 min at room temperature in anhydrous THF with potassium tertbutoxide (1.5 eq) before adding a solution of bromoacetyl chloride (1.5 eq) in THF
dropwise and stirring for a further 1 h. Formation of 98 was supported by 1H NMR
which showed the presence of a new signal at 3.56 ppm consistent with introduction
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of the CH2Br group. New 13C signals at 25.2 ppm and 160.9 ppm, corresponding to
the CH2Br and ester CO groups respectively, further supported formation of 98.
The key bromoacetyl ester intermediate 98 underwent the expected reaction
with 8-acetonyl berberine 95 to afford the desired target (bromide salt), which was
subsequently converted to the chloride salt 96 using a quaternary ammonium anion
exchange resin in an overall yield of 20%. The reaction was carried out by heating 98
and 95 in anhydrous CH3CN in a sealed vial at 60 oC for 3-4 h in the presence of 10
mol % NaI. Column chromatography using EtOAc:hexane (1:1) followed by
EtOAc:hexane:CH3CN (2:2:1) and finally trituration with pentane:methanol (3:1)
afforded pure 96.

Scheme 2.6 Synthesis of berberine-INF55 prodrug 96. Reagents and conditions: (a)
2-bromoethanol, 10N NaOH, acetone, reflux, 40%;

(b) KtOBu, bromoacetyl

chloride, THF, rt, 55% (c) (i) NaI (10 mol %), CH3CN, 60 oC; (ii) IRA-904
quaternary ammonium Cl- anion exchange resin, MeOH, rt, 20%.
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The structure of 96 (chloride salt) was confirmed by NMR spectroscopy and
mass spectrometry. The 1H and

13

C spectra showed characteristic signals for the

berberine, 5-nitro-2-phenyl-indole and ethyl ester portions. The spectra confirmed
loss of the H13 alkene signal of 95 at 5.8 ppm and loss of protons corresponding to
the acetonyl moiety at 2.02, 2.3 and 2.92 ppm. Downfield shifting of the H8 signal
from 5.2 to 10.16 ppm confirmed rearomatisation of the isoquinoline ring. Signals at
3.56 and 4.03 ppm confirmed introduction of the ethyl spacer. Downfield shifting of
the 13C NMR signal for the bromomethyl CH2 group of 98 from 25.2 to 36.9 ppm and
shifting of the carbonyl peak from 160.9 to 170.0 ppm provided further support for
the structure. A peak at m/z 659.2261 observed in the high resolution electrospray
mass spectrum corresponded to the expected C38H33N3O8 [M+H+] ion of 96.
2.7. Antibacterial activity of berberine-INF55 Prodrug 96 against S. aureus
strains with varying NorA expression levels
Antibacterial activity of the berberine/INF55 prodrug 96 was evaluated by
Chao Chen, a Ph.D student in the lab of Prof Kim Lewis at Northeastern University
(Boston, USA). Minimum inhibitory concentrations (MICs) were determined against
a panel of the three S. aureus strains which had been used in previous studies with
SS14 hybrids; i.e. wild type 8325-4, NorA knockout K1758 and NorA
overexpressing K2378 cells. The prodrug showed equivalent MICs against the 83254 and K1758 cell lines (5.6 µM) and a 2-fold higher MIC against K2378 (MIC =
11.23 µM). The very similar MICs for 96 against all three strains (< 2-fold
difference) suggest that like all previous SS14 hybrids the prodrug is not a substrate
for NorA. While the potency of 96 was quite good it was not significantly better than
previous hybrids, suggesting that the proposed mechanism of prodrug activation and
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the ―perfect antimicrobial‖ concept (Section 2.2) were probably not coming into
play. Lack of success with 96 and problems identified in the synthesis of 90 forced
us to abandon the prodrug approach in order to focus on the other aspects of the
thesis.
2.8 Experimental
2.8.1. Chemistry General
Reagents and solvents were used without further purification unless otherwise
stated. All solvents were of analytical reagent (AR) grade. THF and diethyl ether
were dried over sodium and acetonitrile was dried over calcium hydride. INF55 44
was synthesized according to the literature procedure.13 Chloromethyl chloroformate
H

H

was purchased from ABCR GmbH & Co. 2-Phenyl indole, NaH, potassium-tertbutoxide, berberine chloride, 2-bromoethanol, bromoacetyl chloride and palladium
(II) chloride were purchased from Sigma-Aldrich. NaI was purchased from Ajax.
Solvents were removed under reduced pressure (in vacuo) with a Buchi rotary
evaporator attached to a vacubrand CVC2 pump. Solvent residues were removed in
vacuo using a Javac Vector RD-90 double state high vacuum pump. Analytical thin
layer chromatography (TLC) was carried out on Merck 0.2 mm silica gel 60 F254
coated aluminium plates. Compounds were visualised by UV absorbtion (λ 254 nm).
Column chromatography was performed on Merck silica gel 60 (230-400 mesh).
Low resolution electrospray ionisation mass spectra (ESI-MS) were obtained on a
micromass Z-path (LCZ) platform spectrometer. Electron impact high resolution
mass spectra (HRMS) were obtained on a Fisions/VG Autospec spectrometer using
perfluorokerosene as internal standard. ESI HRMS were obtained on a Waters QT
Ultima spectrometer using polyethylene glycol or polypropylene glycol as internal
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standard. 1H, 13C NMR and all 2D-NMR experiments were performed using a Varian
Mercury 300 MHz, Varian Inova 500 MHz or Varian Premium Shielded 500 MHz
spectrometer at 25 oC. Chemical shifts are reported as δ (ppm) relative to internal
TMS (or solvent where indicated). The abbreviations Ar = aryl, s = singlet, d =
doublet, appt = apparent triplet, t = triplet, q = quadruplet, m = multiplet and bs =
broad singlet are used throughout. Compounds are named according to IUPAC
conventions. Previously unreported compounds are annotated with the letter a (as
superscript) following the compound name. Previously reported compounds with
only limited characterisation data available are indicated with the letter b (as
superscript) along with the appropriate reference. Previously reported compounds
that have been fully characterised are annotated with the letter c (as superscript)
along with the appropriate reference. This general chemistry experimental
information also applies in Chapters 3, 4 and 5.
5-nitro-2-phenyl-1H-indole 44c,13
H

H

Synthesis of INF55 was adapted from Noland et al.13
To a stirred solution of 2-phenylindole (5.0 g, 25.9
mmol) in H2SO4 (700 mL) was cooled to -10 oC and
NaNO3 (2.42 g, 28.47 mmol) in H2SO4 (250 mL) was added dropwise over 3-4 h at 10 oC. The reaction was monitored by TLC (EtOAc:hexane, 1:1). Upon completion
the reaction mixture was poured on to a large amount of crushed ice in a 2L beaker
(Caution: Care should be taken due to the large amount of heat produced from the
exothermic acid heat of dissolution) and extracted with EtOAc (3 x 500 mL). The
combined organic extracts were washed with water and brine, dried over anhydrous
Na2SO4 and concentrated vacuo to afford 44 in (5.6 g, 91%) as a yellow solid. 1H
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NMR (500 MHz, CD3COCD3): δ 7.18 (s, 1H, H3), 7.40 (m, 1H, H4‘), 7.51 (t, J = 7.5
Hz, 2H, H3‘), 7.58 (d, J = 9.0 Hz, 1H, H6), 7.92 (d, J = 9.0 Hz, 2H, H2‘), 8.04 (d, J
= 9.0 Hz, 2H, H7‘), 8.57 (s, 1H, H4), 11.19 (bs, NH). ESI-MS m/z Calc. for
U

U

C14H11N2O2 [M+H+] 239.0821; observed 239.0815.
Chloromethyl 5-nitro-2-phenyl-1H-indole-1-carboxylate 92a
To a stirred solution of INF55 44 (500 mg, 2.1 mmol)
in anhydrous THF (15 mL) was added sodium hydride
(100 mg, 4.2 mmol) and the reaction stirred at room
temperature for 30 min. Dropwise addition of
chloromethyl chloroformate (0.28 mL, 3.2 mmol) in anhydrous THF (7 mL) was
added to the reaction mixture over 10-15 min. The reaction mixture was stirred for an
additional 1 h with progress of the reaction monitored by TLC (EtOAc:hexane, 1:4).
If starting material still remained another 1.0 eq of sodium hydride was added,
followed by slow addition of another 1.0 eq of chloromethyl chloroformate. Upon
completion, the reaction was quenched with saturated sodium sulfate solution (10
mL) and diluted with EtOAc (20 mL). The organic layer was separated, washed with
water and brine and dried over MgSO4 before being concentrated in vacuo. The crude
was purified by silica gel flash column chromatography (EtOAc:hexane, 1:4) to
produce 92 as a yellow solid (347 mg, 50%). mp 117-119 oC ; 1H NMR (500 MHz,
CDCl3): δ 5.76 (s, OCH2Cl), 6.75(s, 1H, H3), 7.45 (m, 5H, H2‘- H4‘), 8.23 (d, J =
U

U

9.0 Hz, 1H, H6), 8.31 (d, J = 9.0 Hz, 1H, H7), 8.45 (s, 1H, H4);

13

C NMR (125

MHz, CDCl3): δ 70.0 (OCH2Cl), 111.5 (C3), 115.5(C7), 116.6 (C4), 119.9 (C6),
U

U

128.0 (C4‘), 128.8 (C2& C3‘), 129.4 (C9), 132.1 (C1‘), 140.0 (C5), 143.3 (C2‘),
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144.4 (C8),149.0 (C=O); ESI-MS m/z Calc for C16H11ClN2NaO4 [M + Na+]
353.0305; observed 353.0402.
Iodomethyl 5-nitro-2-phenyl-1H-indole-1-carboxylate 93a
To a solution of 92 (200 mg, 0.60 mmol) in anhydrous
acetone was added sodium iodide (629 mg, 4.2 mmol)
and the reaction mixture was refluxed for 16 h. The
reaction could be monitored by 1H NMR spectroscopy.
The product was concd in vaccuo. The residue obtained was purified by silica gel
flash column chromatography (EtOAc:hexane, 1:3) to yield 93 as an off white solid
(201 mg, 79%). mp 119-120 oC; 1H NMR (500 MHz, CDCl3): δ 5.93 (s, OCH2I),
U

U

6.73 (s, 1H, H3), 7.41-7.46 (m, 5H, H2‘- H4‘), 8.25 (d, J = 9.0 Hz, 1H, H6), 8.32 (d,
J = 9.5 Hz, 1H, H7), 8.46 (s, 1H, H4);13C NMR (125 MHz, CDCl3): δ 31.0 (OCH2I),
U

U

111.7 (C3), 115.9 (C7), 117.0 (C4), 120.3 (C6), 128.4 (C4‘), 129.1 (C2‘), 129.2
(C3‘), 129.4 (C9), 132.4 (C1‘), 140.3 (C5), 143.5 (C2‘), 144.7 (C8), 149.3 (C=O);
ESI-MS m/z Calc for C16H12IN2O4 [M + H+] 422.9842 observed 422.9839.
1-(9,10-dimethoxy-6,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2a]isoquinolin-8-yl)propan-2-one 95b,11
H

H

The synthesis of 95was adapted from the method of
Ki Duk Park et al.11 To a solution of 5 N NaOH (4.6
H

H

mL) was added berberine chloride (1.25 g, 3.36
mmol) and the reaction was stirred at room
temperature for 10 min, before adding acetone (1mL)
dropwise and stirring for a further 1 h. The reaction mixture was filtered and the
solid washed with water (10mL), 80% MeOH and recrystallised from methanol to
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afford 95 (1.05 g, 80%). mp 159-163 °C; 1H NMR (500 MHz, DMSO-d6): δ 2.02 (s,
COCH3), 2.3 (dd, J = 4.0 Hz, 1H, Hb), 2.6 -2.7(m, 2H, H5), 2.92 (dd, J = 4.0 Hz, 1H,
U

U

Ha), 3.1-3.2 (m, 2H, H6), 3.76 (s, 6H, H9a, H10a), 5.2 (t, J = 5.5 Hz, 1H, H8), 5.985.99 (m, 3H, H13 & OCH2O), 6.73 (d, J = 8.5 Hz, H12), 6.74 (s, 1H, H4), 7.24 (s,
1H, H4);

13

CNMR (DMSO-d6, 125 MHz) δ 29.4 (C5), 30.1 (COCH3), 45.6 (CHa
U

U

U

U

&Hb), 46.5 (C6), 53.8 (C8), 55.7 ( C10a), 60.1 (C9a), 94.8 (C13), 100.9 (OCH2O),
U

U

103.9 (C1), 107.8 (C4), 112.1 (C11), 118.1 (C8), 123.1 (C8a), 124.9 (C1a), 127.3
(C9), 128.6 (C4a), 137.8 (C13a), 143.07 (C9), 146.2 (C2), 146.8 (C4), 149.4 (C10).
ESI-MS m/z Calc for C23H24NO5 [M + H]+ requires 394.1654 Found 394.1662.
2-(5-nitro-2-phenyl-1H-indol-1-yl)ethanol 97b
To a stirred solution of INF55 44 (500 mg, 2.1 mmol) in
acetone (10 mL) was added 10N NaOH (20 mL) and 2bromoethanol (0.3 mL, 4.2 mmol) and the reaction
mixture was heated at reflux for 16 h. The reaction
could be monitored by TLC (EtOAc:hexane, 1:4). An additional 2 eq of 2bromoethanol may need to be added for completion of the reaction. Water (10 mL)
and 2N HCl were added to the reaction mixture to pH 6 and extracted with EtOAc (3
x 10 mL). The combined organic extracts were washed with water and brine and
theorganic layer dried over anhydrous MgSO4 and concentrated in vacuo. The crude
material was purified by silica gel flash column chromatography using
EtOAc:hexane (1:4) to produce 97 as an off yellow to pale-green solid (236 mg,
40%). mp 120-122 o C; 1H NMR (500 MHz , CDCl3): δ 3.86 (bt, 2H, H1‘‘), 4.37 (t, J
= 11.0 Hz , 2H, H2‘‘), 6.71 (s, 1H, ArH3), 7.49-7.5 (m, 6H, Ar H1‘,H2‘,H3‘,H7),
8.18 (d, J = 8.5 Hz, 2H, ArH6), 8.57 (s, 1H, ArH4); 13C NMR (500MHz; CDCl3): δ
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42.8 (C1‘‘), 61.8 (C2‘‘), 104.9 (C3), 110.3 (C7), 117.5 (C6), 117.8 (C4), 127.5 (C2),
129.0 (C1‘), 129.1 (C3‘), 129.9 (C2‘), 131.8 (C9), 140.8 (C5), 142.1 (C1‘), 145.0
(C8). ESI-MS m/z Calc. for C16H13N2O3 [M-H-] 281.0926; observed 281.0938.
2-(5-nitro-2-phenyl-1H-indol-1-yl)ethyl 2-bromoacetate 98a
To a stirred solution of 97 (700 mg, 2.47 mmol) in
anhydrous THF (10mL) was added potassium-tertbutoxide (693 mg, 2.5 mmol). Stirring was continued
for 15-20 min before adding bromoacetyl chloride (0.3
mL, 3.7 mmol) in anhydrous THF (5 mL) dropwise for
10-15 min and stirring at rt for 1 h. Reaction progress
was monitored by TLC (EtOAc:hexane, 1:4). Upon completion the reaction mixture
was quenched with saturated NH4Cl solution (20 mL) and extracted with EtOAc (3 x
10 mL). The combined organic extracts were washed with water, brine and the
organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The
crude residue was purified by silica gel column chromatography using
EtOAc:hexane (1:9) to afford 98 as light yellow solid (550 mg, 55%); 1H NMR (500
MHz, CDCl3): δ 3.56 (s, 2H, H4‘‘), 4.31-4.55 (m, 4H, H1‘‘, H2‘‘), 6.72 (s, 1H,
ArH3), 7.46 (m, 6H, Ar H1‘,H2‘,H3‘,H7), 8.15 (d, J = 8.5 Hz, 2H, ArH6), 8.57 (s,
1H, ArH4);

13

C NMR (500MHz; CDCl3): δ 25.2 (C4‘‘), 42.8 (C1‘‘), 64.4 (C2‘‘),

105.4 (C3), 109.9 (C7), 117.7 (C6), 117.9 (C4), 127.6 (C2), 129.1 (C1‘), 129.3 (C3‘),
129.7 (C2‘), 131.5 (C9), 140.6 (C5), 142.3 (C1‘), 144.4 (C8), 160.9 (C=O).

71

9,10-dimethoxy-13-(2-(2-(5-nitro-2-phenyl-1H-indol-1-yl)ethoxy)-2-oxoethyl)5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 96a
To a stirred solution of bromide 98 (70 mg, 0.173
mmol) in anhydrous CH3CN (7 mL) was added
sodium iodide (31.1 mg, 0.207mmol) and the
reaction was heated to 80 oC and stirred for 1.5.
Acetonyl berberine 95 (68.0 mg, 0.173 mmol)
was added to the reaction mixture and stirring
continued at 80 ºC for 4-5 h. Progress of the
reaction was monitored by TLC EtOAc: hexane: Acetone (2:2:1). Following
completion the reaction mixture was filtered through silica gel with copious CH3CN
and the combined filtrate concentrated under reduced pressure. Purification was
achieved by column chromatography on silica gel using EtOAc:hexane (1:1)
followed

by

EtOAc:hexane:CH3CN

(2:2:1)

and

finally

washed

with

pentane/methanol (3:1) to yield 96 as a green to pale-yellow solid (24 mg, 20%). mp
183-185 oC; 1H NMR (500 MHz, CDCl3): δ 3.22 (bt, 2H, H5), 4.03 (s, 2H, Hd), 4.03
(s, 3H, H10a), 4.35 (s, 3H, H9a), 4.4 (t, J = 4.5 Hz, 2H, Ha), 4.61 ( t, J = 5.0 Hz,
2H,Hb), 4.98 (bs, 2H, H6), 6.69 (s, 2H, OCH2O), 6.86 ( m, 2H, H4‘‘, H4), 7.14 (d, J
= 9 Hz, 1H, H7‘), 7.43 (d, J = 4.5 Hz, 1H, H12), 7.44-7.48 (m, 5 H, H2‘‘, H3‘‘, H1),
7.61 (d, J = 9.5 Hz, 1H, H11), 7.97 (d, J = 8.5 Hz,, 1H, H6‘), 8.52 (s, 1H, H4‘), 10.16
(s, 1H, H8);13C NMR (500MHz; CDCl3): 28.1 (C5), 36.9 (Cd), 42.7(Ca), 56.8 (C10a,
OCH3),

57.6 (C6), 62.9 (C9a, OCH3), 64.1 (Cb), 102.1 (C4‘), 105.0 (C3‘), 108.7

(C1), 108.7 (C4), 109.9 (C7‘), 19.4 (C8a), 117.25 (H6‘), 117.4 (H4‘), 118.8 (C12),
121.3 (C13), 124.9 (C2‘), 125.8 (C11), 127.3 (C9‘), 129.0 (C2‘‘), 129.2 (C4‘‘), 129.3
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(C3‘‘), 131.1 (C1‘‘), 133.0 (C12a), 133.8 (C10), 137.4 (C1a), 140.4 (C4a), 141.9
(C8‘), 144.45 (C5‘), 146.02 (C9), 146.49 (C8), 147.35 (C2), 150.21 (C3), 150.45
(C13a), 170.0 (CO); ) ESI-MS m/z Calc. for C38H33 N3O8+ [M+H]+ 659.2262 found
659.2261.
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Chapter 3
Exploring the Mechanism of Berberine-INF55 (5-Nitro-2Phenylindole) Hybrid Antibacterials
3.1 Background
The studies from the Bremner/Kelso described in Section 1.10.2
demonstrated the potential of the berberine-INF55 class of hybrid anti-bacterials but
they didn‘t establish whether the compounds function as originally designed; i.e.
with the INF55 moiety functioning to block MDR pumps (e.g. NorA) and the
berberine moiety providing antibacterial action. The aim of this study was to
disconnect these activities and establish whether the proposed mechanism was
indeed underpinning the activity of the hybrids. Central to the study was the
hypothesis that if the proposed mechanism were at play then there should be some
correlation between the ability of an INF55-type MDR inhibitor to potentiate the
antibacterial activity of berberine and the corresponding activity of a hybrid
incorporating the same MDR inhibitor. In other words, INF55-based MDR
inhibitors that more strongly potentiate the antibacterial activity of berberine should
produce more potent berberine-INF55 hybrids.
Exploring this hypothesis required identification of INF55 44 analogues
which: (1) show differing berberine antibacterial potentiation effects and (2) could be
attached at the berberine 13-position to create hybrids varying only in the structure of
the INF55 component. Checkerboard assays1 carried out by Chao Chen at
H

H

Northeastern University in 8325-4 wild-type, K1758 NorA knockout, and K2378
NorA overexpressing S. aureus cells identified N-Me-INF55 100 and N-Me-INF55
lacking the indole 5-nitro group 101 as suitable INF55 analogues for this study
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(section 3.3.1). This chapter reports the synthesis (my work) and parallel
microbiological evaluation of hybrids 88, 110 and 117, which incorporate INF55 44
and its analogues 100 and 101 respectively (Figure 3.1), alongside their
corresponding berberine/44, 100, 101 combinations in multiple assays (performed at
Northeastern University and Massachusetts General Hospital, Boston) with the aim
of exploring the above hypothesis.

Figure 3.1 Structures of INF55 44, its analogues 100 and101 and corresponding
berberine-INF55 hybrids 88, 110 and 117.
3.2 Synthetic chemistry
3.2.1 Synthesis of INF55 analogues 100 and 101
The synthesis of INF55 44 and its analogues 100 and 101 is summarised in
Scheme 3.1. INF55 44 was obtained in 91% yield via regioselective 5-nitration of 2phenyl indole 99 according to the literature method.2 N-methylated INF55 derivative
H

H

101 was prepared in 80% yield by stirring INF55 44 for two hours at room
temperature with K2CO3 and CH3I in anhydrous DMF. N-methyl-2-phenylindole 101
was prepared in 80% yield by deprotonating 2-phenylindole in anhydrous THF with
NaH at room temperature followed by addition of CH3I and stirring for 2 h.

76

Scheme 3.1 Synthesis of INF55 and analogues. Reagents and conditions: (a) NaH,
CH3I, THF, 80%; (b) NaNO3, H2SO4, -10 °C, 91%;2 (c) K2CO3, CH3I, DMF, 80%.
3.2.2 Synthesis of key intermediate 109
The previously reported synthesis of SS14-P 883 involved reacting 8H

H

allyldihydroberberine with the advanced bromide intermediate 109, which in turn
was prepared via indole 5-nitration and functional group manipulations on the
methyl ester precursor 106. In the prior work, 106 was synthesized from indole and
methyl-4-iodobenzoate using the rhodium (III)-catalysed direct NH-indole C2arylation method reported by Sames et al.4 While this reaction invariably provided
H

H

some of the 2-arylated indole it was found to be an unpredictable reaction when
repeated multiple times, providing product that was difficult to purify and highly
variable yields (max. 28%). An alternative approach to 106 was therefore developed
in this section of thesis work using a more traditional Stille coupling approach to
install the functionalised aryl group at the indole 2-position.
Stille coupling of N-Boc-2-tributylstannylindole 104 (prepared in three steps
via the literature method)5 and methyl-4-iodobenzoate with PdCl2 in refluxing 1,4H

H

dioxane proceeded smoothly to afford 105 in 84% yield (Scheme 3.2). Bocdeprotection of 105 using CH2Cl2:TFA (1:1) subsequently afforded the NH-indole
106 in 79% yield. While the new sequence towards 106 (Scheme 3.2) was longer
than the original route it was found to be practical to carry out and reproducible on a
multi-gram scale.
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Scheme 3.2 Synthesis of intermediate 109. Reagents and conditions: (a) (BoC)2O,
DMAP, THF, rt, 91%;5 (b) n-BuLi, -80 °C, Sn(Bu)3Cl, 48%;5 (c) PdCl2, 1,4-dioxane,
H

H

H

H

methyl-4-iodobenzoate,5 100 °C, 84%; (d) TFA:CH2Cl2 (1:1); 79%; (e) NaNO3,
H2SO4, -10 °C, 79%;3 (f) LiBH4, THF, 40 °C, 70%;3 (g) CBr4, PPh3, THF:Et2O (1:1),
H

H

H

H

75%.3
H

Compound 107 was obtained in 79% yield via regioselective nitration of
indole 106 according to the literature method.3 The presence of a singlet signal at
H

H

8.60 ppm in the 1H NMR spectrum corresponds to the H4 proton of indole,
confirming regioselective nitration at the C5 position. This spectrum was consistent
with the reported 1H NMR data. Selective ester reduction of compound 107 to its
corresponding alcohol 108 was achieved using 4-5 equivalents of LiBH4 in
anhydrous THF at 40-50 oC in 70% yield. LiBH4 needed to be added portionwise for
complete reaction to occur. Loss of the OCH3 signal and the presence of CH2 signal
at 4.5 ppm in the 1H NMR spectrum of 108 confirmed reduction of the ester group.
Loss of the CO signal at 166.7 ppm in the

13

C spectrum provided further evidence.

High resolution mass spectrometry showed a peak at m/z 267.0765 corresponding to
C15H11N2O3 [M-H]- ion. Alcohol 108 was brominated under standard conditions
using CBr4 and PPh3 in THF:ether (1:1) to afford the key intermediate 109 in 75%
yield (Scheme 3.2). The 1H NMR spectrum of 109 was consistent with the reported
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literature.3 A peak at m/z 328.9934 observed in the high resolution electro spray mass
H

H

spectrum corresponded to the expected C15H10BrN2O2 [M-H-] ion.
3.2.3 Synthesis of Berberine-INF55 hybrids 88 and 110
The synthesis of SS14-P 88 was approached through reactions of 8-acetonyl
dehydroberberine 95 with key bromo intermediate 109. Finkelstein bromide to iodide
exchange on 109 with 10 mol% NaI followed by in situ addition of 8-acetonyl
dihydroberberine 95 produced hybrid SS14-P 88 in 40% yield after preparative RPHPLC (Scheme 3.3). Prior to RP-HPLC purification, the compound was pre-purified
using silica gel column chromatography, initially using EtOAc:CH3CN:hexane
(1:1:1) followed by EtOAc:CH3CN:MeOH (1:1:0.3). Preparative RP-HPLC was
carried in the presence of HCl to provide initially mixed Cl-/Br- salts of 88. The
mixture of salts was converted to the pure Cl- salts by stirring 88 with a quaternary
ammonium chloride anion exchange resin in CH3OH at room temperature.
The structure of 88 (chloride salt) was confirmed by NMR and mass
spectrometry. The 1H and 13C spectra showed characteristic signals for the berberine
and 5-nitro-2-phenyl-indole portions. The spectra confirmed loss of the H13 signal of
acetonyl berberine at 5.8 ppm. Downfield shifting of the H8 signal from 5.2 to 10.2
ppm confirmed rearomatisation of the isoquinoline ring. Downfield shifting of the
13

C NMR signal for the bromomethyl CH2 group of 109 from 33.9 to 36.3 ppm in 88

provided further support for the structure. A peak at m/z 659.2261 observed in the
high resolution electrospray mass spectrum corresponded to the expected
C35H28N3O6+ molecular ion. These data were consistent with the reported.3
H

Hybrid 88 was subsequently converted to the N-methyl derivative 110 using
excess of methyl iodide and K2CO3 in DMF. The mixture of Cl-/I- salts initially
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obtained

after silica gel column chromatography using

CH3CN:EtOAc:MeOH

(1:1:0.5) was converted to the pure Cl- salt using a quaternary ammonium chloride
anion exchange resin affording pure 110 in 75% yield.

Scheme 3.3 Synthesis of hybrids 88 and 110 Reagents and conditions: (a) (i) NaI,
80 oC; (ii) IRA-904 quaternary ammonium Cl- anion exchange resin, MeOH, 40%;
(b) MeI, K2CO3, DMF, IRA-904 quaternary ammonium Cl- anion exchange resin,
MeOH, 75%.
The structure of 110 (chloride salt) was supported by NMR and mass
spectrometry data. Signals corresponding to both the berberine and 2-aryl-5-nitro-Nmethyl indole portions of 88 were evident in the 1H NMR spectrum. A singlet at 3.9
ppm and loss of the NH signal of 88 at 13.0 ppm confirmed methylation at the indole
nitrogen. The NOESY spectrum of 110 showed correlations between NCH3 and H7‘
and H2‘‘ (Figure 3.2). Several other informative NOE correlations were observed
including between the methylene proton H5‘‘ to H12 and H1. These confirmed
attachment of INF55 to the berberine 13-position (Figure 3.2). Additional
confirmation of the structure was obtained from high resolution electrospray mass
spectrometry which showed a peak at m/z 600. 2122, corresponding to C36H30N3O6
for 110.
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Figure 3.2 Structure of 110 showing some observed NOESY cross-peaks.
3.2.4 Synthesis of Berberine-INF55 hybrid 117
Synthesis of hybrid 117 involved reacting 8-acetonyldehydroberberine 95
with key halo intermediates 115 or 116. These intermediates were prepared over 5
steps (Scheme 3.4) starting from indole. Indole 102 was N-methylated under standard
conditions using sodium hydride and excess methyl iodide in anhydrous THF
affording N-methyl the compound 111 in 85% yield. Indole 2-tributylstannylation
was performed according to the reported method.5 Lithiation of N-methyl indole 111
H

H

with n-butyllithium at -78 °C followed by trapping of the 2-lithioindole with
tributyltin chloride provided N-(methyl)indol-2-yl]tributylstannane 112 in 75% yield.
The 1H NMR spectrum of 112 was consistent with the reported data.5 PdCl2
H

H

catalysed Stille coupling of 112 with 4-iodomethylbenzoate afforded 113 in 75%
yield. Formation of 113 was supported by 1H NMR which showed an absence of
butyl protons from the stannane and the presence of singlet at 3.94 which supported
introduction of the methyl ester group. New carbon signals at 52.1, 128.9, 129.7,
137.2, 138.6 and 166.7 ppm in the 13C spectrum further supported formation of 113.
A peak at m/z 266.1173 observed in the high resolution electrospray mass spectrum
corresponded to the expected C17H16NO2 [M+H+] ion.
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Reduction of methyl ester 113 with LiAlH4 in anhydrous THF under gentle
reflux conditions gave the corresponding benzylic alcohol 114 in 85% yield. LiAlH4
needed to be added in portions otherwise the reaction did not proceed to completion.
The 1H NMR spectrum confirmed ester reduction with the methyl ester signal at 3.94
ppm disappearing and a new CH2 signal appearing at 4.72 ppm. The

13

C NMR

spectrum showed an absence of carbon signals at 52.1 and 166.7 ppm corresponding
to the OCH3 and C=O signals, respectively. A new carbon signal at 64.9 ppm from
the CH2 carbon confirmed formation of 114.
The alcohol 114 was brominated under standard conditions using CBr4 and
PPh3 in DCM followed by immediate flash chromatography on neutral alumina.
Gradient elution with 100% hexanes to EtOAc:hexane (3:7) afforded the key
precursor 115 in low yields (~ 20%). It was observed that the low yield was due to
decomposition of the unstable bromide. Bromide 115 was therefore immediately
taken into the next reaction. 1H NMR analysis supported formation of 115 through an
upfield shift in the methylene CH 2 protons from 4.72 in 114 to 4.54 ppm in 115. An
upfield shift of the methylene carbon from 62.6 to 33.1 ppm in the

13

C NMR

spectrum further supported formation of 115.
The alternative chloro precursor 116 was prepared by treating 114 with CCl4
:DCM (1:1) and stirring for 10 min, followed by addition of PPh3 (4 eq). TLC
analyses using EtOAc:hexane (8.5:1.5) indicated formation of 116.

Upon

completion of the reaction the mixture was filtered through a plug of neutral alumina
and washed with DCM (3 x 5 mL). The filtrates were concentrated in vacuo and the
residue triturated with pentane to afford the crude 116 in moderate yields (65%). The
material was used immediately and not fully characterised due to its instability.
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Scheme 3.4 Synthesis of 117. Reagents and conditions: (a) MeI, NaH, THF, rt, 85%;
(b) n-BuLi, -78 C, Sn(Bu)3Cl 75%;5 (c) 4-iodomethylbenzoate, PdCl2, THF 80 oC,
H

H

75%; (d) LiAlH4 , THF, 50 oC, 85%; (e) CBr4, PPh3, DCM, 20%; (f) CCl4, PPh3,
DCM (crude yield 65%); (g) (i) NaI, 80 oC; (ii) IRA-904 quaternary ammonium Clanion exchange resin, MeOH, 40%.
The final step in the synthesis of 117 was carried out using a similar
procedure to the one used for preparing 88 (Scheme 3.4). The halo precursors 115 or
116 were subjected to Finkelstein conversion to the iodide using 10 mol% NaI,
before in situ addition of 95. 117 was produced in similar yields (40%) when reacted
with either bromo 115 or chloro 116 precursor. The reaction however, was more
practical to carryout with the chloro precursor allowing production of more material.
Prior to RP-HPLC, the crude 117 mixture was purified by silica gel column
chromatography using EtOAc:CH3CN:hexane (1:1:2) initially followed by
EtOAc:CH3CN:CH3OH (1:1:0.1) to afford 117 (~90% purity) in 60% yield. Further
purification of 117 by preparative RP-HPLC was then carried out in the presence of
HCl to provide initially mixed Cl-/Br- salts. This mixture was then converted to the
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pure Cl- salt by stirring with a quaternary ammonium chloride anion exchange resin
in CH3OH at room temperature, affording the final 117 Cl- salt in 40 % yield.
Formation of hybrid 117 was supported by 1H NMR spectroscopy, which showed
loss of the C13 signal at 5.8 ppm. Downfield shifting of the H8 signal from 5.2 to
9.20 ppm confirmed rearomatisation of the isoquinoline ring. Downfield shifting of
the 13C NMR signal for the bromo/chloro methyl CH2 group of 115 from 4.53 to 5.01
ppm supported formation of 117. NOE correlations between H5‘‘ and H1 and H12
were observed confirming attachment of the INF55 portion to berberine. Other
correlations between the NCH3 and H7‘& H2‘‘ were observed, along with NOEs
between H11 and H10a. A series of sequential NOEs from H4 to H5, H5 to H6 and
H6 to H8 were also observed (Figure 3.3). A peak at m/z 555.2289 observed in the
high resolution electrospray mass spectrum corresponding to C36H31N2O4+ for 117.

Figure 3.3 Structure of hybrid 117 showing key NOE cross-peaks observed in the
2D-NOESY spectrum.
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3.3 Microbiological evaluation
Microbiology experiments were carried out by Chao Chen at Northeastern
University (Boston, USA) and Jonah Larkins-Ford at Massachusetts General
Hospital (Boston).
3.3.1 Checkerboard assays in S. aureus cells with varying NorA expression
levels
Complete growth inhibition was observed in all three S. aureus strains
(8325-4 wild-type, K1758 NorA knockout, and K2378 NorA overexpressing) with
INF55 44 at 1.25 µg/mL in the presence berberine at concentrations below 20
µg/mL. INF55 analogues 100 and 101 at 1.25 µg/mL did not inhibit growth of 83254 and K1758 cells in the presence of berberine at the highest concentration tested
(125 µg/mL) respectively. Growth inhibition of K2378 cells was observed with 100
and 101 at 1.25 µg/mL, but only when berberine was present at 125 µg/mL. N-MeINF55 100 did not inhibit 8325-4 growth at the highest concentration of pump
inhibitor tested (80 µg/mL) with berberine present at 125 µg/mL. These results are
consistent with the following rank order of ability of the three pump inhibitors to
potentiate the antibacterial effects of berberine: INF55 44 > des-nitro-N-Methyl
INF55 101 > N-Methyl INF55 100.
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Figure 3.4 Checkerboard assays comparing potentiation of berberine‘s antibacterial
effects by INF55 44 (♦), 100 (■) and 101 (▲) against (a) 8325-4 wild-type, (b)
K1758 NorA knockout and (c) K2378 NorA overexpressing S. aureus cells.
3.3.2 Anti-bacterial activity of hybrids 88, 110 and 117 against S. aureus strains
with varying NorA expression levels
The checkerboard results indicated that berberine potentiation by the three
INF55-based NorA pump inhibitors 44, 100 and 101 decreases in the order 44 > 101
> 100. Accordingly, if the stated hypothesis is correct (Section 3.1) then hybrids 88,
110 and 117, which incorporate the NorA pump inhibitors 44, 100 and 101,
respectively, should show antibacterial effects in the rank order 88 > 117 > 110. The
minimum inhibitory concentration (MIC) for complete inhibition of bacterial growth
was measured for hybrids 88, 110 and 117 against the same panel of three S. aureus
strains with varying NorA expression levels described above. Vancomycin was
included as a positive control (Table 3.1). All three hybrids showed identical MICs
(0.78 µg/mL) against 8325-4 and K2378 and 2-fold higher potencies (0.39 µg/mL)
against K1758. The MIC of vancomycin was 1 µg/mL against all three strains.
Consistent MICs (< 2-fold difference) for the hybrids across the panel of S. aureus
strains with varying NorA expression levels confirmed that they are poor substrates
for NorA. The lack of variation in MICs for 88, 110 and 117 within each individual
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species and across the entire panel is a feature that has been observed with previous
hybrids from Bremner/Kelso Groups (section 1.10.2), providing further support that
the molecular target(s) of berberine-INF55 hybrids is(are) tolerant of structural
variations within the INF55 portion. However, lack of variation in the MICs of
hybrids 88, 110 and 117 contradicts the above hypothesis which, if correct, should
have produced measurable variations in the hybrid MICs in the rank order 88 < 117
< 110.
S. aureus
strains
8325-4

K1758

K2378

Compound

MIC
(μg/ml)

88

0.78

110

0.78

117

0.78

vancomycin

1

88

0.39

110

0.39

117

0.39

vancomycin

1

88

0.78

110

0.78

117

0.78

vancomycin

1

Table 3.1 Minimum inhibitory concentrations (MIC) of hybrids 88, 110, and 117
and vancomycin (control) against wild-type (8325-4), NorA knockout (K1758) and
NorA overexpressing (K2378) S. aureus strains.
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3.3.3 Uptake of compounds into S.aureus cells with varying NorA expression
levels
Uptake of hybrids 88, 110, 117, berberine and berberine in the presence of
INF55 44 and analogues 110 and 117 into 8325-4, K1758 and K2378 S. aureus cells
was compared using the previously reported fluorescence-based method.6 Binding
of berberine or hybrids to DNA (intercalation) upon entering cells causes an
increase in fluorescence at 517 nm (excitation at 355 nm), while expulsion of
compounds from cells via efflux leads to lower fluorescence intensity, thus
providing a qualitative measure of compound efflux susceptibility. Figure 3.5
indicates that berberine (3 µM) alone does not accumulate significantly in any of the
three S. aureus strains, consistent with its high efflux susceptibility. Low berberine
uptake into the NorA knockout strain K1758 suggests that pumps other than NorA
also must contribute to its efflux. Uptake of berberine did not increase in any of the
strains in the presence of equimolar 101 and only modest increases were observed in
all strains when compounds 44 and 100 were present. These results suggest that Nor
A inhibition by INF55 44 and analogues 100 and 101 has only a minor effect on
berberine uptake, possibly due to the action of other pumps not affected by these
inhibitors. Nonetheless, the ability of INF55 analogues (44 in particular) to
potentiate the antibacterial activity of berberine (Figure 3.4) suggests that this
seemingly slight effect on accumulation is sufficient to confer berberine with robust
antibacterial effects.
Significantly larger increases in fluorescence were observed with hybrids 88,
110 and 117 (3 µM), confirming that they accumulate to a much greater extent than
berberine or berberine in the presence 44, 100 and101. Uptake of each hybrid was
88

consistent across the three strains further confirming that each is not a substrate for
NorA (in agreement with the MIC data, Table 3.1).

Figure 3.5 Uptake of hybrids 88 (◊), 110 (□), 117 (∆), berberine (●) and berberine
in the presence of 44 (♦), 100 (■) and 101 (▲) into (a) 8325-4 wild-type, (b) K1758
NorA knockout and (c) K2378 NorA overexpressing S. aureus cells. Uptake was
measured by monitoring fluorescence at 517 nm (excitation at 355 nm) and is
expressed in arbitrary fluorescence units (A.U). All compounds were present at 3
µM.
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For these experiments it was necessary to confirm that the high fluorescence
produced by hybrids was due to increased bacterial cell uptake and not due to
increased

fluorescence

intensity

of

hybrid/DNA

complex(es)

relative

to

berberine/DNA complex(es). Cell-free control measurements were thus carried out to
compare the fluorescence upon binding to calf thymus DNA (CT-DNA) of hybrids
88, 110, 117, berberine and berberine in the presence of 44, 100 and 101. Figure 3.6
shows that the complexes formed between all three hybrids and CT-DNA exhibited
less fluorescence than berberine/DNA complexes, supporting the conclusion that
higher cellular accumulation of 88, 110 and 117 in S. aureus cells must have
occurred compared to accumulation of berberine alone or berberine/44,100,101
mixtures.

Figure 3.6 Increases in 517 nm fluorescence (excitation 355 nm) upon binding of
hybrids 88 (◊), 110 (□) and 117 (∆), berberine (●) and berberine in the presence of 44
(♦), 100 (■) and 101 (▲) to calf thymus DNA. All compounds were present at a
concentration of 3 µM.
3.3.4 Antibacterial activity against Methicillin-Resistant S. aureus and
E. faecalis
Part of the microbiological evaluation conducted with the compounds was to
investigate and compare the effects of hybrids and berberine/EPI combinations in
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two separate C. elegans live infection models (performed by collaborators at
Massachusetts General Hospital, Boston). These two models involve infecting C.
elegans with either Methicillin-resistant S. aureus (Strain MW2) or E. faecalis (strain
MMH594) and measuring survival of the worms relative to controls. As part of the
workup to performing those experiments it was necessary to measure the MIC of
each compound (including berberine, pump inhibitors and hybrids) against the two
bacterial strains in liquid cultures. These results are tabulated in Table 3.2.

Bacterial
strains

Compound

MIC
(μg/ml)

berberine

50

44

> 100

100

> 100

MRSA

101

> 100

MW2

88

3.13

110

3.13

117

< 1.56

vancomycin

< 1.56

berberine

> 100

44

> 100

100

> 100

E. faecalis

101

> 100

MMH594

88

3.13

110

3.13

117

3.13

vancomycin

< 1.56

Table 3.2 Minimum inhibitory concentrations (MIC) of INF55 44, analogues 100
and 101 and hybrids 88, 110 and 117 and vancomycin (control) in liquid cultures of
MRSA MW2 and E. faecalis MMH59.
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Berberine was found to show an MIC of 50 µg/mL against MRSA MW2 and
slightly reduced potency (MIC 100 µg/mL) against E. faecalis MMH594. All three
pump inhibitors 44, 100 and 101 showed no activity against either strain when
administered alone at < 100 µg/mL. Once again it was observed that the three
hybrids 88, 110 and 117 showed very similar activities to one another against both
antibacterial strains. The hybrids all showed MICs of 3.13 µg/mL against both
strains, except 117, which showed an MIC of 1.56 µg/mL against MW2.
In the workup to performing the two live infection models it was also
necessary to carry out checkerboard assays to explore the potentiation effects of
berberine in the presence of INF55 44 and analogues 100 and 101 against MW2 and
MMH594 in liquid cultures. These results are shown in Figure 3.7.

Figure 3.7 Checkerboard assays comparing potentiation of berberine‘s antibacterial
effects by INF55 44 (♦) and analogues 100 (■) and 101 (▲) in liquid cultures of: (a)
MRSA MW2 and (b) E. faecalis MMH594.
INF55 44 again proved to be the most potent berberine potentiator of the
three pump inhibitors. Concentrations of 44 above 25 µg/mL with low concentrations
of berberine present (< 10 µg/mL) killed all S. aureus MW2 cells. Identical activity
to 44 was observed with 101 against these cells, while 100 was clearly a less potent
berberine potentiator requiring > 50 µg/mL to show any effect. All three pump
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inhibitors were less effective potentiators against E. faecalis MMH594 cells.
Concentrations of 44 greater than 50 µg/mL were required to produce any effect in
these cells, along with higher concentrations of berberine. Compound 101 showed
weaker activity than 44, requiring at least 100 µg/mL to show an effect. Compound
100 showed no potentiation effects at the highest concentrations tested.
These results support the following rank order of berberine potentiation
activity against MRSA MW2 and E. faecalis MMH594 for the three pump inhibitors:
INF55 44 >101> 100. This order is in agreement with the rank order observed
against the three S. aureus strains 8325-4, K1758 and K2378 (Section 3.3.1).
3.3.5 Activity of compounds in two C. elegans live infection models
A C. elegans/MRSA MW2 live infection model has been developed by our
collaborators at Massachusetts General Hospital (Boston). Details of the model are
yet to be published. Briefly, C. elegans worms are infected with MRSA MW2 and
their survival monitored over several days. In the absence of antimicrobials the
worms all die during the course of the experiment (reported as 0 % survival, Figure
3.8a). In the presence of vancomycin all of the worms survive making this drug an
effective positive control.
Varying concentrations (0-200 µg/mL) of berberine, pump inhibitors INF55
44, 100 and 101 and hybrids 88, 110 and 117 were submitted to the assay to
investigate their effects on worm survival. Berberine was found to produce increased
survival relative to the negative control (DMSO 2%) at concentrations above 50
µg/mL, consistent with its MIC against this species (Table 3.2). None of the pump
inhibitors 44, 100 or 101 showed any creative effect at any of the concentrations
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tested. The three hybrids all showed robust curative effects but there was no
statistically significant difference between them.

Figure 3.8 Rescue of C. elegans worms infected with (a) MRSA MW2 and (b) E.
faecalis MMH594. Worms were treated with increasing concentrations of berberine,
INF55 44 and analogues 100, 101 and hybrids 88, 110, and 117. All concentrations
are in µg/mL. Vancomycin and tetracycline were included as positive controls in the
MRSA and E. faecalis experiments, respectively. DMSO was included as a negative
control in both experiments.
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The C. elegans/E. faecalis infection model developed by our collaborators at
MGH is very similar to the MRSA model, with details having been previously
reported.6 C. elegans worms are infected with E. faecalis MMH594 and their
H

H

survival monitored over several days. In the absence of antimicrobials all worms die,
whereas in the presence of the positive control antibiotic (tetracycline) all worms
survive. Administration of berberine and all three pump inhibitors 44, 100, and 101
produced no significant survival over the concentration range 0-200 µg/mL. The lack
of an effect with berberine in this case was consistent with its poor activity (MIC >
100 µg/Ml) against E. faecalis MMH594 in liquid cultures (Table 3.2). The three
hybrids 88, 110 and 117 once again all showed strong curative effects at
concentrations above 6.25µg/mL, but there were no significant differences in activity
between the compounds.
3.3.6. Conclusions and future directions
This study aimed to test the hypothesis that berberine-INF55 hybrid
antibacterials impart their antibacterial activities via their two components exerting
their individual effects; i.e. berberine acting to kill bacterial cells while the INF55
portion serves to block the NorA (and potentially other) pumps to decrease efflux of
hybrids. Preliminary checkerboard experiments with three S. aureus strains varying
in NorA expression levels identified INF55 analogues 100 and 101 as pump
inhibitors with berberine potentiation potencies lower than INF55 44 making them
suitable compounds for testing the hypothesis. These compounds were then
synthesized as described in Section 3.2.1. Berberine-INF55 hybrid antibacterials
incorporating each of the three pump inhibitors 44, 100 and 101 (i.e. hybrids 88, 110
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and 117, respectively) were then successfully synthesised for the study using a mix
of literature and newly developed chemistry.
Examining the activity of the hybrids against strains of S. aureus carrying
varying levels of NorA showed that the compounds show essentially identical
activities against all three strains, contradicting the proposed hypothesis. Uptake of
the hybrids into the same S. aureus strains was confirmed using fluorescence-based
cell assays, where it was also shown that uptake of berberine into these cells is not
greatly increased in the presence of pump inhibitors 44, 100 and 101. The final C.
elegans live MRSA and E. faecalis infection experiments clearly demonstrated a
robust curative effect from each of the hybrids in both models. No significant
difference in worm survival was observed between the three hybrids in either model.
This confirmed that while there are significant differences in the berberine
potentiation potencies of the three pump inhibitors, these do not produce
corresponding differences in antibacterial effects in the corresponding berberine–
INF55 hybrids. It can now be concluded that the mechanisms of antibacterial action
of these hybrids must be different to the mechanisms at play when berberine is coadministered with INF55-based pump inhibitors.
Other 13-susbstituent berberine derivatives including 13-alkylberberines (e.g.
13-ethyl berberine) show higher antibacterial activity than berberine.7 For example
H

H

structure-activity relationships revealed that by simply increasing the alkyl chain
length from methyl to ethyl in 13-substituted berberines reduces MIC 2-fold.7 DNA
H

H

binding studies of 13-phenyl alkyl berberines8,9 revealed that by increasing alkyl
H

H

H

H

chain length upto a threshold length of 3, enhances intercalative binding affinity.
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Further studies with berberine-INF55 hybrids which examine their DNA binding
properties would therefore seem warranted.
3.4. Experimental
3.4.1. Chemistry−General
The general Chemistry information was as described in Section 2.8.1. 2Phenyl indole 99, indole 102, methyl iodide, tributyltinchloride, n-butyl lithium,
palladium(II) chloride, carbontetrabromide, triphenylphosphine, lithium aluminium
hydride, lithium aluminium borohydride and IRA-904 quaternary ammonium Clanion exchange resin were purchased from Sigma-Aldrich. Boc anhydride was
purchased from Auspep, 4-Iodomethyl benzoate was synthesised by MeOH/H2SO4
(cat.) esterification of 4-iodo benzoic acid, which was purchased from Matrix
scientific. Synthesis of INF55 44 was as described in Section 2.8.1. Compound 111
was prepared by stirring indole 102 with NaH (4-5 eq) in anhydrous THF for 15 min
and then adding methyl iodide (4-5 eq) in THF dropwise over 30 min, with stirring
continued for 3 - 4 h. Standard work-up conditions afforded pure 111 in 85% yield.
Compound 112 was synthesized according to the procedure of Labdie et al.4
RP-HPLC purifcations of hybrids 88, 110 and 117 was performed using
gradient elutions with solvents A (100% H2O, 0.1% HCl) and B (90% CH3CN, 10%
H2O, 0.1% HCl) on a Sunfire TM Prep C18 OBDTM (5µM) steel jacketed column run
at 20 mL.min-1. Analytical HPLC analysis were perfomed using a Shimadzu CLASSLC10 VP HPLC system with detection at 254 nm. The analyses were performed
using gradient elution with solvent A and B on a Phenomenex Luna µM C18 column
run at 1mL. min-1 with detection at 254 nm.
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Previously unreported compounds are annotated with the letter a (as
superscript) following the compound name. Previously reported compounds that
were synthesised using new methadologies are annotated with b superscripts.
Previously reported compounds that have been fully characterised are annotated with
the letter c (as superscript) along with the appropriate reference.
1-methyl-5-nitro-2-phenyl-1H-indole 100b
To a stirred solution of INF55 44 (1g, 4.198 mmol) in
anhydrous DMF (10 mL) was added oven dried K2CO3
(1.74 g, 12.6 mmol) and stirred for 15-20 min at rt.
Methyl iodide (0.8 mL, 12.6 mmol) in DMF (5 mL) was
then added dropwise at rt and stirred for 1-2 h. The progress of the reaction was
monitored by TLC (EtOAc:hexane, 1:4). The reaction mixture was diluted with
water and was extracted with EtOAc (3 x 10 mL), the organic layer was washed with
water and brine and dried over anhydrous Na2SO4 before concentrating in vacuo to
afford 100 as a yellow solid (847 mg, 80%). mp 175-178 oC; 1H NMR (300 MHz,
CDCl3): δ 3.80 (s, 3H, OCH3), 6.71 (s, 1H, H3), 7.37 (d, J = 6.0 Hz, 1H, H7), 7.487.51 (m, 5H, H2‘-H4‘), 8.14 (d, J = 6.0 Hz, 1H, H6), 8.58 (s, 1H, H4); 13C NMR (75
MHz, CDCl3): δ 31.9 (NCH3), 103.7 (C3), 109.4 (C7), 117.2 (C6), 117.5 (C4), 127.0
U

U

(C9), 128.7 (C2‘, C4‘), 129.3 (C3‘), 131.4 (C1‘), 140.9 (C2), 141.8 (C5), 144.7 (C8).
ESI-MS m/z Calc. for C15H13N2O2 [M+H+] 253.0977; observed 253.0970.
1-methyl-2-phenyl-1H-indole 101b
To a stirred solution of 2-phenyl indole 99 (1.0 g, 5.17
mmol) in anhydrous THF (10 mL) was added sodium
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hydride (372 mg, 15.51 mmol) and the reaction stirred for 15 min at rt. Methyl iodide
(2.20 g, 15.51 mmol) in anhydrous THF (10 mL) was added dropwise to the reaction
mixture and stirred for 1-2 h. The reaction was monitored by TLC (EtOAc:hexane,
1:9). The reaction mixture was quenched with saturated sodium sulphate and
extracted with ethyl acetate (3 x 10 mL). The organic layer was separated, dried over
anhydrous MgSO4 and was concd in vacuo to afford 101 as a white solid (857 mg,
80%). mp 110-112 oC; 1H NMR (500 MHz, CDCl3): δ 3.86 (s, 3H, NCH3), 6.54 (s,
U

U

1H, H3), 7.12 (t, J = 8.0 Hz, 1H, H5), 7.22 (t, J = 7.0 Hz, 1H, H6), 7.30-7.36 (m,
2H, H4‘, H7), 7.40-7.48(m, 4H, H2‘H3‘), 7.61 (d, J = 7.5 Hz, 1H, H4);

13

C NMR

(125 MHz, CDCl3): δ 31.1 (NCH3), 101.7 (C3), 109.6 (C7), 119.2 (C5), 120.5 (C4),
U

U

121.7 (C6), 127.8 (C4‘), 128.0 (C9), 128.5 (C2‘), 129.4 (C3‘), 132.8 (C1‘), 138.4
(C2), 141.6 (C8); ESI-MS m/z Calc for C15H14N [M+H+] 208.1126; observed
208.1126.
tert-butyl 1H-indole-1-carboxylate 103c,5
To a stirred solution of indole 102 (10 g, 85.3 mmol) in anhydrous THF
(150 mL) was added DMAP (4.16 gm, 34.12 mmol, 0.4 eq), The
mixture was stirred for 15 min before adding Boc2O (20.5 mL, 89.56
mmol) and stirring continued overnight at room temperature, TLC (EtOAc:hexane,
1:9) showed complete reaction. The reaction mixture was diluted with ethyl acetate
(100 mL) and washed with water (2 x 100 mL), brine and dried over MgSO4. The
organic layer was concentrated in vacuo and the residue purified by flash column
chromatography (EtOAc:hexane,1:9) to afford 103 as a light yellow oil (16.8 g,
91%); 1H NMR (CDCl3, 500 MHz): δ 1.65 (s, 9H, Boc-CH3), 6.54 (s, 1H, H3), 7.20
U

U

99

(appt, J = 7.5 Hz, 1H, H5), 7.29 (appt, J = 7.5 Hz, 1H, H6), 7.53-7.57 (m, 2H, H2,
H4), 8.15 (d, J = 7.0 Hz, 1H, H7).
tert-butyl 2-(tributylstannyl)-1-indole-1-carboxylate 104c,5
H

A solution of N-Boc indole 103 (10 g, 46.02 mmol)
in anhydrous THF (300 mL) was cooled to -78 oC
and a solution of 1.6 M n-butyl lithium (28.7 mL,
46.02 mmol) in hexanes (1.6 M) was added
dropwise. The resulting yellow solution was stirred
for 2 h before adding tributyltinchloride (12.5 mL,
46.2 mmol) in anhydrous THF dropwise at -78 oC.
The reaction was stirred for a further 0.5 h at -78 oC and then allowed to warm to -20
o

C. After completion, the reaction was quenched with saturated ammonium chloride

(100 mL) and diluted with ethyl acetate. The aqueous layer was washed with ethyl
acetate (3 x 200 mL). The combined organic extracts were washed with water, brine
and then dried over anhydrous MgSO4 and concentrated in vacuo. The residue was
purified by flash column chromatography on silica gel using hexane to produce 104
as a colorless oil (11.2 g, 48%); 1H NMR (500 MHz, CDCl3): δ 0.88 (t, J = 7 Hz 9H,
H1‘), 0.86 (t, J = 8.5, 6H, H2‘), 1.2-1.3 (m, 6H, H3‘), 1.54 (t, J = 7.5 Hz, 6H, H4‘),
1.6 (s, 9H, Boc-H3‘‘), 6.71 (s, 1H, H3), 7.14-7.22 (m, 2H, H5, H6), 7.50 (d, J = 8.0
Hz, 1H, H7), 7.95 (d, J = 8.0 Hz, 1H, H4); 13C NMR (125 MHz, CDCl3): δ 11.6
(C4‘), 13.7 (C1‘), 27.4 (C2), 28.2 (C3‘‘), 29.2 (C3), 83.7 (C2‘‘), 115.3 (C4), 118.6
(C3), 120.0 (C7), 122.2 (C5), 123.2 (C6), 132.4 (C9), 137.4 (C8), 143.3 (C2), 152.2
(C=O).
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tert-butyl 2-(4-(methoxycarbonyl)phenyl)-1H-indole-1-carboxylate 105b
To a stirred solution of 104 (5 g, 9.87 mmol) in
anhydrous 1,4-dioxane (50 mL) was added 4iodomethylbenzoate

(2.04

g,

7.78

mmol),

palladium(II) chloride (43.62mg, 0.24 mmol) and
the reaction mixture was purged with nitrogen for
15 min. The reaction mixture was then heated to
100 oC and stirred for one 1h while monitoring by TLC (EtOAc:hexane, 1:9). The
reaction mixture was cooled, diluted with ethyl acetate (100 mL) and stirred over
15% potassium fluoride solution (300 mL) for 15 min. The precipitate was removed
by filtration and washed well with ethyl acetate 200 mL. The organic layer was
separated, washed with water and brine, dried over anhydrous Na2SO4 and
concentrated in vacuo. The residue was purified by silica gel column
chromatography (EtOAc:hexane, 1.5:8.5) to afford 105 as a white semi-solid (2.3 g,
84%). mp 79-83 oC; 1H NMR (500 MHz, CDCl3): δ 1.32 (s, 9H, H3‘‘), 3.94 (s, 3H,
COOCH3), 6.6 (s, 3H, H3), 7.2 (appt, J = 7.5 Hz, 1H, H5), 7.35 (appt, J = 7.5 Hz,
U

U

1H, H6), 7.50 (d, J = 7.5 Hz, 2H, H2‘), 7.56 (d, J = 7.5 Hz, 1H, H4), 8.07 (d, J = 7.5
Hz, 2H, H3‘‘), 8.21(d, J = 8.5 Hz, 1H, H7); 13C NMR (125 MHz, CDCl3): δ 27.6
(C3‘‘), 52.1 (COOCH3), 83.8 (C2‘‘), 110.7 (C3‘), 115.2 (C7), 123.4 (C5), 125.1
U

U

(C6), 128.3 (C2), 128.8 (C4), 129.0 (C2‘), 129.2 (C3‘), 137.9 (C1‘), 139.4 (C1‘),
149.9 (C1‘‘), 166.86 (COOCH3). ESI-MS m/z Calc. for C21H21NNaO4 [M+Na+]
U

U

374.1368, found 374.1368.
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Methyl 4-(1H-indol-2-yl)benzoate 106b
To a stirred solution of 105 (2.3 g, 6.55 mmol) in
anhydrous DCM (7 mL) was added trifluoroacetic
acid (7 mL) and the reaction mixture was stirred for 12 h. The mixture was concentrated in vaccuo and the
residue redissolved in ethyl acetate (100 mL). The EtOAc layer was washed with
water and brine and dried over anhydrous Na2SO4 before concentrating in vacuo. The
residue was purified by flash column chromatography (EtOAc:hexane, 1:2) to afford
106 as an off-white crystalline solid (1.3 g, 79%). mp 204-205 °C; 1H NMR (500
MHz, CD3COCD3): δ 3.90 (s, 3H OCH3); 7.029-7.059 (m, 2H, H3, H5), 7.14 (appt,
J = 7.0 Hz, 1H, H6), 7.45 (d, J = 8.5 Hz, 1H, H4), 7.59 (d, J = 8.0 Hz, 1H, H7), 7.96
(d, J = 8.5 Hz, 2H, H2‘), 8.05 (d, J = 8.5 Hz, 2H, H3‘), 11.01 (bs, NH);
U

U

13

C NMR

(125 MHz, CD3COCD3): δ 52.2 (OCH3), 101.8 (C3), 112.2 (C4), 120.6 (C5), 121.4
U

U

(C7), 123.3 (C6), 125.6 (C2‘), 129.3 (C9), 129.9 (C4‘), 130.8 (C3‘), 137.3 (C8),
137.8 (C2‘), 138. 8 (C1‘), 166.9 (C=O). ESI-MS m/z Calc for C16H14NO2 [M+H+]
requires 252.1025; found 252.1014.
Methyl 4-(5-Nitro-1H-indol-2-yl)benzoate 107b,3
H

Compound 106 (3 g, 11.93 mmol) was dissolved
in conc. H2SO4 (180 mL) in a 500 mL round
bottom flask and cooled to -20 oC. A solution of
NaNO3 (1 g, 12.53 mmol) in conc. H2SO4 (150 mL) was then added drop wise very
slowly (addition funnel) to cooled solution over 3h. After the addition was finished,
TLC analysis (EtOAc:hexane, 1:1) showed complete consumption. The reaction
mixture was poured onto a large amount of crushed ice in a 2L beaker (Careful!
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Large amount of heat is produced due to exothermic dissolution of H2SO4) and
stirred until all ice had melted. The precipitated crude product was filtered and
washed with water. The filter cake was re-dissolved in EtOAc, and dried over
MgSO4 and concd in vacuo. The crude residue was purified by flash column
chromatography using acetone in hexane (1:1) to yield 107 (2.8 g, 79%) as a bright
yellow solid. mp 283-285 °C; 1H NMR (500 MHz, CD3COCD3): 3.93 (s, 3H, OCH3);
U

U

7.34 (s, 1H, H3), 7.63 (d, 1H, J = 10.0 Hz, H6), 8.03-8.12 (m, 5H, H2‘, H3, H8),
8.61 (s, 1H, H4), 11.58 (br.s, NH);
U

U

13

C NMR (125 MHz, CD3COCD3): δ 52.4

(OCH3), 103.7 (C3), 112.6 (C6), 118.3 (C2), 118.5 (C7), 126.3 (C3‘), 129.2 (C9),
U

U

130.6 (C2‘), 131.0 (C4‘), 136.5 (C1‘), 141.6 (C5) 142.9 (C2), 166.7 (C=O). ESI-MS
m/z Calc for C16H11N2O4 [M-H-] requires 295.0719 found 295.0707.
(4-(5-nitro-1H-indol-2-yl)phenyl)methanol 108c,3
H

To a stirred solution of methyl ester 107 (1 g, 3.37
mmol) in anhydrous THF was added LiBH4 (73
mg, 3.37 mmol) and the reaction mixture was
slowly heated to 40 oC. Another 3 eq of LiBH4 was added in portion wise for every
20-30 min and the reaction mixture was stirred at that same temp for 2-3 h while
monitoring by TLC (EtOAc:hexane, 1:1). Upon completion the reaction mixture was
slowly quenched by dropwise addition of saturated aqueous NH4Cl solution (10 mL).
After bubbling had ceased, the mixture was diluted with water and extracted with
EtOAc (3 x10 mL). The organic layer was separated and dried over anhydrous
MgSO4 before being concentrated in vacuo. The crude residue was purified by flash
column chromatography (EtOAc:hexane, 1:1) to afford compound 108 as a yellow
powder (630 mg, 70%). mp 215–217 oC; 1H NMR (500 MHz, DMSO-d6): δ 4.5 (s,
103

2H, CH2OH), 5.26 (t, J = 5.5 Hz, 1H, OH), 7.15 (s, 1H, H3), 7.45 (d, J = 7.5 Hz, 1H,
U

U

H3‘), 7.54 (d, J = 9 Hz, 1H, H7), 7.86 (d, J = 8.5 Hz, 1H, H2‘), 8.06 45 (d, J = 6.0
Hz, 1H, H6), 12.25 (s, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 62.5 (CH2OH),
U

U

100.0 (C3), 111.5 (C7), 116.7 (C6), 116.8 (C4), 125.1 (C2‘), 127.0 (C3‘), 127.9 (C9),
129.3 (C1‘), 140.2 (C2‘), 140.9 (C5), 141.4 (C8), 142.9 (C4‘). ESI-MS m/z Calc for
C15H11N2O3 [M-H-] requires 267.0770 found 267.0765.
2-(4-(bromomethyl)phenyl)-5-nitro-1H-indole 1093
H

To a stirred solution of alcohol 108 (100 mg;
0.37 mmol) in anhydrous THF: anhydrous ether
(1:1, 10 mL) was added CBr4 (493 mg, 1.48
mmol) and stirred at rt for 10-15 min. PPh3
(388.1mg, 1.48 mmol) was then added to the mixture and stirring continued for 0.51h while monitoring by TLC (EtOAc:hexane, 1:1). The reaction mixture was filtered
through silica gel washed with ethyl acetate (3 x 10 mL). The combined filtrates
were concd in vacuo. The residue was purified by column chromatography on silica
gel using (EtOAc:hexane, 1:4 to 3:7) and the resulting product was triturated with nhexane (to removes traces of CBr4 and PPh3 to yield the bromide 109 (93mg, 75%) as
a bright yellow to orange powder. mp 199-201 °C (decomp); 1H NMR (500 MHz,
CD3COCD3): δ 4.69 (s, 2H, CH2Br), 7.18 (s, 1H, H3), 7.56-7.61 (m, 3H, H3‘, H6),
U

U

7.90 (d, J = 8.5 Hz, 2H, H2‘), 8.03 (d, J = 2.5 Hz, 1H, H7‘), 8.54 (s, 1H, H4), 11.74
(s, 1H, NH); 13C NMR (125 MHz, CD3COCD3): δ 33.9 (CH2Br), 102.2 (C3), 112.3
U

U

(C6), 117.8 (C4), 117.9 (C7), 126.5 (C2‘), 129.2 (C9), 130.7 (C3‘), 132.2 (C1‘),
139.3 (C4‘), 141.4 (C5), 141.9 (C2), 142.6 (C8). ESI-MS m/z Calc for C15H10BrN2O2
[M-H-] requires 328.9926 found 328.9934.
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9,10-dimethoxy-13-(4-(5-itro-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]diolo[4,5]isoquinolino[3,2-a]isoquinolin-7-ium chloride 88b
To a stirred solution of key bromide 109 (100
mg, 0.30 mmol) in anhydrous CH3CN (10 mL)
was added sodium iodide (49 mg, 0.33mmol)
and the mixture stirred for 1 h at 70 oC. 8acetonyl dehydroberberine 95 (118.8 mg, 0.30
mmol) was then added and stirring continued at
70 oC for another 3-4 h. The reaction was
monitored by TLC (MeOH:CHCl3, 1:9) or
EtOAc:hexane (1:4) and ESI-MS. After completion the reaction was diluted with
CH3CN (5 mL) and the product adsorbed onto silica gel via evaporation of the
solvent.

Purification

was

then

performed

using

column

chromatography

(EtOAc:CH3CN:hexane, 1:1:1) initially followed by (EtOAc:CH3CN:MeOH,
1:1:0.3) to afford semi pure 88. Further purification was carried out using RP-HPLC
(gradient from A 0% to 100% B over 30 min, Rt = 18.75 min). Fractions containing
the product were concentrated by freeze-drying to yield pure 88 as a yellow
amorphous solid (75 mg, 40% after HPLC). mp 218-220 °C (decomp);1HNMR (500
MHz, DMF-d6): δ 3.26 (s, 2H, H5), 4.03 (s, 3H, OCH3), 4.11 (s, 3H, OCH3), 4.84 (s,
2H, H5‘‘), 5.15 (bs, 2H, H6), 6.06 (s, 2H, OCH2O), 7.04 (s, 1H, H1), 7.11 (s, 1H,
U

U

H4), 7.17 (s, 1H, H3‘), 7.32 (d, J = 7.5 Hz, 2H, H3‘‘), 7.62 (d, J = 9.0 Hz, 1H, H6‘),
7.81-7.93 (m, 3H, H11, H2‘‘), 8.07 (m, 2H, H7‘, H12), 8.46 (s, 1H, H4‘), 10.1 (s,
1H, H8), 13.05 (s, 1H, NH);

13

C NMR (125 MHz, DMF-d6): δ 28.3 (C5), 36.3

(C5‘‘), 57.4 (C10a), 58.1 (C6), 62.5 (C9a), 101.3 (C3), 103.1 (OCH2O), 109.1
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(C1,C4), 112.4 (C6), 117.4 (C4‘, C7‘), 121.2 (C1a), 122.4 (C8a), 122.5 (C12), 126.8
(C11), 127.0 (C2‘‘), 128.9 (C9‘), 129.5 (C3‘‘), 130.8 (C1‘‘), 131.0 (C12a), 133.9
(C4a), 135.0 (C4‘‘), 138.4 (C13a), 140.3 (C13), 141.6 (C2‘), 142.0 (C5), 142.1
(C8‘), 145.4 (C9), 146.2 (C8), 147.5 (C2), 150.4 (C2), 151.2 (C10), ESI-MS m/z
Calc for C35H28N3O6+ [M-Cl-] 586.1973; observed 586.1997.
9,10-dimethoxy-13-(4-(1-methyl-5-nitro-1H-indol-2-yl)benzyl)-5,6-dihydro[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 110a
To a stirred solution of hybrid 88 (70 mg,
1.12 mmol) in anhydrous DMF (5 mL) was
added K2CO3 (464 mg, 3.36 mmol) and the
mixture stirred for 15 min. Methyl iodide
(0.21 mL, 3.36 mmol) in DMF (2 mL) was
added dropwise to the reaction mixture and
stirring continued 1-2 h. The reaction was
monitored by ESI-MS. Upon complete
consumption of the starting material, the mixture was concentrated in vacuo and the
residue purified by silica gel flash column chromatography (CH3CN:EtOAc:MeOH,
1:1:0.5) to yield the mixed Cl-/I- salt. The salt mixture was stirred with IRA-904
quaternary ammonium Cl- anion exchange resin in MeOH (5 mL) at rt for 1 h. After
filtration and concentration, the title compound 110 was obtained as a yellow
amorphous solid (53.3 mg, 75%). mp 208-212 °C (decomp); 1HNMR (500 MHz,
DMF-d6): δ 3.34 (s, 2H, H5), 3.91 (s, 3H, NCH3), 4.15 (s, 3H, OCH3), 4.21 (s, 3H,
OCH3), 5.00 (s, 2H, H5‘‘), 5.18 (bs, 2H, H6), 6.17 (s, 2H, OCH2O), 6.92 (s, 1H,
U

U

H3‘), 7.16 (s, 1H, H1), 7.29 (s, 1H, H4), 7.48 (d, J = 6.5 Hz, 2H, H3‘‘), 7.71 (d, J =
106

7.5 Hz, 2H, H2‘‘), 7.75 (d, J = 8.5 Hz, 1H, H7‘), 8.01 (m, 1H, H12), 8.11 (d, J = 8.5
Hz,1H, H6‘), 8.18 (d, J = 9.0 Hz,1H, H11), 8.59 (s, 1H, H4‘), 10.40 (s, 1H, H8); 13C
NMR (125 MHz, DMF-d6): δ 28.3 (C5), 32.2 (NCH3), 36.2 (C5‘‘), 57.4 (OCH3),
U

U

U

U

58.0 (C6), 62.6 (OCH3), 103.1 (OCH2O), 104.4 (C3‘), 109.1 (C4), 109.2 (C1), 111.2
U

U

U

U

(C7‘), 117.3 (C6‘), 117.6 (C4‘), 121.1 (C1a), 122.5 (C8a), 122.5(C12), 126.8 (C11),
127.6 ( C9‘), 129.4 (C3‘‘), 130.6 (C2‘‘), 130.9 (C4‘‘), 133.9 (C12a), 135.2 (C4a),
138.5 (C13a), 140.9 (C13), 141.9 (C5‘), 142.2 (C8‘), 145.1 (C2‘), 145.6 (C9), 146.8
(C8), 147.6 (C2), 150.4 (C3), 151.3 (C10); ESI-MS m/z Calc for C36H30N3O6 [M-Cl-]
600.2129; observed 600.2122.
Methyl 4-(1-methyl-1H-indol-2yl)benzoate 113a
A

stirring

solution

of

(N-Methylindol-2-yl)

tributylstannane 112 (5.0 g, 11.89 mmol) in
anhydrous

THF

was

charged

with

4-

iodomethylbenzoate (2.18 g, 8.32 mmol) and Pd
Cl2 (97.6 mg, 0.832 mmol). The reaction mixture was purged with nitrogen for 30
min and then heated at reflux for 3-4 h with monitoring by TLC (EtOAc:hexane,
1:5). The crude reaction mixture was adsorbed onto silica gel and purified by flash
column chromtography with petspirit:EtOAc (9.5:0.5 to 8:2) to yield 113 as an offwhite solid (2.36 g, 75%). mp 105 oC; 1H NMR (500 MHz, CDCl3): δ 3.75 (s, 3H,
NCH3), 3.94 (s, 3H, OCH3), 6.63 (s, 1H, H3), 7.15 (appt, J = 7.5 Hz, 1H, H5), 7.26
(appt, J = 7.5 Hz, 1H, H6), 7.36 (d, J = 8.0 Hz, 1H, H4), 7.58 (d, J = 8.5 Hz, 2H,
H2‘), 7.64 (d, J = 7.5 Hz, 1H, H7), 8.12 (d, J = 9.8 Hz, 2H, H3‘);

13

C NMR (125

MHz, (CDCl3): δ 31.3 (NCH3), 52.1 (OCH3), 102.8 (C3), 109.7 (C4), 120.1(C5),
120.74 (C7), 122.2 (C6), 127.8 (C2), 128.9 (C3‘), 129.2 (C9), 129.7 (C2‘), 137.2
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(C4‘), 138.6 (C1‘), 140.1 (C8), 166.7 (C=O); ESI-MS m/z Calc for C17H16NO2
[M+H+] 266.1181; observed 266.1173.
(4-(1-methyl-1H-indol-2yl)phenyl)methanol 114a
To a stirred solution of 113 (250 mg, 0.94 mmol) in
anhydrous THF was added LiAlH4 (34 mg, 0.94 mmol)
and the temperature gently raised to 40 oC. Another 3-4
eq of LiAlH4 was added in portions over 20-30 min and the reaction mixture was
stirred at that same temp for 3-4 h. The reaction was monitored by TLC (EtOAc:
petspirit, 2:3) and upon completion was slowly quenched by dropwise addition of
saturated aqueous NH4Cl solution. After bubbling ceased the mixture was diluted
with water and extracted with EtOAc (3 x 10 mL). The organic layer was dried over
anhydrous MgSO4 and concentrated in vacuo to yield 114 as an off-white solid (190
mg, 85%). mp 97-99 oC; 1H NMR (500 MHz, (CD3)2SO): δ 3.71 (s, 3H, N-CH3),
4.72 (s, 2H, CH2), 6.54 (s, 1H, H3), 7.13 (appt, J = 7.5 Hz, 1H, H5), 7.24 (appt, J =
U

U

15.5 Hz, 1H, H6), 7.34 (d, J = 8.5 Hz, 1H, H7), 7.43 (d, J = 8.0 Hz, 2H, H3‘), 7.49
(d, J = 8.5 Hz, 2H, H2‘), 7.62 (d, J = 8.0 Hz, 1H, H4);
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C NMR (125 MHz,

(CD3)2SO): δ 31.1 (NCH3), 64.9 (C5‘), 101.6 (C3), 109.5 (C7), 119.8 (C5), 120.4
U

U

(C4), 121.6 (C6), 127.0 (C3‘), 127.9 (C2), 129.4 (C2‘), 132.1 (C9), 138.3 (C1‘),
140.4 (C8), 141.2 (C4‘); ESI-MS m/z Calc for C16H16NO [M+H+] 238.1232;
observed 238.1224.
2-(4-bromomethyl)phenyl)-1-methyl-1H-indole 115a
To a stirred solution of compound 114 (300 mg, 1.26
mmol) in anhydrous DCM was added CBr4 (1.25 g, 3.78
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mmol), and the mixture stirred for 10 min. PPh3 (991 mg, 3.78 mmol) was then
added and stirring continued for 20-30 min. TLC analysis (EtOAc:hexane, 1:4)
indicated complete consumption of the alcohol. The product was filtered over neutral
alumina and the bed washed with DCM (3 x 10 mL). The combined filtrates were
concentrated in vacuo, keeping the water bath temperature below 40 oC. The residue
was purified by neutral alumina column chromatography, eluting initially by with
petspirit (~ 50 mL) followed by with ether:hexane:EtOAc (1:1:0.2). The combined
pure fractions (observed as violet color) were concentrated in vacuo to yield 115 as a
violet solid (76 mg, 20%). The compound was used immediately, as it is unstable.
mp 95-96 oC; 1H NMR (500 MHz, (CD3)2SO): δ 3.75 (s, 3H, N-CH3), 4.53 (s, 2H,
CH2Br), 6.60 (s, 1H, H3), 7.13 (appt, J = 7.5 Hz, 1H, H5), 7.24 (appt, J = 7.5 Hz,
U

U

1H, H6), 7.34 (d, J = 8.5 Hz,1H, H7), 7.47 (m, 4H, H2‘, H3‘), 7.62 (d, J = 8 Hz, 1H,
H4);
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C NMR (125 MHz,(CD3)2SO): δ 31.2 (NCH3), 33.1 (CH2Br), 102.4 (C3),
U

U

U

U

109.6 (C7), 119.6 (C5), 120.5 (C4), 121.8 (C6), 127.8 (C9), 129.2 (C2‘), 129.6 (C3‘),
132.9 (C2), 137.2 (C1‘) 138.5 (C8), 140.7 (C4‘); ESI-MS m/z Calc for C16H15BrN
[M+H+] 300.0388; observed 300.0396.
2-(4-chloromethyl)phenyl)-1-methyl-1H-indole 116a
A solution of compound 114 (300 mg, 1.26 mmol) in
CCl4:DCM (1:2, 7 mL), was stirred for 10 min at room
temperature. PPh3 (991 mg, 3.78 mmol) was then added
and stirred for 1 h. TLC (EtOAc:hexane, 1:4) indicated complete consumption of
alcohol. The product was filtered over neutral alumina bed and washed with
dichloromethane (3 x 5 mL). The combined filtrates were concentrated in vacuo,
keeping the water bath temperature below 40 o C. The residue obtained was triturated
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with pentane (3 x 4 mL) to afford the crude 116 (210 mg, 65%). The crude
compound was used immediately and due to its instability was unable to be
characterised.
9,10-dimethoxy-13-(4-(1-methyl-1H-indol-2-yl)benzyl)-5,6-dihydro[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 117a
To a solution of bromide/chloride 115/116 (150/128
mg, 0.501 mmol) in anhydrous CH3CN (10 mL) was
added sodium iodide (12.7 mg, 0.531 mmol) and the
reaction

was

stirred

for

Acetonyldehydroberberine

1
95

h

at
(196.8

70

o

C.

mg,

0.501mmol) was then added and continued stirring
for another 3-4 h at 70

o

C. The reaction was

monitored by TLC (EtOAc:hexane, 1:4) to observe
consumption of the bromide/chloride 115/116) and also by ESI MS. The mixture was
purified by silica gel column chromatography (EtOAC:CH3CN:hexane, 1:1:2)
followed by EtOAc:CH3CN:Methanol (1:1:0.1). The semi-pure compound was
further purified by preparative RP-HPLC using a gradient from 0% A to 100% B
over 30 min (Rt = 21.5 min). The fractions containing purified product were
concentrated by freeze-drying to yield 117 as a yellow solid (118 mg, 40% after
HPLC). mp 186-189 oC; 1H NMR (500 MHz, DMF-d6): δ 3.37 (s, 2H, H5), 3.83 (s,
3H, NCH3), 4.15 (s, 3H, OCH3), 4.23 (s, 3H, OCH3), 5.01 (s, 2H, H5‘‘), 5.22 (bs,
2H, H6), 6.20 (s, 2H, OCH2O), 6.63 (s, 1H, H3‘), 7.10 (appt, J = 7.5 Hz, 1H, H5‘),
7.20-7.25 (m, 3H, H1, H4, H6‘), 7.48 (d, J = 7.5 Hz, 2H, H3‘‘), 7.53 (d, J = 8.5 Hz,
1H, H7‘), 7.62 (d, J = 7.5 Hz, 1H, H4‘), 7.69 (d, J = 8.0 Hz, 2H, ArH2‘‘), 8.04 (d, J
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= 7.5 Hz, 1H, H12), 8.22 (d, J = 7.5 Hz, 1H, H11) 9.42 (s, 1H, H8); 13C NMR (125
MHz, DMF-d6): δ 28.3 (C5), 31.5 (NCH3), 36.2 (C5‘‘), 57.4 (C10a), 58.2 (C6), 62.6
U

U

(C9a), 102.1 (C3‘), 103.1 (OCH2O), 109.1 (C4), 109.2 (C1), 110.6 (C7‘), 120.2
U

U

(C5‘), 120.8 (C4‘), 121.1 (C1a), 122.2 (C6‘), 122.4 (C8a), 122.5 (C12), 126.8 (C11),
128.6 (C9‘), 129.2 (C3‘‘), 130.4 (C2‘‘), 131.1 (C2‘), 131.9 (C13), 134.0 (C12a),
135.1 (C4a), 138.5 (C13a), 139.3 (C8‘), 139.9 (C4‘‘), 141.4 (C1‘‘), 145.5 (C9),
146.5 (C8), 147.6 (C2), 150.4 (C3), 151.2 (C10); ESI-MS m/z Calc. for C36H31N2O4+
[M-Cl-] 555.2278; observed 555.2289.
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Section 2
Synthesis and Biological Evaluation of
Clostridium Selective Antimicrobials
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Chapter 4
Diarylacylhydrazones: Clostridium-Selective Antibacterials with
Activity Against Stationary-Phase Cells

4.1 Introduction
Clostridium difficile-associated diarrhoea (CDAD), also known as C. difficile
infection (CDI), is the leading cause of infectious nosocomial gastrointestinal
illness.1,2 Steadily increasing CDI rates in US hospitals,1 emergence of epidemic and
H

H

H

H

hypervirulent strains (e.g. BI/NAP1/027),3 increased incidences of community
acquired CDI4 and enormous costs to healthcare systems (estimated at $3.2
billion/year in the US alone)5 have focused considerable attention on this disease
over the past decade.6,7
C. difficile is a Gram-positive, rod-shaped, spore-forming anaerobe
transmitted via the oral-fecal route. In its vegetative form it is highly sensitive to
oxygen but its spores are heat stable, insensitive to standard disinfectants, able to
survive for long periods in the environment and they can passage intact through the
acidic stomach. C. difficile typically resides asymptomatically in the human
gastrointestinal tract until normal microflora are disrupted, such as following broadspectrum antibiotic treatments, after which it can overgrow producing up to six
toxins, including the well-studied toxin A (TcdA) and toxin B (TcdB). Ensuing CDI
can range in severity from mild diarrhoea to life-threatening pseudomembranous
colitis (PMC) and toxic megacolon.6
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Treatments for CDI historically have involved antibiotic withdrawal followed
by oral metronidazole 118 (500 mg t.i.d, 10-14 days) or vancomycin 119 (125-250
mg q.i.d, 10 days) but treatment failure remains as a significant and increasing
problem (reportedly > 35% for metronidazole and 1-16% for vancomycin).2 For
patients who develop severe CDI (diarrhoea with leucocytosis, PMC or toxic shock)
metronidazole is effective in 76% of cases and vancomycin 97%.2 Upwards of 2030% of patients can experience recurrent CDI with intermittent episodes arising over
months and sometimes years.8 A major risk factor for recurrent CDI is failure to reestablish normal protective gut microflora due to the action of metronidazole and
vancomycin on gut commensals and the ineffectiveness of these antibiotics against
C. difficile spores.2
In 2011 the US Food and Drug Administration (FDA) approved fidaxomicin
120 (Dificid®, Optimer Pharmaceuticals Inc.),9 an oral macrocyclic narrow-spectrum
antibiotic developed specifically for CDI. Fidaxomicin shows very high in vitro
potency against C. difficile (minimum inhibitory concentrations (MICs) against
clinical isolates 0.008–0.25 mg/L) and reduced activity against gut commensals, in
particular Bacteroides species.10 This and lower post-treatment C. difficile spore
counts10 are thought to contribute to reduced CDI recurrence with fidaxomicin.11,12
Relapse rates for infections caused by the BI/NAP1/027 hypervirulent strain,
however, are the same for vancomycin and fidaxomicin13,14 and many hospitals have
been slow to embrace the new drug due to its high cost (> US$2700 per treatment,
c.f. metronidazole US$22 and vancomycin $1270).15
While the proper place for fidaxomicin in clinical practice is still being
established the search continues for alternative and, ideally, more cost-effective
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agents. Attractive new compound classes would include those that show high
selectivity for C. difficile over gut commensals along with activity against the
stationary-phase cells responsible for spore formation.16 In a recent high-throughput
screening (HTS) and counter-screening campaign our collaborator Prof Kim Lewis at
Northeastern University (Boston USA) identified that certain diarylacylhydrazones
are clostridium-selective agents.17 This chapter reports the activity and selectivity of
the diaryacylhydrazone screening hits, describes structure-activity studies around the
class with additional synthesized analogues synthesised by me and reports that a
representative member is active against stationary-phase C. difficile cells. Evidence
is presented that selective anti-Clostridium activity in the class may arise, in part,
through a protonophoric mechanism.

Figure 4.1 Current antibiotic treatments for C. difficile infections.
4.2 Statement of contribution
This project was carried out in collaboration with Northeastern University.
My contribution involved completing all of the synthetic chemistry and interpretation
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of structure-activity relationships. All high-throughput screening and microbiology
results were produced by researchers at Northeastern.
4.3 Screening for hits against C. difficile
High-throughput screening was carried out at Northeastern to identify hits
against C. difficile CD196.17 Hits were subjected to a counter-screening panel of ten
bacterial species representing the major taxonomic groups from the human gut
environment in order to identify Clostridium-selective compounds. Counterscreening species were chosen from the Data Analysis and Coordination Centre
(DACC) for the Human Microbiome Project (http://www.hmpdacc.org/), part of the
National Institutes of Health (NIH) Roadmap for Medical Research, and included
abundant members of the gut flora, e.g. Bacteroides thetaiotaomicron, organisms of
clinical significance, e.g. Escherichia coli, Enterococcus faecalis and Staphylococcus
aureus, along with representatives from each of the predominant phyla. Clostridium
perfringens was included to identify species-specific anti-C. difficile compounds.
Four acylhydrazones carrying aryl substituents at R1 and R2 (i.e.
diarylacylhydrazones 121-124, Figure 2) were initially identified as hits. Follow-up
measurements showed that the minimum inhibitory concentrations (MIC) of 121-124
against C. difficile CD196 ranged from 1.56-6.25 μg/mL and that the compounds
exhibited similar MICs against Clostridium perfringens. Minimum bactericidal
concentrations (MBC) of 122 and 123 against CD196 were equivalent to their MICs,
confirming that the compounds are bactericidal. Quinolinium acetate, chloride and
mesylate salts of 124 showed identical activity to the free base form of 124.
Compound 121 was shown to have activity similar to vancomycin (< 2-fold
difference in MIC) against five C. difficile clinical isolates (Figure 4.2 b).
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Importantly, compounds 121-124 were essentially inactive (MIC > 50 μg/mL) across
the gut commensal panel with only 122 and 123 showing weak activity (MIC = 12.525 μg/mL) against B. fragilis and B. thetaiotaomicron. In contrast, metronidazole
118, vancomycin 119 and fidaxomicin 120 all showed high potency against C.
difficile accompanied by significant activity against commensals (Figure 4.2a).
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Figure 4.2 (a) Activity of metronidazole 118, vancomycin 119, fidaxomicin 120 and diarylacylhydrazones 121-124 against C. diffcile CD196
and a panel of gut commensals.
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Figure 4.2 (b) Activity of compound 121 and vancomycin against five C. difficile
clinical isolates.
Three structural motifs common in hits 121-124 were: (1) an acyl hydrazone,
(2) an aryl ring at R1 and (3) an aryl ring at R2 carrying an ortho-hydroxy substituent.
Follow-up similarity searches of Northeastern‘s libraries identified six additional
diarylacylhydrazones containing the 2-hydroxynaphthalene group at R2 available for
examination (Figure 4.3 (a), compounds 125-130). Compounds 125-127, which
incorporate phenyl, m-bromophenyl and o-hydroxynaphthyl groups at R1,
respectively, displayed MICs against CD196 in the range 6.25-12.5 μg/mL.
Compounds 128-130, which carry 4-nitrophenyl, 3-nitrophenyl and 3,5-dinitrophenyl
substituents at R1, respectively, all showed no activity against CD196. These findings
indicate that substituents on the aryl group at R1 can dramatically impact potency. A
further nine compounds with structures related to 121-124 but lacking one or more of
the above structural criteria (Figure 4.3 (b), 131-139) were selected from the libraries
for testing and found to be inactive. Diarylacylhydrazones with aryl rings at R1 and
ortho-hydroxy substituted aryl rings at R2 thus appear to present the minimal
structural requirements for selective anti-Clostridium activity in this class.
Encouraged by these results, analogues 140-151 (Figure 4.4) were chosen for
synthesis to answer specific structure-activity questions about the class. The
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discussion of the rationale for choosing these analogues along with their MICs
against the gut panel (data shown in Figure 4.4) is preceeded by a discussion of how
the compounds were synthesised (my contribution).

Figure 4.3 (a) Activity of additional diarylacylhydrazones containing 2hydroxynaphthyl groups at R2 identified in Northeastern‘s screening libraries (b)
Compound from Northeastern‘s screening libraries that were structurally related to
diarylacylhydrazones and found to be inactive against C. difficile CD196.
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Figure 4.4 Activity of synthesized diarylacylhydrazones 140-151 against C. diffcile CD196 and a panel of gut commensals.
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4.4 Synthetic Chemistry
4.4.1 Synthetic strategy towards diarylacylhydrazones
The general synthetic route pursued towards diarylacylhydrazones is outlined
in Scheme 4.1. The strategy involved condensing of aroylhydrazines with various
aromatic aldehydes by heating in ethanol or methanol.

Scheme 4.1 General strategy for synthesis of diarylacylhydrazones.
Synthesis

of

the

target

diarylacylhydrazones

required

access

to

aroylhydrazine precursors 152-156 (Figure 4.5), which could be submitted to
condensation with the requisite aromatic aldehydes. These key precursors were
synthesized in gram quantities (except 152, which was commercially available).

Figure 4.5 Aroylhydrazine precursors required for the synthesis of target
diarylacylhydrazones 122-124 and 140-151.
4.4.2 Synthesis of aroylhydrazines 153-156
Synthesis of 153 (Scheme 4.2) was achieved in 2 steps. The first step
involved conversion of 4-chlorobenzoic acid 157 to its corresponding methyl ester
158 in 90% yield using catalytic amount of H2SO4 in refluxing methanol. In the
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second step, the ester 158 was heated to reflux with hydrazine hydrate in ethanol to
afford 153 in 91% yield.

Scheme 4.2 Synthesis of 153. Reagents and conditions: (a) MeOH, H2SO4 (cat.),
reflux 90% (b) Hydrazine monohydrate, EtOH reflux, 91%.
Aroylhydrazine 154 was prepared in gram quantities over 3 steps via the key
quinoline carboxylic acid intermediate 160. Acid 160 was prepared in 90% yield
using Pfitzinger reaction from 5-bromoisatin 159 in acetone containing KOH.18 The
Pfitzinger mechanism (Scheme 4.3) involves KOH hydrolysis of the amide bond of
5-bromo isatin 159 to yield the potassium salt of 5-bromo isatoic acid 159a.
Condensation of the aniline group of 159a with acetone affords the imine
intermediate 159b which can tautomerise to the enamine 159c. A condensation
reaction between the enamine and ketone groups subsequently yields the final
quinoline carboxylic acid 160 after acidic workup.

Scheme 4.3 Mechanism of Pfitzinger reaction to produce key quinoline carboxylic
acid intermediate 160.
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Formation of the quinoline 160 was supported by 1H NMR and high
resolution mass spectrometry. Diagnostic singlet signals at 2.68 ppm and 8.81 ppm in
the 1H NMR spectrum corresponded to the methyl and quinolone H5 protons.
Esterification of 160 was achieved under standard conditions utilizing catalytic
H2SO4 in methanol. The work up involved removal of MeOH under reduced
pressure, adjusting the pH to 7 with aqueous ammonia solution and extracting with
EtOAc. Purification of the crude ester was achieved by flash column
chromatography (EtOAC:hexane, 1:4), affording methyl ester 161 in 65% yield. The
161 was converted to the aroylhydrazine 154 using excess hydrazine hydrate.
Heating the reaction at reflux for 4 h produced a white precipitate, which was filtered
and washed with EtOH to produce 154 in 90% yield (Scheme 4.4). 1H NMR
confirmed formation of 154 with loss of the methyl ester signal at 3.96 ppm and
appearence of new signals at 4.58 and 9.79 ppm, attributed to the NH and NH2
respectively. The spectral data was consistent with the literature.19

Scheme 4.4 Synthesis of 154. Reagents and conditions: (a) MeOH, H2SO4 (cat.)
reflux 65%, (c) NH2NH2.H2O, MeOH reflux, 90%.19
The pyrazole-containing aroylhydrazine precursor 155 was obtained from the
commercially available acid 162, which was converted to its methyl ester 163 using
catalytic amount of H2SO4 in methanol affording 163 in 85% yield. The ester 163
was converted to its corresponding aroylhydrazine 155 using excess NH2NH2.H2O
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refluxing in ethanol. A white precipitate was filtered and washed with ethanol:ether
(1:9) affording the precursor 155 in 91% yield (Scheme 4.5).20 1H NMR confirmed
introduction of the hydrazine, with signals appearing at 3.3 and 9.79 ppm,
corresponding to the NH and NH2 protons, respectively.

Scheme 4.5 Synthesis of 155. Reagents and conditions: (a) MeOH, H2SO4 (cat.),
reflux, 85%; (b) hydrazine monohydrate, EtOH, reflux, 91%.20
Synthesis of N-methylaroylhydrazine 156 was adapted from a procedure
reported by Benstead et al.21 The procedure involved addition of p-toloylchloride
164 (0.15M in dichloromethane) to an N-methyl hydrazine solution (1.5M) in
dichloromethane slowly via syringe pump at 0 oC for 1 h, before allowing the
reaction to warm to room temperature and stirring for another 2 h (Scheme 4.6). The
reaction mixture was poured into a saturated aqueous Na2CO3 solution and extracted
with DCM to afford 156 in 91% yield. The 1H NMR spectrum of 156 was consistent
with reported data.21

Scheme 4.6 Synthesis of 156. Reagents and conditions: (a) N-methyl hydrazine (1.5
M) in DCM, 0 oC to rt, 91%.21

127

4.4.3 Synthesis of diarylacylhydrazones
The aroylhydrazine precursors 152-156 were condensed with the requisite
aryl aldehydes in EtOH as shown in Table 4.1. Precipitation of the product was
observed in all reactions, which was filtered and recrystallised from EtOH. The
desired products were all confirmed by 1H NMR spectroscopy and high resolution
mass spectrometry. The diarylacylhydrazone structures were evidenced by the
presence of an N=CH signal ranging from 8.45-9.46 ppm. All compounds existed in
the (E)-trans hydrazone configuration, except for the quinoline-based compounds
124, 143 and 147, which existed as mixtures of the (E)-trans and (Z)-cis hydrazones
in the NMR solvent (DMSO-d6).
Table 4.1 Summary of the synthesis of diarylacylhydrazones 122-124 and 140-151
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*The literature status for each compound is indicated by: a = novel compound, b = published
compound with limited/no characterisation, or c = fully characterised published compound. Full
characterisation has been provided for all novel compounds and compounds with limited or no
characterisation.
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4.5 Microbiological evaluation of compounds 140-151
Compound 140 (INP0400) carrying a p-chlorophenyl group at R1 and a 2hydroxynaphthyl group at R2 was synthesized because it had previously been
reported as an inhibitor of type III secretion in the common bacterial pathogen
Chlamydia trachomatis.22 The MIC of 140 against CD96 was found to be 6.25
µg/mL and it showed higher potency against C. Perfringens (MIC < 0.78 µg/mL,
U

U

Figure 4.4). The compounds selectivity for clostridium species over gut commensals
was similar to 122, showing only weak activity against B. fragilis and B.
thetaiotaomicron (MIC = 12.5 µg/mL) and no other activity across the panel.
Compound 141, which substituted the ortho-hydroxynaphthyl group present at R2 in
123 with the ortho-vanillyl moiety of 124, was synthesized to probe the effect of
interchanging the two different R2 groups present in diarylacylhydrazone screening
hits. Clostridium-selective activity was observed with 141 showing MICs of 12.5 and
6.25 μg/mL against C. difficile and C. perfringens, respectively, and no other activity
across the panel (Figure 4.4). Replacing the ortho-hydroxynaphthyl group at R2 of
123 with the ortho-vanillyl moiety (i.e. compound 142), however, abolished all
activity, including against both Clostridium species. Total loss of activity across the
panel was similarly observed with 143, where the ortho-vanillyl group at R2 in 124
had been replaced with the ortho-hydroxynaphthyl group. These results demonstrate
that the Clostridium-selective activity of diarylacylhydrazones is structure-dependent
and is affected by substituents on aryl groups at both R1 and R2.
The importance of the ortho-hydroxy group at R2 was established next with
compounds 144-147. Transferring the hydroxyl group of 122 to the naphthyl 4position (compound 144) led to total loss of activity, as did removing the ortho130

hydroxy group altogether from compounds 122, 123 and 124 (i.e. compounds 145,
146, and 147, respectively). Methylation of the acylhydrazone ‗amide‘ nitrogen of
122 (compound 148), its ortho-phenolic group at R2 (i.e. compound 149) or both of
these groups (compound 150) similarly removed all activity (Figure 4.4).
It was noted that diarylacylhydrazones structurally resemble nitrofurans, an
older class of broad spectrum antibiotics that have seen widespread historical use in
humans and in veterinary medicine.23 Nitrofurans typically contain an acylhydrazone
substituted with a 5-nitrofuranyl group at the position corresponding to R2 in
diarylacylhydrazones. A variety of substituents, both aryl and non-aryl, can be
present at the position corresponding to R1 (e.g.

R1 = p-hydroxyphenyl,

nifuroxazide; R1 = NH2, nitrofurazone; R1 = hydantoin, nitrofurantoin; R1 =
oxazolidinone, furazolidone). The novel nitrofuran 151, carrying a 3-methylpyrazole
group at R1 and thus high structural similarity to 123, was synthesised to explore the
possibility that nitrofurans and diarylacylhydrazones might share overlapping
antibacterial mechanism(s) of action. However, 151 showed broad spectrum activity
across the panel, including high potency against C. difficile CD196 (MIC = 0.78
μg/mL, Figure 4.4). This finding confirmed that diarylacylhydrazones and
nitrofurans exert their antibacterial effects via different mechanisms.
4.6 Activity of protonophores against C. difficile
Identifying that nitrofurans invoke different antibacterial mechanisms and
that anti-Clostridium activity is lost in diarylacylhydrazones upon methylation of the
‗amide‘ nitrogen and/or the ortho-phenolic group present at R2 led to speculation that
the compounds might be exerting their selective effects through a protonophoric
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mechanism. To test this hypothesis, MIC measurements were obtained with three
well-known

membrane-active

protonophores;

carbonyl

cyanide

m-

chlorophenylhydrazone 64 (CCCP),24 pentachlorophenol 165 (PCP),25 and 2,4dinitrophenol 166 (2,4-DNP)26 (Figure 4.6) against CD196 and the gut panel. It was
reasoned that if Clostridium-selective activity were observed with one or more of
these it would support a protonophoric mechanism for diarylacylhydrazones. CCCP
64 was found to be highly active against CD196 (MIC = 1.56 μg/mL) and also
showed high selectivity, affecting only one other panel member (B. longum, MIC =
3.25 μg/mL).
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Figure 4.6 Activity of known protonophores against C. diffcile CD196 and a panel of gut commensals.
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In contrast to diarylacylhydrazones, CCCP 64 showed no activity against C.
perfringens. PCP and 2,4-DNP showed only weak activity across the panel and no
selectivity towards Clostridium, indicating that selective action against Clostridium
is not a general effect of protonophores. The similarity between the
activity/selectivity observed with CCCP 64 and diarylacylhydrazones implies that a
protonophoric mechanism probably plays some role in the mechanism. That CCCP
and diarylacylhydrazones both carry hydrazone moieties may be important but this
remains to be determined.
4.7 Activity of diarylacylhydrazones against stationary phase C. difficile cells
Recent reports indicate that perturbing membrane function represents a
promising strategy towards novel anti-C. difficile therapeutics,27 especially since
some membrane–active agents affect the quiescent/stationary-phase cells responsible
for spore formation.28 Two membrane-active agents oritavancin (vancomycin
analogue)29 and CB-183,315 (daptomycin analogue)30 are in clinical development for
CDI. Several membrane-active compounds (including CCCP) were recently shown
to kill C. difficile cells in both logarithmic and stationary-phase cultures.31 The
activity of diarylacylhydrazones 122 and 123 was thus examined against stationaryphase C. difficile CD196 cells alongside CCCP 64, with metronidazole 118,
vancomycin 119 and fidaxomicin 120 included for comparison.
CD196 cells were grown to stationary phase according to Northeasteren‘s inhouse procedure and treated with 1x, 5x, 10x and 20x the previously determined
MIC (μg/mL) concentrations of each compound. Metronidazole 118, vancomycin
119 and fidaxomicin 120 showed little or no activity at all concentrations tested
(Figure 4.7a-c). Compound 122 showed some ability to kill stationary-phase cells but
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the data was not reproducible (not shown) and it was suspected that the poor
solubility of 122 in the assay medium may have been responsible. Switching to the
more soluble 123 produced reproducible dose-dependent cell-killing effects (Figure
4.7d), that were remarkably similar to those observed with CCCP (Figure 4.7e),
supporting the postulate that diarylacylhydrazones and CCCP may indeed exert their
selective anti-Clostridium effects through overlapping (protonophoric) mechanisms.

Figure 4.7 Activity against stationary-phase C. difficile CD196 cells of: (a)
metronidazole 118 (b) vancomycin 119 (c) fidaxomicin 120 (d) 123 (e) CCCP 64
DMSO was present at a final concentration of 1% v/v in all assay solutions.
4.8 Cytotoxicity of diarylacylhydrazones against human cells
Given the known effects of CCCP 64 as a protonophoric uncoupler of
oxidative phosphorylation,32 it was of interest to examine human cell cytotoxicity as
a preliminary indicator of druggability (or otherwise) in the diarylacylhydrazone
class. Compounds 122 and 123 were examined alongside miconazole (positive
control), metronidazole 118 vancomycin 119 and CCCP 64 for cytotoxicity against
human FaDu and Hep G2 cells using a standard 96-well resazurin-based cell viability
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assay. The positive control miconazole showed the expected cytotoxic concentration
(50 μg/mL) against both cell lines. Metronidazole 118 and vancomycin 119 showed
no toxicity at or below 200 μg/mL against either cell line. Compounds 122 and 123
showed no cytotoxicity against either cell line at 100 μg/mL, the highest
concentration tested, while CCCP was found to be toxic at 50 μg/mL (Figure 4.8).

Figure 4.8 Cytotoxicity against human FaDu and Hep G2 cells.
4.9 Conclusions and future directions
This work has demonstrated that certain diarylacylhydrazones are narrowspectrum antibacterials with selectivity for C. difficile and C. perfringens over other
gut commensals. The demonstrated structure-dependence of the selectivity is
significant because other diarylacylhydrazones have previously been shown to have a
wider spectrum of antibacterial activity.33 The activity of 123 against stationaryphase C. difficile cells and its low human cell cytotoxicity indicate that further
investigations with the class are warranted towards creating cost-effective antibiotics
for CDI that may reduce treatment failure and relapse rates. Recently I repeated the
synthesis of this compound and provided more than 1 g to our Northeastern
University collaborators, who will study its in vivo effects in their hampster C.
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difficile infection model. Identifying that CCCP 64 shows similar activity to
diarylacylhydrazones against the gut panel and against stationary phase C. difficile
cells suggests that a protonophoric mechanism may play a role in the selectivity,
although many questions remain. One avenue worth exploring is the possible
involvement of dynamin-like proteins, which are important mediators of membrane
remodelling in bacteria (called dynamins in eukaryotes).34 Inhibition of dynamins by
diarylacylhydrazones is well characterised35 and compounds structurally very similar
to those studied here were recently shown to prevent uptake of C. difficile TcdA into
eukaryotic cells.36
4.10 Experimental
4.10.1 Chemistry−General
The general chemistry information was as described in Section 2.8.1. pToulic acid hydrazide 152 was purchased from Trans World Chemicals. 3-Methyl1H-pyrazole-5-carboxylic acid 162 was purchased from Butt Park Ltd. Compound
156 was synthesized according to a procedure adapted from Benstead et al.21 All
reagents and arylaldehydes were purchased from Sigma Aldrich.
The literature status for each compound is indicated by: a = novel compound,
b = published compound with limited/no characterisation, or c = fully characterised
published compound. Full characterisation has been provided for all novel
compounds and compounds with limited or no characterisation data available in the
literature.
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4.10.2 General synthetic procedures for diarylacylhydrazones
General Method A: Aroylhydrazine (1.0 eq) was dissolved in absolute EtOH
along with the requisite aldehyde (1.0 eq) and the reaction mixture was heated to
reflux with stirring for 3–4 h. The reaction mixture was cooled and the precipitate
filtered and recrystallised from EtOH.
General Method B: Aroylhydrazine (1.0 eq) was dissolved in absolute EtOH
along with the requisite aldehyde (1.0 eq) and the reaction mixture was heated to
reflux with stirring for 3–4 h. The mixture was cooled to rt and concentrated in
vacuo. The residue was absorbed onto silica gel using EtOAc as solvent and purified
by flash chromatography (on silica gel) using pet. spirit:EtOAc mixtures from 90:10
to 70:30.
4-Chlorobenzohydrazide 153b
Compound 153 was synthesized over 2 steps. To a stirred
solution of p-chlorobenzoic acid 157 (2.0 g, 12.77 mmol) in
MeOH (50 mL) was added catalytic H2SO4 (0.5 mL) and the
mixture was heated to reflux for 4-5 h. Upon completon the
reaction was concentrated in vacuo and the residue obtained was diluted with water
(30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were
dried over Na2SO4 and concentrated in vacuo to yield ester 158 (1.96 g, 90%). A
stirred solution of the methyl ester 158 (1.5 g, 8.79 mmol) in ethanol (25 mL) was
treated with hydrazine monohydrate (1 mL, 26.3 mmol) and the mixture heated to
reflux for 6-7 h. The reaction was monitored by TLC (MeOH:DCM, 1:9). Upon
consumption of the starting ester reaction mixture was cooled to room temperature
and the precipitate obtained was filtered and recrystallised from ethanol to afford 153
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as a white crystalline solid (1.35 g, 91%). mp 164-166 oC; 1H NMR (500 MHz,
(CD3)2SO): δ 4.45 (s, 2H, NH2), 7.51 (d, J = 8.0 Hz, 2H, H3), 7.83 (d, J = 8.5 Hz,
U

U

2H, H2), 9.84 (s, 1H, CONH); 13C NMR (125 MHz, (CD3)2SO): δ 128.3 (C3), 128.8
U

U

(C2), 132.0 (C1), 135.8 (C4), 164.7 (CO).
U

U

6-Bromo-2-methylquinoline-4-carboxylic acid 160c,18
Synthesis of this compound was based on the method of
Zemtsova et al.18 A mixture of 5-bromoisatin 159 (4.0 g, 17.5
mmol) in a solution of KOH (8.0 g, 14.3 mmol) and H2O (16 mL)
was stirred for 5 min at room temperature. Acetone (19.2 mL,
41.8 mmol) was added and the mixture heated to reflux for 8 h. The mixture was
neutralised to pH 5-6 with 10% HCl and the precipitate filtered, washed with water
and dried to produce 160 as a white solid (4.2 g, 90%). mp 265-267 oC; 1H NMR
(500 MHz, (CD3)2SO): δ 2.72 (s,3H, ArCH3), 7.81-7.99 (m, 3H, H7, H8, H3), 8.93
U

U

(s, 1H, H5); ESI-MS m/z Calc for C11H9BrNO2 [M+H+] 265.9817; observed
265.9818
Methyl 6-bromo-2-methylquinoline-4-carboxylate 161b, 37
To a stirred solution of acid 160 (5.0 g, 18.9 mmol) in MeOH
(100 mL) was added catalytic H2SO4 (1 mL) and the reaction
mixture was heated to reflux for 4-5 h. The reaction was
monitored by TLC (EtOAc:hexane, 1:4). Upon completion the
reaction mixture was cooled to rt and adjusted to pH7 by dropwise addition of
saturated aqueous ammonia. The reaction mixture was concentrated in vacuo and the
residue was diluted with H2O and extracted with EtOAc (3 x 100 mL). The combined
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organic extracts were washed with water and brine and the separated organic layer
was dried over anhydrous Na2SO4. The crude residue was purified by silica gel flash
column chromatography (EtOAc:hexane, 1:9) to afford 161 as a light yellowish
crystalline solid (3.42 g, 65%). mp 147-150 oC; 1H NMR (500 MHz, CDCl3): δ 2.68
(s, 3H, ArCH3), 3.96 (s, 3H, OCH3), 7.74 (d, 1H, J = 9.0 Hz, ArH7), 7.70 (s, 1H,
U

U

U

U

ArH3), 7.86 (d, 1H, J = 9.0 Hz, ArH8), 8.81 (s, 1H, ArH5);

13

C NMR (125 MHz,

CDCl3): δ 25.0 (ArCH3), 52.6 (OCH3), 121.4 (C10), 123.9 (C3), 124.2 (C6), 127.6
U

U

U

U

(C5), 130.6 (C7), 132.9 (C8), 133.3 (C4), 147.2 (C9), 158.7 (C2), 165.9 (C=O); ESIMS m/z Calc for C12H11BrNO2 [M+H+] 279.9973 found 279.9965.
6-Bromo-2-methylquinoline-4-carbohydrazide 154b, 19
To a stirred solution of methyl ester 161 (1.6 g, 5.71 mmol) in
anhydrous MeOH (40 mL) was added hydrazine monohydrate
(1.38 mL, 28.55 mmol) and the reaction mixture was heated at
reflux overnight. The reaction mixture was cooled to rt and the
precipitated product was filtered and washed with ethanol (10 mL). The filtrate was
concentrated to half volume and the further precipitate was filtered. The combined
solids were washed with ethanol (5 mL) and dried in vacuo to afford 154 as a white
solid (1.45 g, 90%). mp 248-249 oC; 1H NMR (500 MHz, CDCl3): δ 2.5 (s, 3H,
ArCH3), 4.58 (s, 2H, NH2), 7.38 (s, 1H, ArH3), 7.74-7.79 (m, 2H, ArH7, H8), 8.19
U

U

U

U

(s, 1H, ArH5), 9.79 (s, 1H, NH);
U

U

13

C NMR (125 MHz, CDCl3): δ 25.4 (ArCH3),
U

U

121.0 (C10), 121.7 (C3), 124.7 (C6), 128.0 (C5), 131.5 (C8), 133.4 (C7), 140.5 (C4),
146.9 (C9), 160.2 (C2), 166.1 (C=O); ESI-MS m/z Calc for C11H9BrN3O [M-H+]
U

U

279.9973 found 279.9971.
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3-Methyl-1H-pyrazole-5-carbohydrazide 155b, 20
Compound 155 was synthesized over 2 steps from the
commercially

available

3-methyl-1H-pyrazole-5-carboxylic

acid 162. The acid 162 (1.0 g, 7.92 mmol) which was converted
into the corresponding methyl ester using MeOH (30) mL and catalytic H2SO4. The
reaction conditions and work up procedure were similar to that used in the
preparation of 161, which afforded pure 163 (940 mg, 85%). A stirred solution of the
methyl ester 163 (940 mg, 6.71 mmol) in ethanol (20 mL) with hydrazine
monohydrate (2 mL, 41.1 mmol) was heated to reflux for 4-5 h. The reaction was
monitored by TLC (MeOH:DCM, 1:9). Upon consumption of the starting material
the reaction mixture was cooled to room temperature and water (15 mL) was added.
The precipitate was filtered and the cake washed with ether:ethanol (1: 9) to produce
155 as a white solid (855 mg, 91%). mp 148-150 oC; 1H NMR (500 MHz,
(CD3)2SO): δ 2.19 (s, 3H, CH3), 3.3 (s, 2H, NH2), 6.3 (s, 1H, H4), 9.79 (s, 1H, NH),
U

U

12.9 (s, 1H, H1); 13C NMR (125 MHz, (CD3)2SO): δ 24.9 (CH3), 104.4 (C4), 140.1
U

U

(C3), 145.9 (C5), 156.3 (C=O).
U

U

(E)-N'-((2-hydroxynaphthalen-1-yl) methylene)-4-methylbenzohydrazide 122b, 38
To a stirred solution of p-toulic acid hydrazide 152
(7 g, 46.6 mmol) in 50% aqueous ethanol (500 mL)
was added 2-hydroxynaphthaldehyde (8.02 g, 46.6
mmol) followed by a solution containing glacial
acetic acid (11.5 mL) in 200 mL of 95% aqueous ethanol. The reaction mixture was
heated to reflux for 3 h. Upon cooling, the precipitate was filtered and recrystallised
from ethanol to afford the title compound 122 as a greenish solid (13.1 g, 93 %), mp.
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245-248 oC; 1H NMR (500 MHz, (CD3)2SO): δ 2.36 (s, 3H, ArCH3), 7.21 (d, J = 8.5
U

U

Hz, 1H, ArH3), 7.35 (d, J = 8 Hz, 2H, Ar H3‘), 7.38 (m, J = 7.5 Hz, ArH6), 7.57 (t, J
= 7.5 Hz, ArH7), 7.87 (d, J = 8 Hz, 2H, ArH2‘), 7.90 (d, J = 8.5 Hz, 2H, ArH4 &
H5), 8.19 (d, J = 8.5 Hz, 1H, ArH8), 9.45 (s, 1H, N=CH), 12.15 (bs, 1H, OH), 12.8
U

U

U

U

(bs, 1H, NH); 13C NMR (125 MHz, (CD3)2SO): δ 21.1 (ArCH3), 108.6 (ArC1), 119.0
U

U

U

U

(ArC3), 120.6 (ArC8), 123.6 (ArC6), 127.7 (ArC2‘), 127.8 (ArC8), 127.9 (C10),
129.0 (C3‘), 129.3 (ArC1‘), 129.8 (ArC9), 142.4 (ArC4‘), 146.7 (N=CH), 158.0
U

U

(ArC2), 162.5 (C=O); ESI-MS m/z Calc for C19H16N2O2Na [M+Na+] 327.1109;
observed 327.1101.
(E)-N'-((2-hydroxynaphthalen-1-yl)methylene)-3-methyl-1H-pyrazole-5carbohydrazide 123b, 20
To a stirred solution of 3-methyl-1H-pyrazole-5carbohydrazide 155 (100 mg, 0.71 mmol) and 2hydroxy-1-naphthaldehyde (122.8 mg, 0.71mmol) in
ethanol (10 mL) was added acetic acid (0.1 mL, 1.77
mmol) and reaction mixture was heated to reflux for 3-4 h. Upon cooling a
precipitate formed an was filtered and recrystallised from EtOH to afford the title
compound 123 as a yellow solid (157 mg, 75%). mp 280-282 oC; 1H NMR (500
MHz, (CD3)2SO): δ 2.30 (s, 3H, ArCH3), 6.54 (s, 1H, ArH4‘), 7.21 (d, J = 9.0 Hz,
U

U

1H, ArH3), 7.39 (appt, J = 7.5 Hz, 1H, ArH6), 7.58 (appt, J = 7.5 Hz, 1H, ArH7),
7.88 (d, J = 8.5 Hz, 1H, ArH5), 7.90 (d, J = 9.0 Hz, 1H, ArH4), 8.12 (d, J = 8.5 Hz,
1H, ArH8), 9.61 (s, 1H, N=CH), 12.02 (s, 1H, ArOH), 12.92 (s, 1H, NH), 13.18 (s,
U

U

U

U

1H, NH1‘); 13C NMR (125 MHz, (CD3)2SO): δ 10.1 (Ar CH3), 104.7 (ArC4‘), 108.3
U

U

U

U

(ArC1), 118.7 (ArC3), 120.16 (ArC8), 123.2 (ArC6), 127.4 (ArC7), 127.5 (ArC10),
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128.7 (ArC5), 131.5 (ArC9), 132.2 (ArC4), 140.0 (ArC3‘), 145.0 (ArC5‘), 146.3
(N=CH), 157.6 (ArC2), 157.7 (C=O); ESI-MS m/z Calc for C16H15N4O2 [M+H+]
U

U

295.1195; observed 295.1187.
(E)-6-bromo-N'-(2-hydroxy-3-methoxybenzylidene)-2-methylquinoline-4carbohydrazide 124b 19
Compound 124 was produced using General method A
with 6-bromo-2-methylquinoline-4-carbohydrazide 154
(1

g,

3.56

mmol)

and

2-hydroxy-3-methoxy-

benzaldehyde (543 mg, 3.56 mmol). The title
compound 124 was obtained as an off-white solid (1.13
g, 77%) in (E:Z = 93:7). mp 259-260 oC; 1H NMR (500 MHz, (CD3)2SO): δ 2.71 (s,
3H, ArCH3), 3.83 (s, 3H, ArOCH3), 6.87 (appt, J = 7.9 Hz, 1H, ArH5), 7.07 (d, J =
U

U

U

U

7.03 Hz, 1H, ArH4), 7.24 (d, J = 7.9 Hz, 1H, ArH6), 7.74 (s, 1H, ArH3‘) 7.89-7.98
(m, 2H, ArH7‘ & H8‘ ), 8.38(t, J = 1.9 Hz, 1H, ), 8.61 (s, 1H, N=CH), 10.59 (s, 1H,
U

U

ArOH ), 12.36 (s, 1H, NH); 13C NMR (500 MHz, (CD3)2SO): δ 24.8 (ArCH3), 55.7
U

U

U

U

U

U

(ArOCH3), 114.0 (ArC4), 118.9 (ArC1), 119. 1 (ArC5), 119.82 (ArC6‘), 120.2
U

U

(ArC6), 121.5 (ArC5‘), 123.8 (ArC10‘), 127.0 (ArC3‘), 130.9 (ArC8‘), 132.9
(ArC7‘), 146.3 (ArC9‘), 147.1 (ArC2), 147.9 (ArC3), 148.6 (N=CH), 159.3 (ArC2‘),
U

U

162.0 (C=O); ESI-MS m/z Calc for C19H15BrN3O3 [M-H-] 412.0297 found 412.0292.
U

U

(Z)-6-bromo-N'-(2-hydroxy-3-methoxybenzylidene)-2-methylquinoline-4carbohydrazide 124
1

H NMR (500 MHz, (CD3)2SO): δ 2.69 (s, 3H, ArCH3),
U

U

3.8 (s, 3H, ArOCH3), 6.63 (appt, J = 7.9 Hz, 1H,
U

U
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ArH5), 7.07 (d, J = 7.0 Hz, 1H, ArH4), 7.24 (d, J = 7.9 Hz, 1H, ArH6), 7.56 (s, 1H,
ArH3‘) 7.89-7.98 (m, 2H, ArH7‘ & H8‘ ), 8.38 (t, J = 1.9 Hz, 1H), 8.61 (s, 1H),
10.59 (s, 1H, ArOH ), 12.36 (s, 1H, NH);
U

U

U

U
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C NMR (125 MHz, (CD3)2SO): δ 24.8

(ArCH3), 55.6 (ArOCH3), 113.2 (ArC4), 118.6 (ArC5), 119.2 (ArC1), 119.4
U

U

U

U

(ArC6‘), 120.2 (ArC6), 120.8 (ArC7‘), 123.3(ArC10‘), 126.9 (ArC3‘), 130.9
(ArC8‘), 132.7 (ArC7‘), 144.05 (N=CH), 145.9 (ArC9‘), 146.0 (ArC2), 147.7
U

U

(ArC3), 159.2 (ArC2‘), 167.6 (C=O).
U

U

(E)-4-chloro-N'-((2-hydroxynaphthalen-1-yl)methylene)benzohydrazide 140b, 39
Compound 140 was produced using General
method A with 153 (500 mg, 2.93 mmol) and 2hydroxynapthaldehyde (504 mg, 2.93 mmol),
affording 140 as a yellowish solid (870 mg, 91%).
mp 254 256 oC; 1H NMR (500 MHz, (CD3)2SO): δ 7.22 (d, J = 9.0 Hz, 1H, ArH3),
7.37 (appt, J = 7.5 Hz, 1H, ArH6), 7.58 (appt, J = 8.0 Hz, 1H, ArH7), 7.62 (d, J = 8.5
Hz, 1H ArH3‘), 7.86 (d, J = 8.0 Hz, 1H, ArH5), 7.90 (d, J = 8.5 Hz, 1H, ArH4), 8.0
(d, J = 8.5 Hz, 1H, ArH2‘), 8.21, (d, J = 9.0 Hz, 1H, ArH8), 9.46 (C=NH), 12.2 (s,
U

U

1H, OH), 12.70 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO): δ 108.5 (C1), 118.8
(C3), 120.6 (C9), 123.4 (C6), 123.6 (C8), 127.8 (C10), 128.6 (C3‘), 128.9 (C7),
129.5 (C2‘), 131.3 (C1‘), 131.6 (C9), 132.7 (C5), 132.9 (C4), 136.9 (C4‘). 147.2
(C=NH), 158.1 (C2‘), 161.5 (C=O); ESI-MS m/z Calc for C18H14ClN2O2 [M-H-]
U

U

U

U

325.0744 found 325.0742.

144

(E)-N'-(2-hydroxy-3-methoxybenzylidene)-4-methylbenzohydrazide 141b,19,20
Compound 141 was produced using General Method A
with p-toulic acid hydrazide 152 (430 mg, 2.86 mmol)
and 2-hydroxy-3-methoxybenzaldehyde (435 mg, 2.86
mmol). The title compound 141 was obtained as an
off-white solid (692 mg, 85%). mp 184-85 oC; 1H NMR (500 MHz, (CD3)2SO): δ
2.36 (s, 3H, ArCH3), 3.79 (s, 3H, ArOCH3), 6.85 (m, J = 9.0 Hz, 1H, ArH5), 7.01 (d,
U

U

U

U

J = 8.0 Hz, 1H, ArH4), 7.11 (d, J = 7.5 Hz, 1H, ArH6), 7.32 (d, J = 8.0 Hz, 2H,
ArH2‘), 7.83 (d, J = 8.0 Hz, 2H, ArH3‘), 8.62 (s, 1H, N=CH), 11.03 (s, 1H, Ar-OH),
U

12.01 (s, 1H, NH);

U

13

C NMR (125 MHz, (CD3)2SO): δ 21.0 (ArCH3), 55.9
U

U

(ArOCH3), 113.98 (ArC4), 118.9 (ArC1), 119.1 (ArC5), 121.1 (ArC6), 127.7
U

U

(ArC2‘), 129.2 (ArC3‘), 129.9 (ArC1‘), 142.2 (ArC4‘), 147.2 (ArC2), 148.0 (ArC3),
148.3 (N=CH), 162.2 (C=O); ESI-MS m/z Calc for C16H17N2O3 [M+H+] 285.1239;
U

U

observed 285.1233.
(E)-N'-(2-hydroxy-3-methoxybenzylidene)-3-methyl-1H-pyrazole-5carbohydrazide 142b,20
Compound 142 was produced using General Method A
with 3-methyl-1H-pyrazole-5-carbohydrazide 155 (100
mg,

0.71

mmol)

and

2-hydroxy-3-

methoxybenzaldehyde (108.5 mg, 0.71 mmol). The
title compound 142 was obtained as an off-white solid (146 mg, 75%). mp 237-238
o

C; 1H NMR (500 MHz, (CD3)2SO): δ 2.28 (s, 3H, ArCH3), 3.79 (s, 3H, ArOCH3),
U

U

U

U

6.52 (s, 1H, ArH4‘), 6.82 (appt, J = 7.5 Hz, 1H, H5), 6.98-7.02 (m, 2H, ArH4,
ArH6), 8.67 (s, 1H, N=CH), 11.25 (s, 1H, ArOH), 11.95 (s, 1H, NH), 13.12 (s, 1H,
U

U

U

U
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ArNH1‘); 13C NMR (125 MHz, (CD3)2SO): δ 10.3 (ArCH3), 55.82 (ArOCH3), 104.9
U

U

U

U

U

U

(ArC4‘), 113.7 (ArC4), 118.84 (ArC1), 118.9 (ArC5), 121.3 (ArC6), 140.1 (ArC3‘),
145.2 (ArC5‘), 147.1 (ArC2), 147.7 (ArC3), 148.3 (N=CH), 158.2 (C=O); ESI-MS
U

U

m/z Calc. for C13H15N4O3 [M+H+] 275.1144; observed 275.1148.
(E)-6-bromo-N'-((2-hydroxynaphthalen-1-yl)methylene)-2-methylquinoline-4carbohydrazide 143a
Compound 143 was produced using General
Method

A

with

6-bromo-2-methylquinoline-4-

carbohydrazide 154 (500 mg, 1.78 mmol) and 2hydroxy-1-naphthaldehyde (306 mg, 1.78 mmol).
The title compound 143 was obtained as a light
yellow solid (658 mg, 85%) (E:Z = 95:5). mp 247-248 oC; 1H NMR (500 MHz,
(CD3)2SO): δ 2.74 (s, 3H, ArCH3), 7.20 (d, J = 9.0 Hz, 1H, ArH3), 7.41 (appt, J =
U

U

7.5 Hz, 1H, ArH6), 7.6 (appt, J = 7.5 Hz, 1H, ArH7) 7.81 (s, 1H, ArH5‘), 7.89-8.14
(m, ArH4, H5, H6‘& H7‘), 8.34 (d, J = 8.5 Hz, 1H, ArH8), 9.37(N=CH), 12.44 (s,
U

1H, ArOH), 12.50 (C=ONH);
U

U

U

U

13

U

C NMR (125 MHz, (CD3)2SO): δ 24.8 (ArCH3),
U

U

109.9 (ArC1), 119.25 (ArC3), 120.4 (ArC10‘), 120.6 (ArC8), 122.0 (ArC4‘), 124.1
(ArC6), 125.4 (ArC10), 127.6 (ArC3‘), 128.1 (ArC7), 128.3 (ArC6‘), 129.4 (ArC5‘),
131. 5 (ArC4‘), 132.0 (ArC9), 133.5 (ArC7‘), 133.7 (ArC8‘), 138.7 (ArC4‘), 146.8
(ArC9‘), 148.5 (N=CH), 158.6 (ArC2), 162.3 (C=O); ESI-MS m/z Calc for
U

U

U

U

C22H17BrN3O2 [M+H+] 434.0504; observed 434.0501

146

(Z)-6-bromo-N'-((2-hydroxynaphthalen-1-yl)methylene)-2-methylquinoline-4carbohydrazide 143a
1

H NMR (500 MHz, (CD3)2SO): δ 2.70 (s, 3H,

ArCH3), 6.92 (appt, J = 7.5 Hz, 1H, ArH7), 7.05 (d, J
U

U

= 9 Hz, 1H, ArH3), 7.19 (appt, J = 7.5 Hz, 1H, ArH6),
7.70 (d, J = 8 Hz, 1H, ArH5), 7.74 (d, J = 8.5 Hz, 1H,
ArH7‘) 7.83 (d, J = 8.5 Hz, 1H, ArH4), 7.96 (m, 1H,
ArH8‘), 8.34 (d, J = 8.5 Hz, 1H, ArH8), 8.92 (N=CH), 10.52 (s, 1H, ArOH), 12.33
U

U

U

U

(C=ONH); 13C NMR (125 MHz, (CD3)2SO): δ 24.7 (ArCH3), 100.1 (ArC1), 118.4
U

U

U

U

(ArC3), 120.0 (ArC10‘), 121.6 (ArC8), 123.2 (ArC6), 123.7 (ArC10), 127.2 (ArC3‘),
127.5 (ArC7), 128.5 (ArC6‘), 129.0 (ArC5), 131.2 (ArC9), 131.5 (ArC4), 133.1
(ArC7‘), 133.3 (ArC8‘), 142.0 (ArC10‘), 144.3 (N=CH), 146.4 (ArC9‘), 157.4
U

U

(ArC2), 159.8 (ArC2‘), 168.2 (C=O); ESI-MS m/z Calc for C22H17BrN3O2 [M+H+]
U

U

434.0504; observed 434.0501.
(E)-N'-((4-hydroxynaphthalen-1-yl)methylene)-4-methylbenzohydrazide 144a,
Compound 144 was produced using General
Method A with 4-hydroxy naphthaldehyde (583
mg, 3.39 mmol) and p-toulic acid hydrazide 152
(510 mg, 3.39 mmol). The title compound 144
was obtained as a creamy yellow solid (937 mg,
91%). mp 240-241 oC; 1H NMR (500 MHz, (CD3)2SO): δ 2.36 (s, 3H, ArCH3), 6.97
U

U

(d, J = 8.5 Hz, 1H, ArH3), 7.32 (d, J = 8.0 Hz, 2H, Ar H3‘), 7.53 (appt, J = 7.5 Hz,
ArH6), 7.63 (appt, J = 8.0 Hz, ArH7), 7.74 (d, J = 9.5 Hz, 1H, ArH3), 7.86 (d, J =
8.0 Hz, 1H, ArH4), 8.24 (d, J = 8.5 Hz, 1H, ArH5), 8.95-8.96 (m, 2H, ArH8 and
147

N=CH) 10.85 (bs, 1H, OH), 11.75 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO): δ
U

U

U

U

U

U

21.1 (ArCH3), 108.2 (ArC3), 120.5 (ArC1), 122.8 (ArC5), 124.5 (ArC8), 124.8
U

U

(ArC10) 125.2 (ArC6), 127.6 (ArC2‘), 127.7 (ArC7), 129.1(ArC3‘), 130.2 (ArC1),
130.7 (ArC1‘), 131.7 (ArC9) 141.7 (ArC4‘) 141.7 (N=CH), 155.7 (ArC4), 162.8
U

U

(C=O); ESI-MS m/z Calc for C19H16N2O2Na [M+Na+] 327.1109; observed 327.1101.
(E)-4-methyl-N'-(naphthalen-1-ylmethylene)benzohydrazide 145b, 19,20
Compound 145 was produced using General
Method A with p-toulic acid hydrazide 152 (400
mg, 2.66 mmol) and 1-naphthaldehyde (415 mg,
2.66 mmol). The title compound 145 was obtained
as an off-white solid (537 mg, 70%). mp 209-210 oC; 1H NMR (500 MHz,
(CD3)2SO): δ 2.37 (s, 3H, ArCH3), 7.35 (d, J = 7.5 Hz, 2H, ArH3‘), 7.59 (m, 2H,
U

U

ArH6 and H3), 7.66 (appt, J = 7.5 Hz, 1H, ArH7), 7.90 (d, J = 7.5 Hz, 2H, ArH2‘),
7.93 (d, J = 7.0 Hz, 1H, ArH5), 8.03 (m, 2H, ArH4 and H2), 8.87 (d, J = 8.5 Hz, 1H,
ArH8), 9.11(s, 1H, N=CH), 11.87 (s, 1H, NH);
U

U

U

13

U

C NMR (125 MHz, (CD3)2SO): δ

21.2 (Ar CH3), 124.32 (ArC8), 125.5 (ArC2), 125.7 (ArC6), 126.2 (ArC7), 126.4
U

U

(ArC3), 127.7 (ArC2‘), 128.8 (ArC5), 128.9 (ArC3‘), 129.6 (ArC1‘), 130.3 (ArC9),
130.6 (ArC4) 133.6 (ArC10) 147.4 (N=CH), 163.0 (C=O); ESI-MS m/z Calc for
U

U

C19H17N2O [M+H+] 289.1341; observed 289.1335.
(E)-3-methyl-N'-(naphthalen-1-ylmethylene)-1H-pyrazole-5-carbohydrazide
146b, 20
Compound 146 was produced using General method
A with 3-methyl-1H-pyrazole-5-carbohydrazide 155
148

(70 mg, 0.50 mmol) and 1-naphthaldehyde (78 mg, 0.5 mmol). The title compound
146 was obtained as an off white solid (99 mg, 71%). mp 256-257 oC; 1H NMR (300
MHz, (CD3)2SO): δ 2.30 (s, 3H, ArCH3), 6.55 (s, 1H, ArH4‘), 7.56-7.64 (m, 2H,
U

U

ArH2, H3,H6), 7.93-8.7 (m, 3H, ArH4, H5,H7), 8.77 (d, J = 6.6 Hz, 1H, ArH8), 9.26
(s, 1H, N=CH), 11.7 (s, 1H, NH), 13.15 (s, 1H, ArNH1‘);
U

U

U

U

U

13

U

C NMR (75 MHz,

(CD3)2SO): δ 10.3 (ArCH3), 104.9 (ArC4‘), 124.0 (ArC8), 125.6 (ArC2), 126.2
U

U

(ArC6), 126.7 (ArC3), 127.1 (ArC7), 128.7 (ArC5), 129.9 (ArC1), 130.2 (ArC4),
130.3 (ArC9), 133.5 (ArC10), 140.1 (ArC3‘), 145.9 (ArC5‘), 146.9 (N=CH), 158.4
U

U

(C=O); ESI-MS m/z Calc for C16H15N4O [M+H+] 279.1246; observed 279.1244.
(E)-6-bromo-N'-(3-methoxybenzylidene)-2-methylquinoline-4-carbohydrazide
147a
Compound 147 was produced using General Method A
with 6-bromo-2-methylquinoline-4-carbohydrazide 154
(500 mg, 1.78 mmol) and m-anisaldehyde (242 mg,
1.78 mmol). The title compound 147 was obtained as
an off-white solid (604 mg, 85%) (E:Z = 95:5). mp
221-223 oC; 1H NMR (500 MHz, (CD3)2SO): δ 2.70 (s, 3H, ArCH3), 3.81 (s, 3H, ArU

U

OCH3), 6.83 (t, J = 7.5 Hz, 1H, ArH5), 7.04 (d, J = 6 Hz, 1H, ArH3), 7.37 (d, J = 7.0
U

U

Hz, 1H, ArH6), 7.70 (s, 1H, ArH3‘), 7.90-7.96 (m, 2H, ArH5, H7‘, H8‘), 8.33
(N=CH); 13C NMR (125 MHz, (CD3)2SO): δ 24.8 (ArCH3), 55.2 (ArOCH3), 111.3
U

U

(ArC2), 116. 7 (ArC6), 119.4 (ArC6‘), 120.3 (ArC4), 121.4 (ArC3‘), 123.9
(ArC10‘), 127.0 (ArC5‘), 130.9 (ArC5), 131.0 (ArC8‘), 132.9 (ArC7), 138.9
(ArC10‘), 146.3 (ArC9‘), 148.9 (N=CH); 159.4 (ArC2‘), 159.5 (ArC3), 162.3
U

U

(C=O); ESI-MS m/z Calc for C19H17BrN3O2 [M+H+] 398.0504; observed 398.0503.
149

(Z)-6-bromo-N'-(3-methoxybenzylidene)-2-methylquinoline-4-carbohydrazide
147
1

H NMR (500 MHz, (CD3)2SO): δ 2.55 (s, 3H, ArCH3),
U

U

3.45 (s, 3H, ArOCH3), 6.69 (t, J = 7.5 Hz, 1H, ArH5),
U

U

6.86 (d, J = 8.0 Hz, 1H, ArH4), 7.07 (m, J = 8.0 Hz, 1H,
ArH6), 7.17 (t, J = 7.5 Hz, 1H, ArH3‘), 7.90-7.94 (m,
2H, ArH5, H7‘ and H8‘), 8.33 (N=CH);

13

C NMR (500

MHz, (CD3)2SO): δ 24.8 (ArCH3), 54.2 (ArOCH3), 110.8 (ArC1), 116.0 (ArC6),
U

U

119.2 (ArC6‘) 119.4 (ArC4), 123.6 (ArC10‘), 127.1 (ArC5‘), 130.0 (ArC4), 130.9
(ArC8‘), 132.6 (ArC7‘), 135.1 (ArC1‘), 140.9 (ArC4‘), 144.6 (N=CH), 145.8
U

U

(ArC9‘), 159.2 (ArC3‘), 168.1 (C=O); ESI-MS m/z Calc for C19H17BrN3O2 [M+H+]
398.0504; observed 398.0503.
(E)-N'-((2-hydroxynaphthalen-1-yl)methylene)-N,4-dimethylbenzohydrazide
148a,
Compound 148 was produced using General
Method B with N-methyl-p-toulic hydrazide 156
(500

mg,

3.04

mmol)

and

2-hydroxy-1-

naphthaldehyde (524 mg, 3.04 mmol). The title
compound 148 was obtained as an off white solid (552 mg, 52%). mp195-97 oC; 1H
NMR (300 MHz, CDCl3): δ 2.44 (s, 3H, ArCH3), 3.66 (s, 3H, NCH3), 7.05 (d, J = 9
U

U

U

U

Hz, 1H, ArH3), 7.29 (d, J = 7.8 Hz, 2H, ArH3‘), 7.35 (appt, J = 7.8 Hz, 1H, ArH6),
7.51-7.53 (m, 3H, Ar H2‘, ArH7), 7.71 (d, J = 9.3 Hz, 1H, ArH4), 7.75 (d, J = 8.1
Hz, 1H, ArH5), 8.01 (d, J = 8.7 Hz, 1H, ArH8) 8.70 (s, 1H, N=CH), 11.04 (bs, 1H,
U

ArOH);
U

U

13

U

C NMR (75 MHz, CDCl3): δ 21.5 (ArCH3), 28.4 (NCH3), 108.1 (ArC1),
U

U

U

U

150

119.0 (ArC3), 119.5 (ArC8), 123.4 (ArC6), 127.3 (ArC7), 128.1 (ArC5, C10), 129.0
(ArC2‘), 129.1 (ArC3‘), 131.7 (ArC9), 132.04 (ArC1‘), 132.4 (ArC4), 139.0
(N=CH), 140.9 (ArC4‘), 157.1 (ArC2), 170.9 (C=O); ESI-MS m/z Calc for
U

U

C20H19N2O2 [M+H+] 319.1447; observed 319.1445.
(E)-N'-((2-methoxynaphthalen-1-yl)methylene)-4-methylbenzohydrazide
149b,19,20
Compound 149 was produced using General
Method A with p-toulic acid hydrazide 152 (430
mg,

2.86

mmol)

and

2-methoxy-1-

naphthaldehyde (533 mg, 2.86 mmol). The title
compound 149 was obtained as an off white solid (820 mg, 73%). mp 191-193 oC;
1

H NMR (500 MHz, (CD3)2SO): δ 2.37 (s, 3H, ArCH3), 3.99 (s, 3H, OCH3), 7.33 (d,
U

U

U

U

J = 7.5 Hz, 2H, ArH3‘), 7.42 (appt, J = 7.5 Hz, 1H, ArH6), 7.51 (d, J = 9.0 Hz, 1H,
ArH3), 7.57 (appt, J = 7.5 Hz, 1H, ArH7), 7.89 (d, J = 7.0 Hz, 2H, ArH2‘), 8.04 (d, J
= 9.0 Hz, 1H, ArH4), 9.15 (s, 1H, N=CH), 9.41 (d, J = 8.5 Hz, 1H, ArH8), 11.84 (bs,
U

U

1H, NH); 13C NMR (125 MHz, (CD3)2SO): δ 21.0 (Ar CH3), 56.0 (ArOCH3), 113.4
U

U

U

U

U

U

(ArC3), 114.3 (ArC1), 124.0 (ArC6), 125.9 (ArC8), 127.8 (ArC2‘), 128.4 (ArC10),
128.8 (ArC3‘), 130.5 (ArC1‘), 130.7 (ArC9), 132.6 (ArC4), 141.7 (ArC4‘), 145.1
(N=CH), 157.7 (ArOCH3), 162.8 (C=O); ESI-MS m/z Calc for C20H18N2O2Na
U

U

U

U

[M+Na+] 341.1266; observed 341.1270

151

(E)-N'-((2-methoxynaphthalen-1-yl)methylene)-N,4-dimethylbenzohydrazide
150a
Compound

150 was produced using General

Method B with N-4-dimethylbenzohydrazide 156
(500

mg,

3.04

mmol)

and

2-methoxy-1-

naphthaldehyde (566 mg, 3.04 mmol) The title
compound 150 was obtained as an off-white
solid (860 mg, 85%). mp 168-70 oC; 1H NMR (500 MHz, CDCl3): δ 2.44 (s, 3H,
ArCH3) 3.63 (s, 3H, NCH3), 3.99 (s, 3H, ArOCH3), 7.04 (appt, J = 7.5 Hz, 1H,
U

U

U

U

U

U

ArH7), 7.2-7.24 (m, 3H, ArH3‘, H3), 7.27 (appt, J = 7.5 Hz, 1H, ArH6), 7.59 (d, J =
8.0 Hz, 2H, ArH2‘), 7.69 (d, J = 8.0 Hz, 1H, ArH5), 7.81 (d, J = 9.0 Hz, 1H, ArH4),
8.59 (s, 1H, N=CH), 8.62 (d, J = 9.0 Hz, 1H, ArH8); 13C NMR (125 MHz, CDCl3): δ
21.4 (ArCH3), 28.5 (NCH3), 56.6 (ArOCH3), 112.5 (ArC3), 115.1 (ArC1), 123.9
U

U

U

U

U

U

(ArC8), 126.3 (ArC6), 127.4 (ArC7), 128.1 (ArC5), 128.3 (ArC3‘), 128.9 (ArC2‘),
129.1 (ArC10), 130.8 (ArC9), 132.2 (ArC4), 133.3 (ArC1‘), 137.7 (N=CH), 139.6
U

U

(ArC4‘), 157.8 (ArC2), 172.1 (C=O); ESI-MS m/z Calc for C21H21N2O2 [M+H+]
333.1603; observed 333.1603.
(E)-3-methyl-N'-((5-nitrofuran-2-yl)methylene)-1H-pyrazole-5-carbohydrazide
151b
Compound 151 was produced using General
Method

A

with

3-methyl-1H-pyrazole-5-

carbohydrazide 155 (200 mg, 1.42 mmol) and 5nitro-2-furaldehyde (201 mg, 1.42 mmol). The title
compound 151 was obtained as a yellow solid (281 mg, 75%). mp 278-280 oC; 1H
152

NMR (300 MHz, (CD3)2SO): δ 2.28 (s, 3H, ArCH3), 6.52 (s, 1H, ArC4‘), 7.19 (d, J =
U

U

3.0 Hz, 1H, ArH3), 7.77 (d, J = 3.0 Hz, 1H, ArH4), 8.45 (s, 1H, N=CH), 12.1 (s, 1H,
U

U

NH), 13.1 (s, 1H, ArNH1‘); 13C NMR (75 MHz, (CD3)2SO): δ 10.3 (ArCH3), 105.1
U

U

U

U

U

U

(ArC4‘), 114.5 (ArC3), 114.7 (ArC4), 134.8 (N=CH), 140.3 (ArC3‘), 145.3 (ArC5‘),
U

U

151.8 (ArC5), 152.2 (ArC2), 158.6 (C=O); ESI-MS m/z Calc for C10H10N5O4
[M+H+] 264.0773; observed 264.0719.
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Chapter 5
Preliminary Synthesis and Structural-Activity Studies with NSC293884; a new Clostridium-Selective Antibacterial

5.1 High-throughput screening identifies a second new class of Clostridiumselective antibacterials
Chapter 4 described studies with diarylacylhydrazones as a prototypical new
class of Clostridium-selective antibacterials, identified during a high-throughput
screening and counter screening campaign carried out at Northeastern University. As
a part of that campaign more than 8000 compounds from the NCI (Set V) were
screened and 104 hits against C. difficile were identified (Figure 5.1). After counterscreening 30 compounds were identified as selective for C. Difficile. Of these 30
compounds NSC 293884 167 appeared to show very potent activity (MIC 1.56
µg/mL, Figure 5.2) and was chosen for further study.

Figure 5.1 Summary of NCI (set V) screening carried out at Northeastern
University. Compound NSC 293884 167 was identified as a potent and selective hit
against C. difficile CD196 (see Figure 5.2 for activity data).
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As a part a preliminary investigation into whether 167 could be developed
towards a new therapeutic for CDI it was necessary to first resynthesise the
compound in pure form and show the antibacterial profile of

the compound

identified during screening could be reproduced. A second requirement was to
identify whether the chemistry used to synthesize 167 was amenable to formation of
analogues, which would allow future structure-activity studies to be carried out.
The aim of this section of thesis work was to synthesize 167 in pure form and
prepare two analogues. These compounds were to then be forwarded to Northeastern
University for microbiological evaluation.
5.2 Synthesis of NSC 293884 167
One possible synthetic route towards 167 that was considered involved using
the method reported by Junek et al1. This synthesis involves performing a
Knoevenagel condensation of pthalic anhydride 170 with malononitrile to form 171.
Condensation of 171 with p-toulidine under acidic conditions then produces 172.
Intramolecular cyclisation of 172 under acidic conditions subsequently produces 167
(Scheme 5.1). Overall this procedure involved 3 steps, yields for the final step were
not reported, 1 making this procedure less attractive than an alternative procedure that
was identified in the literature.

Scheme 5.1 Proposed synthesis of 167 (a) malononitrile, CH3COONa (b) ptoluidine, HCl, reflux (c) HCl (Conc.), reflux.
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The synthetic pathway that was ultimately implemented to produce 167 (and
analogues) was adapted from Renfrew et al.2 The 2-step procedure involved a
H

H

Knoevenagel condensation of phthalic anhydride 170 with ethylcyanoacetate in the
presence of triethylamine in toluene. Upon addition of triethylamine a yellow colour
was immediately observed and on continuous reflux an intense orange colour
developed which remained until completion of the reaction. The organic layer was
extracted with water and the aqueous layer adjusted to pH 7 by addition of conc.
HCl. The solid that separated was filtered, dried and recrystallised from methanol.
The solid corresponded to the intermediate 173 which was obtained as a white
powder in 58% yield. 1H NMR data for 173 was consistent with the literature.2
H

H

Compound 173 was then be subjected to reaction with aryldiazonium salts in alkaline
medium whereupon they underwent cyclization to form the target heterocycle.
Reaction with p-tolyldiazonium chloride produced 167. It was considered that this
second step was amenable to formation of analogues simply by switching to other
aryldiazonium salts. Accordingly, analogues 168 and 169, carrying 3,4-dimethoxy
and 4-phenoxy substitutents, respectively, were targeted.
The requisite diazonium salts were prepared in situ by dropwise addition of a
2N sodium nitrite solution to the corresponding aniline in 2N HCl at 0 oC. The
solution was filtered and the filtrate added dropwise to 171 in aqueous sodium
carbonate solution. Precipitation of the product was observed in all three reactions
and the solids obtained were filtered, washed with water and purified either by
recrystallization or column chromatography.
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Scheme 5.2 Synthesis of 293884 167and its analogues 168 and 169. Reagents and
conditions: (a) ethylcyanoacetate , triethylamine , toluene, reflux, 58%;2 (b) ArN2+Cl; 2N Na2CO3 in H2O, 0 oC - rt, 167 85%,2 168 77%, 169 61 %.
Compound 167 was recrystallized from methanol, producing a pale yellow
powder in 85% yield. The 1H NMR spectrum supported formation of 167 with new
proton signals observed at 2.39, 7.36 and 7.46 ppm, which corresponded to the ptolyl substituent. The spectrum was consistent with the reported.1 A peak at m/z
H

H

314.0930 in high resolution mass spectrum was also consistent with the molecular
formula C19H12N3O2 [M+H]+ for 167.
The 3,4-dimethoxy analogue 168 was produced as a brownish red solid in
77% yield after recrystallization from methanol. The 1H NMR spectrum supported
formation of 168 with the presence of signals at 3.82, 3.76 and 7.11-7.14 ppm,
corresponding to the methoxy and aryl signals, respectively. A

13

C NMR was not

able to obtain with 168 due to rapid precipitation of the compound in all NMR
solvents.
The 4-phenoxyphenyl analogue 169 was produced initially as reddish orange
solid. After purification by silica gel column chromatography using EtOAc:hexane
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(1:4 to 2:3) afforded pure 169 as a light yellow powder in 61% yield. Formation of
169 was supported by 1H NMR, 13C NMR and high resolution mass spectrometry.
The presence of new aryl signals in the 1H NMR spectrum at 7.12, 7.15, 7.21, 7.44
and 7.59 ppm confirmed introduction of the phenoxyphenyl substituent. The
presence of new carbonyl signals at 157.7 and 183.6 ppm in the

13

C spectrum

indicated cyclized product and the overall count of 20 carbons was consistent with
formation of 169. An m/z peak at 392.1036 in the high resolution mass spectrum was
consistent with the molecular formula C24H14N3O3 [M+H+] for 169.
5.3 Microbiological evaluation of compounds 167-169
The activity of compounds 167-169 was evaluated against C. difficile CD196
and the panel of gut commensals described in Chapter 4. Clostridium-selective
activity was observed with the synthesized 167 (Figure 5.2), confirming the results
previously obtained at Northeastern with the NCI sample of the compound.
Compound 167 showed some activity (MIC 3.125-6.25 µg/mL) against B.
thetaiotamicron which was not observed with the diarylacylhydrazones (Chapter 4).
The 3,4-dimethoxy analogue 168 showed no activity against Clostridium species,
although it showed potent activity against S. mutans. Excitingly, the 4-phenoxy
analogue 169 showed very high potency against CD196 (MIC 0.78 µg/mL) and no
activity against any other panel member (including C. perfringens) making it a truly
C. difficile selective compound.
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Figure 5.2 MIC values of synthetic NSC 293884 167 and its analogues 168 and 169.
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5.4 Conclusions and future directions
While the studies performed here were limited in scope some key results
were obtained which can be built upon in future efforts directed towards creating
new antibiotics for CDI that show very high selectivity for C. difficile over gut
commensals. Firstly, in preparing a pure synthetic version of 167 and showing that it
exhibits the same activity profile as the NCI compound, we‘ve been able to confirm
that this is the chemical structure of the active species. In adapting the synthetic
procedure for 167 reported by Renfrew et al2 to produce two novel analogues we‘ve
demonstrated that the chemistry should be robust enough to allow preparation of
many more analogues, thus permitting a wider structure-activity exploration with the
class. One obvious approach would be to create analogues of the intermediate 171
carrying substituents on the benzene ring, which could then be reacted with various
aryldiazonium salts. In producing such a library and submitting the compounds to an
SAR study, it is possible that an analogue might be found which satisfies the many
properties that would be required in a new drug for CDI. The fact that 168 showed no
activity against CD196 suggests that compounds are showing structure-dependant
activity and may be hitting a specific protein target. The exquisite selectivity of 169
against C. difficile has generated excitement in our collaboration and plans are being
put in place to extensively explore this compound and the class.
5.5 Experimental
5.5.1 Chemistry−General
The general chemistry information is described in Section 2.8.1. Pthalic
anhydride 170, ethylcyanoacetate, p-toulidine, 3,4-dimethoxyaniline, and 4-
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phenoxyphenyl amine were purchased from Sigma-Aldrich. Triethylamine was
purchased from Ajax.
The literature status for each compound is indicated by: a = novel compound,
b = published compound with limited/no characterisation, or c = fully characterised
published compound. Full characterisation has been provided for all novel
compounds and compounds with limited or no characterisation.
(Z)-ethyl 2-(2-carbamoyl-3-hydroxy-1H-inden-1-ylidene)-2-cyanoacetate 173b, 2
H

The synthesis of 171 was adapted from Renfrew et al.2 To a
H

H

stirred solution of pthalic anhydride (11.1 g, 74.94 mmol) and
ethylcyanoacetate (5.65 g, 49.95 mmol) in toluene (300 mL)
was added triethylamine (6.86 mL, 49.95 mmol). The reaction
immediately changed to a yellow colour. After heating at
reflux for 24 h the reaction had become orange and the resulting orange yellowish
mixture was heated at reflux for 24 h. The mixture was extracted with water (3 x 500
mL) and the aqueous extracts were combined and added to a stirring solution of
crushed ice and conc. HCl (10 mL) and stirred for 30 min. The precipitate was
filtered and washed with water (100 mL) dried and recrystallised from MeOH to
produce 171 as a white solid (4.15 g, 58%). mp 190-193 o C; 1H NMR (300 MHz,
(CD3)2SO): δ 1.29 (t, 3H, CH2-CH3), 4.28 (q, 2H, COCH2), 4.96 (s, 1H, OH), 7.39
U

U

U

U

U

(m, 1H, H4), 7.93-8.0 (m, 4H, NH2, H5, H6), 8.73 (d, J = 11.0 Hz, H7);
U

U

13

U

C NMR

(75 MHz, (CD3)2SO): δ 13.9 (CH3), 61.2 (C2), 62.3 (COCH2), 99.1 (C1‘), 116.1
U

U

U

U

(CN), 124.4 (C4), 125.4 (C7), 134.6 (C5), 136.2 (C6), 138.5 (C9), 144.7 (C8), 161.1
U

U

(COOEt), 165.5 (CONH2), 194.9 (C3).
U

U

U

U

165

3,9-dioxo-2-(p-tolyl)-3,9-dihydro-2H-indeno[2,1-c]pyridazine-4-carbonitrile
167b,2
H

p-Toulidine (1.07 g, 9.3 mmol) was dissolved in 2N
HCl (20 ml, 37.2 mmol) and the solution cooled to 0 o
C. 2N sodium nitrite solution (5 mL, 9.3 mmol) was
then added dropwise to the stirring mixture and the
reaction stirred for 5-10 min. The excess nitrite was quenched with a minimum
amount of 2 N sulfamic acid (2 mL) solution in H2O. The mixture was filtered and
the filtrate added dropwise via syringe pump over 40 min to a suspension of 173
(2.84 g, 9.207 mmol) in H2O (300 mL) containing 2 N Na2CO3 (30 mL, 27.9 mmol)
at 5 oC. After completion of the reaction the yellowish orange solid was filtered off
and washed with H2O and MeOH (70:30). Recrystallization from MeOH afforded
167 as a yellow solid (2.66 g, 85%). mp 257-259 oC; 1H NMR (500 MHz,
(CD3)2SO): δ 2.39 (s, 3H, ArCH3), 7.36 (d, J = 7.5 Hz, 2H, H3‘), 7.46 (d, J = 7.5 Hz,
U

U

2H, H2‘), 7.92 (t, J = 7.0 Hz, 1H, H7), 8.01- 8.05 (m, 2H, H6, H8), 8.28 (d, J = 7.5
Hz, 2H, H5);

13

C NMR (125 MHz, (CD3)2SO): δ 2.07 (ArCH3), 102.0 (C4), 113.1
U

U

(CN), 125.1 (C8), 125.2 (C5), 125.4 (C2‘), 129.3 (C3‘), 135.1 (C7), 135.9 (C1‘),
U

U

137.1(C6), 137.4 (C8a), 137.9 (C5a), 138.8 (C4a‘), 141.0 (C4‘), 146.1 (C9a), 156.9
(C3), 183.9 (C9); ESI-MS m/z Calc for

C19H12N3O2 [M+H+] 314.0930 found

314.0930.
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2-(3,4-dimethoxyphenyl)-3,9-dioxo-3,9-dihydro-2H-indeno[2,1-c]pyridazine-4carbonitrile 168a
Synthesis of 168 was performed in similar manner
to that of 167. 3,4-dimethoxyaniline (250 mg,
1.632 mmol) was dissolved in MeOH:CHCl3 (4:1;
5 mL) and 2 N HCl (3.25 mL) was added before
cooling the mixture to 0 oC. 2 N sodium nitrite solution (1 mL, 1.63 mmol) was
added dropwise and stirred for 10-20 min at same temperature. The excess sodium
nitrite was quenched with minimum amount of 2N sulfamic acid (0.5 mL) solution in
H2O and the mixture filtered. The filtrate was added dropwise over 15 min to a
suspension of 173 (449 mg, 1.61 mmol) in 2N Na2CO3 solution (2.5 mL, 4.89 mmol)
and the reaction mixture was stirred for 10 min. The dark reddish precipitate
obtained was filtered, washed with water (3 x 10 mL) and the cake obtained was
recrystallised from EtOH to afford 168 as a reddish solid (439 mg, 77%). mp 259261 oC; 1H NMR (500 MHz, (CD3)2SO): δ 3.73 (s, 3H, OCH3), 3.79 (s, 3H, OCH3),
U

U

U

U

7.07-7.12 (m, 3H, H2‘H3‘), 7.87- 8.25 (m, 4H, H5-H8).
3,9-dioxo-2-(4-phenoxyphenyl)-3,9-dihydro-2H-indeno[2,1-c]pyridazine-4carbonitrile 169a
The synthesis of 169 was carried out in a
similar manner to that of 167. To a stirred
solution of 4-phenoxyaniline (300 mg, 1.62
mmol) in MeOH:CHCl3 (1:1, 5 mL) was
added 2N HCl (3.24 mL, 6.48 mmol). The mixtures was cooled to 0 oC before adding

167

2 N sodium nitrite solution (0.81 mL, 1.62 mmol) dropwise over 10-20 min at 0 oC.
Upon complete addition stirring was continued for 5-10 min. The excess sodium
nitrite was quenched with a minimum amount of 2 N sulfamic acid (0.7 mL) solution
in H2O. The mixture was filtered and the filtrate added dropwise over 30 min to a
suspension of 173 (456 mg, 1.6 mmol) in water (15 mL) containing 2 N Na2CO3
(3.89 ml 7.29 mmol). The reaction mixture was stirred for 10 min before the reddish
orange precipitate was filtered and washed with water (3 x 10 mL). The cake
obtained was dissolved in EtOAc (20 mL) and the solution dried over Na2SO4. The
organic layer was concentrated in vacuo and the residue purified by silica gel column
chromatography (EtOAc:hexane, 1:4 to 2:3) to afford 169 as a light yellow powder
(382 mg, 61%). mp 254-256 oC; 1H NMR (500 MHz, (CD3)2SO): δ 7.12 (d, J = 8.5
Hz, 2H, H3‘), 7.15 (d, J = 9.0 Hz, 2H, H2‘‘), 7.21 (appt, J = 7.5 Hz, 1H, H4‘‘), 7.44
(appt, J = 8.0 Hz, 2H, H3‘‘), 7.59 (d, J = 9.0 Hz, 2H, H2‘), 7.92 (t, J = 7.5 Hz, 1H,
H7), 8.02 (d, J = 7.5 Hz, 1H, H8), 8.05 (t, J = 7.5 Hz, 1H, H6), 8.30 (d, J = 8.0 Hz,
1H, H8); 13C NMR (125 MHz, (CD3)2SO): δ 102.0 (C4), 112.9 (NC), 118.0 (C2‘‘),
U

U

119.1 (C3‘), 124.0 (C4‘‘), 124.9 (C8), 125.0 (C5), 127.3 (C2‘), 130.3 (C3‘‘), 134.9
(C7), 135.3 (C1‘), 135.8 (C8a), 137.0 (C6), 137.4 (C5a), 140.9 (C9a), 146.0 (C4a),
155.7 (C1‘‘), 156.0 (C4‘), 157.7 (C3), 183.6 (C9); ESI-MS m/z Calc for C24H14N3O3
[M+H+] 392.1035 found 392.1036.
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Chapter 6. Conclusions and Future Directions
The Berberine-INF55 hybrids (Section 1.10.2) had previously been identified
as a promising class of potent antimicrobials, but their MIC‘s were above 10 µM. In
efforts to improve their potency new dual action prodrug forms of SS14-type
molecules were designed and one such compound 96 was successfully produced
based on the concept of the ―perfect antimicrobial‖ (Section 2.1). Compound 96 was
evaluated for antibacterial activity against three strains of S. aureus but the results
demonstrated that it shows similar MIC‘s to the previous hybrids 86-88. One future
possibility to explore alternative ―perfect antimicrobials‖ that link INF55 via a
carbamate tether as found in the failed prodrug target 90 to ―reactive species‖ other
than berberine (Figure 6.1). The idea would be to choose the masked reactive
species such that it could be linked to INF55 via the methyl carbamate linkage in
such a way that once inside bacterial cells a reaction would ensue that triggers
release of two agents and CO2. Design of such prodrugs are ongoing in the Kelso
Lab at UOW.

Figure 6.1 Future INF55 prodrugs based on the ―perfect antimicrobial‖ concept will
link some masked reactive species other than berberine to INF55 via carbamate
linkages.
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In Chapter 3 the antibacterial mechanism of Berberine-INF55 of hybrids was
probed to explore whether berberine portion functions as the antimicrobial and the
INF55 portion functions as a NorA inhibitor in S.aureus. INF55 44 and two of it
analogues 100 and 101 which showed reduced efflux pump inhibitory activity were
designed and successfully synthesised. It was hypothesised that corresponding hybrid
antimicrobials 88, 110 and 117 that incorporate these pump inhibitors 44, 100, 101
respectively should have shown antibacterial potencies that matched the potencies of
their inhibitors. To explore the hypothesis, three hybrids 88, 110 and 117 were
successfully synthesised using newly developed chemistry. The checker board assays
showed that potentiation of berberine by the three INF55 based NorA pump
inhibitors showed in the order 44 > 101 > 100. The hybrids 88, 110, 117, have all
show identical activities against the S. aureus strains, contradicting the hypothesis.
Fluorescence-based cell assays revealed that the hybrids also show similar
accumulation in the S. aureus strains. All three hybrids clearly showed robust
curative effects in C. elegans live MRSA and E. faecalis infection models. It was
concluded from these findings that the mechanism of action of hybrids was probably
not as designed so further mechanism of action studies are warranted. Future work
with the hybrids will investigate whether changing the position of the INF55 moiety
relative to berberine affects the antibacterial activity the compounds. One example
would be to explore is moving the INF55 portion from the 13-position to the 8position of berberine (Figure 6.2).
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Figure 6.2 Future work with Berberine-INF55 hybrids could involve investigating
the effect of moving the INF55 portion from the 13-position to the 8-position.

Section 2 of the thesis investigated new agents that show selective anticlostridium agents over other gut commensals. High-throughput screening by
Northeastern

University

initially

identified

4

hits

(121-124)

from

the

diarylacylhydrazones class of compounds, which were active against C. difficile
CD196 and essentially inactive (CD > 50 µg/mL) across the gut commensals. In
comparison with current antibiotics metranidazole 118, vancomycin 119 and
fidaxomicin 120 used for CDAD, these compounds show much higher selectivity for
C. difficile over the gut commensals. To explore structure-activity questions in this
new class of diarylcylhydrazones several analogues 140-150 were synthesised in
good yields (70-90%). SAR work revealed that the o-hydroxy group in one aryl ring
and the hydrogen of the amide nitrogen are essential for activity against C. difficile.
CCCP 64 showed a similar activity profile to the diarylacylhydrazones against the
gut panel and stationary phase C.difficile suggesting a protonophoric mechanism may
play a role in the selectivity. Interestingly one of the lead compounds 123 showed
low toxicity towards human cell lines (FaDu and HepG2) as well as activity against
stationary-phase cells. Future investigations are warranted with these compounds.
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Towards the end of my studies I repeated the synthesis of 123 and produced more
than 1 g for in vivo studies in a hamster C. difficile infection model. These studies are
currently underway at Northeastern University.
In summary, this work has shown that certain diarylacylhydrazones are
narrow-spectrum antibacterials with selectivity for C. difficile and C. perfringens
over other gut commensals. Future studies will aim to explore the mechanism of
action of these compounds by using affinity chromatography. This technique can
allow identification of the target protein of the compounds. In this strategy a
derivative of 122 will be linked to sepharose beads by a poly ethylene glycol (PEG)
linker. Introduction of the linker at the C-3 position of diarylacylhydrazone 122
could

be

a

feasible

synthetic

strategy

(Figure

6.3).

The

immobilised

diarylacylhydrazone 122 ligand affinity matrices will be incubated with C. difficile
CD196 cell extracts and loaded into a column. Unbound proteins will be removed by
extensive washing, while the bound proteins will subsequently be eluted with buffers
to obtain the specific target molecules. Once the target molecule is identified followup with molecular and cell biology studies will be undertaken to confirm its identity,
structure and function (Figure 6.3).
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Figure

6.3.

Affinity

chromatography

with

purified

and

characterised

diarylacylhydrazone 122.
Affinity chromatography techniques could also be used to probe the
mechanism of action of compounds 167-169, as described in Chapter 5. Introduction
of the PEG linker at C-6 position of 167 (Figure 6.4) could be a feasible synthetic
strategy coupling to sepharose beads, followed by affinity of similar affinity
chromatography techniques as described then be used to identify the cellular target(s)
of this interesting new class of C. difficile-selective agents.

Figure 6.4 Affinity chromatography with compounds 167-169.
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